US20150018526A1 - Cytotoxins comprising modified bouganin toxin for the treatment of cancer - Google Patents

Cytotoxins comprising modified bouganin toxin for the treatment of cancer Download PDF

Info

Publication number
US20150018526A1
US20150018526A1 US14/242,181 US201414242181A US2015018526A1 US 20150018526 A1 US20150018526 A1 US 20150018526A1 US 201414242181 A US201414242181 A US 201414242181A US 2015018526 A1 US2015018526 A1 US 2015018526A1
Authority
US
United States
Prior art keywords
bouganin
protein
modified
cell
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US14/242,181
Inventor
Matthew Baker
Francis J. Carr
Koen Hellendoorn
Jeannick Cizeau
Glen C. MACDONALD
Joycelyn Entwistle
Denis G. BOSC
Nicholas R. Glover
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Viventia Bio Inc
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Priority to US14/242,181 priority Critical patent/US20150018526A1/en
Assigned to VIVENTIA BIOTECH INC. reassignment VIVENTIA BIOTECH INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BOSC, DENIS GEORGES, CIZEAU, JEANNICK, ENTWISTLE, JOYCELYN, MACDONALD, GLEN CHRISTOPHER, GLOVER, NICHOLAS RONALD
Assigned to MERCK PATENT GMBH reassignment MERCK PATENT GMBH ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: HELLENDOORN, KOEN, CARR, FRANCIS J., BAKER, MATTHEW
Assigned to MERCK PATENT GMBH reassignment MERCK PATENT GMBH ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: VIVENTIA BIOTECH INC.
Publication of US20150018526A1 publication Critical patent/US20150018526A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/168—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6819—Plant toxins
    • A61K47/6825—Ribosomal inhibitory proteins, i.e. RIP-I or RIP-II, e.g. Pap, gelonin or dianthin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins

Definitions

  • the invention relates to modified bouganin proteins and cytotoxins containing the modified proteins useful as therapeutics against cancer. Specifically, T-cell epitopes are removed or altered to reduce immunogenicity of the bouganin toxins.
  • T-cell epitopes are commonly defined as any amino acid residue sequence with the ability to bind to MHC Class II molecules.
  • T-cell epitope means an epitope which when bound to MHC molecules can be recognized by a T-cell receptor (TCR), and which can, at least in principle, cause the activation of these T-cells by engaging a TCR to promote a T-cell response.
  • TCR T-cell receptor
  • HLA-DR human leukocyte antigen group DR
  • isotypes HLA-DQ and HLA-DP perform similar functions.
  • individuals bear two to four DR alleles, two DQ and two DP alleles.
  • the structure of a number of DR molecules has been solved and these appear as an open-ended peptide binding groove with a number of hydrophobic pockets which engage hydrophobic residues (pocket residues) of the peptide [Brown et al (1993) Nature 364: 33; Stern et al (1994) Nature 368: 215].
  • Polymorphism identifying the different allotypes of class II molecule contributes to a wide diversity of different binding surfaces for peptides within the peptide binding groove and at the population level ensures maximal flexibility with regard to the ability to recognize foreign proteins and mount an immune response to pathogenic organisms.
  • MHC Class II molecules are expressed by professional antigen presenting cells (APCs), such as macrophages and dendritic cells amongst others. Engagement of a MHC class II peptide complex by a cognate T-cell receptor on the surface of the T-cell, together with the cross-binding of certain other co-receptors such as the CD4 molecule, can induce an activated state within the T-cell. Activation leads to the release of cytokines further activating other lymphocytes such as B cells to produce antibodies or activating T-killer cells as a full cellular immune response.
  • APCs professional antigen presenting cells
  • T-cell epitope identification is the first step to epitope elimination as recognized in WO98/52976; WO00/34317; WO02/069232; WO02/079232; and WO02/079415.
  • predicted T-cell epitopes are removed by the use of judicious amino acid substitution within the protein of interest.
  • An exemplary method uses B-cell lines of defined MHC allotype as a source of MHC class II binding surface and may be applied to MHC class II ligand identification [Marshall K. W. et al. (1994) J. Immunol.
  • Biological assays of T-cell activation offer a practical option to providing a reading of the ability of a test peptide/protein sequence to evoke an immune response.
  • Examples of this kind of approach include the work of Petra et al using T-cell proliferation assays to the bacterial protein staphylokinase, followed by epitope mapping using synthetic peptides to stimulate T-cell lines [Petra, A. M. et al (2002) J. Immunol . 168: 155-161].
  • T-cell proliferation assays using synthetic peptides of the tetanus toxin protein have resulted in definition of immunodominant epitope regions of the toxin [Reece J. C. et al (1993) J.
  • WO99/53038 discloses an approach whereby T-cell epitopes in a test protein may be determined using isolated sub-sets of human immune cells, promoting their differentiation in vitro and culture of the cells in the presence of synthetic peptides of interest and measurement of any induced proliferation in the cultured T-cells.
  • the same technique is also described by Stickler et al. [Stickler, M. M. et al (2000) J. Immunotherapy 23:654-660], where in both instances the method is applied to the detection of T-cell epitopes within bacterial subtilisin.
  • Such a technique requires careful application of cell isolation techniques and cell culture with multiple cytokine supplements to obtain the desired immune cell sub-sets (dendritic cells, CD4+ and or CD8+T-cells) and is not conducive to rapid through-put screening using multiple donor samples.
  • T-cell epitopes As depicted above and as consequence thereof, it would be desirable to identify and to remove or at least to reduce T-cell epitopes from a principal therapeutically valuable but originally immunogenic peptide, polypeptide or protein.
  • the invention is conceived to overcome the practical reality that soluble proteins introduced with therapeutic intent in humans can trigger an immune response resulting in development of host antibodies that bind to the soluble protein.
  • the present invention seeks to address this by providing bouganin proteins with reduced propensity to elicit an immune response.
  • the inventors have identified the regions of the bouganin molecule comprising the critical T-cell epitopes driving the immune responses to this protein.
  • the present invention relates to a modified bouganin protein wherein the modified bouganin has a reduced propensity to elicit an immune response.
  • the modified bouganin has a reduced propensity to activate T-cells and the modified bouganin is modified at one or more amino acid residues in a T-cell epitope.
  • the T-cell epitopes are selected preferably from the group consisting of:
  • AKVDRKDLELGVYKL epitopope region R1, SEQ ID NO: 2
  • LGVYKLEFSIEAIHG epipe region R2, SEQ ID NO: 3
  • the present invention also relates to a cytotoxin comprising a targeting moiety attached to a modified bouganin protein of the invention.
  • the targeting moiety is a ligand that binds to a cancer cell.
  • the ligand is an antibody or antibody fragment that binds to a cancer cell.
  • the antibody recognizes Ep-CAM or tumor-associated antigen.
  • the present invention provides a cytotoxin comprising VB6-845 or VB6-011.
  • the invention provides a method of inhibiting or destroying cancer cells comprising administering a cytotoxin of the invention to the cancer cells.
  • the present invention also relates to a method of treating cancer by administering a cytotoxin of the invention to an animal in need thereof.
  • a process for preparing a pharmaceutical for treating an animal with cancer comprising the steps of identifying T-cell epitopes of bouganin, modifying one or more amino acid residues in a T-cell epitope to prepare a modified bouganin having reduced propensity to activate T-cells; preparing a cytotoxin have a cancer-binding ligand attached to a modified bouganin; and suspending the cytotoxin in a pharmaceutically acceptable carrier, diluent or excipient.
  • the invention provides a pharmaceutical composition for treating an animal with cancer comprising the cytotoxin of the invention and a pharmaceutically acceptable carrier, diluent or excipient.
  • cytotoxins, compositions and methods of the present invention may be used to treat various forms of cancer such as colorectal cancer, breast cancer, ovarian cancer, pancreatic cancer, head and neck cancer, bladder cancer, gastrointestinal cancer, prostate cancer, small cell and non small cell lung cancer, sarcomas, gliomas, T- and B-cell lymphomas.
  • cancer such as colorectal cancer, breast cancer, ovarian cancer, pancreatic cancer, head and neck cancer, bladder cancer, gastrointestinal cancer, prostate cancer, small cell and non small cell lung cancer, sarcomas, gliomas, T- and B-cell lymphomas.
  • the invention also provides the T-cell epitope peptides of the bouganin protein and the modified T-cell epitope peptides of the invention.
  • FIG. 1 shows results of activity assays of the T-cell epitope depleted modified bouganin proteins Bou156 (panel A) and Bou157 (panel B).
  • Bou156 comprises the substitutions V123A, D127A, Y133N and I152A.
  • Bou157 comprises the substitutions V123A, D127A, Y133Q and I152A. Both assay sets are conducted using wild type protein and a disabled modified bouganin (Y70A) as controls.
  • Activity is expressed as % measured luciferase activity versus concentration of bouganin protein in the assay.
  • FIG. 2 shows T-cell proliferation assay results for three synthetic peptides and 2 different PBMC donor samples.
  • the peptides designated DeI-41, DeI-44 and DeI-50 were tested at 1 ⁇ M final concentration (panel A) and 5 ⁇ M final concentration (panel B).
  • These peptides are derived from the immunogenic regions of the bouganin molecule and contain substitutions designed to eliminate their immunogenicity.
  • FIG. 3A illustrates the dicistronic unit encoding the pro-sequences
  • FIG. 3B illustrates the nucleic acid coding sequence (SEQ ID NO:15) and the amino acid sequence (SEQ ID NO:16) of the pro-sequences
  • FIG. 3C illustrates the assembled VB6-845 protein without the pelB sequences.
  • FIG. 4 illustrates the map of the expression vector pING3302. Inserts of the examples were ligated in 3302 vector using EcoRI and XhoI restriction sites.
  • FIGS. 5A-C illustrates the control Fab anti-Ep-CAM construct without the plant toxin, de-bouganin (VB5-845).
  • FIG. 5A illustrates the dicistronic unit encoding the pro-sequences
  • FIG. 5B illustrates the nucleic acid coding sequence (SEQ ID NO:17) and the amino acid sequence (SEQ ID NO:18) of the pro-sequences
  • FIG. 5C illustrates the assembled VB5-845 protein without the pelB sequences.
  • FIGS. 6A-C illustrates the Fab anti-Ep-CAM de-bouganin construct VB6-845-C L -de-bouganin, wherein the Bou156 is linked at the C-terminus of the C L domain.
  • FIG. 6A illustrates the dicistronic units encoding the pro-sequences
  • FIG. 6B illustrates the nucleic acid coding sequence (SEQ ID NO:19) and the amino acid sequence (SEQ ID NO:20) of the pro-sequences
  • FIG. 6C illustrates the assembled VB6-845-C L -de-bouganin protein without the pelB sequences.
  • FIGS. 7A-C illustrates the Fab anti Ep-CAM, de-bouganin construct, VB6-845-NV H -de-bouganin, wherein Bou156 is linked to the N-terminus of the V H domain.
  • FIG. 7A illustrates the dicistronic units encoding the pro-sequences
  • FIG. 7B illustrates the nucleic acid coding sequence (SEQ ID NO:21) and the amino acid sequence (SEQ ID NO:22) of the pro-sequences
  • FIG. 7C illustrates the assembled VB6-845-NV H -de-bouganin protein without the pelB sequences.
  • FIGS. 8A-C illustrates the Fab anti-Ep-CAM de-bouganin construct, VB6-845-NV L -de-bouganin, wherein Bou156 is linked to the N-terminus of the V L domain.
  • FIG. 8A illustrates the dicistronic units encoding the pro-sequences
  • FIG. 8B illustrates the nucleic acid coding sequence (SEQ ID NO:23) and the amino acid sequence (SEQ ID NO:24) of the pro-sequences
  • FIG. 8C illustrates the assembled VB6-845-NV L -de-bouganin protein without the pelB sequences.
  • FIG. 9 is a Western Blot illustrating the expression of VB6-845 (construct of FIG. 3 ) and VB6-845-CL-de-bouganin (Bou156) (construct of FIG. 6 ) in the supernatant of induced E104 cells at lab-scale.
  • FIGS. 10A-B illustrates the results of the flow cytometry reactivity studies.
  • FIG. 10A illustrates the reactivity of VB6-845 (construct of FIG. 3 ) and VB6-845-C L -de-bouganin (construct of FIG. 6 ) in Ep-CAM-positive cell lines CAL 27 and OVCAR-3 and Ep-CAM-negative cell line A-375
  • FIG. 10 B illustrates the results of the same tests conducted with VB6-845 (construct of FIG. 3 ) and VB6-845-gelonin (construct of FIG. 14C ) and control (PBS).
  • FIG. 11 is a graph illustrating the flow cytometry results of the competition assay with VB6-845 at 1 and 10 ⁇ g/mL and increased concentration of ProxiniumTM in NIH:OVCAR-3 cells as described in Example 7. The same experiment was performed with 4B5-PE which is used as a negative control.
  • FIG. 12 is a graph illustrating the results of the cell free translation assay comprising purified VB6-845 or de-bouganin proteins at various concentrations as described in Example 7.
  • FIGS. 13A-C illustrates the results of the MTS cytotoxicity assay of Example 8 comparing the cytoxocity of VB6-845 (construct of FIG. 3 ), VB6-845-CL-de-bouganin (construct of FIG. 6 ) and de-bouganin (Bou156) in CAL 27 ( FIG. 13A ) and NIH:OVCAR3 ( FIG. 13B ) cells.
  • FIGS. 14A-B illustrate the results of the MTS cytotoxicity assay of Example 8 comparing the cytoxocity of VB6-845 (construct of FIG. 3 ), VB6-845-gelonin (construct of FIG. 14C ) and gelonin in CAL 27 ( FIG. 14A ) and NIH:OVCAR3 ( FIG. 14B ) cells.
  • FIG. 14C illustrates the nucleic acid coding sequence (SEQ ID NO:25) and the amino acid sequence (SEQ ID NO:26) of the VB6-845-gelonin construct.
  • FIG. 15 illustrates the nucleic acid coding sequence (SEQ ID NO: 27) and the amino acid sequence (SEQ ID NO:28) of the pro-sequences of VB6-011.
  • FIG. 16 illustrates the results of the MTS cytotoxicity assay of Example 9 showing the cytotoxicity of VB6-011 in MB-435S cells.
  • the inventors have identified T-cell epitopes in bouganin, and have designed and made modified bouganin proteins that have reduced propensity to activate human T cells compared to the non-modified bouganin protein.
  • the present invention relates to a modified bouganin protein wherein bouganin has been modified in order to have a reduced propensity to elicit an immune response, preferably a T-cell response, as compared to a non-modified bouganin protein.
  • Mature bouganin protein is a single polypeptide of 250 amino acids with a molecular weight of approximately 26,200 Da [Den Hartog et al (2002) Eur. J. Biochem. 269: 1772-1779; U.S. Pat. No. 6,680,296].
  • Bouganin is a type 1 ribosome inactivating protein (RIP) originally isolated from the plant Bougainvillea spectabilis Willd [B perfumesi et al (1997) Planta 203: 422-429].
  • the RIPs from plants are RNA N-glycosidases that depurinate the major ribosomal RNA of cells, thereby damaging the ribosomes and leading to a cessation of protein synthesis and cell death
  • the amino acid sequence of the mature bouganin protein (depicted in single-letter code) is:
  • non-modified bouganin protein means a bouganin protein that has not been modified in order to reduce its propensity to elicit an immune response.
  • the sequence of wild-type or a non-modified bouganin is shown in SEQ ID NO:1.
  • non-modified bouganin also includes modifications to SEQ ID NO:1 as long as such modifications do not reduce the propensity to elicit an immune response. Examples of modifications that can be made to SEQ ID NO:1 include peptide fragments and conservative amino acid substitutions that do not reduce the immunogenicity of the protein.
  • modified bouganin protein means a bouganin protein that has been modified as compared to the non-modified bouganin protein (described above) wherein said modification reduces the propensity of the bouganin to elicit an immune response.
  • Modified bouganin protein can also be referred to as deimmunized bouganin.
  • the “modified bouganin protein” can be a modified full length sequence or a modified fragment of the non-modified bouganin protein.
  • the “modified bouganin protein” may also contain other changes as compared to the wild-type bouganin sequence which do not alter immunogenicity of the peptide.
  • the modified bouganin protein will preferably have the same biological activity as the non-modified bouganin.
  • the term “reduced propensity to elicit an immune response” as used herein means that the modified bouganin protein is less immunogenic than non-modified bouganin.
  • the term “immune response” includes both cellular and humoral immune responses.
  • the modified bouganin has a reduced propensity to activate T-cells.
  • reduced propensity to activate human T-cells means the modified bouganin protein has a reduced propensity to activate human T-cells as compared to the non-modified bouganin protein.
  • One of skill in the art can test whether or not a modified bouganin has a reduced propensity to activate T-cells using assays known in the art including assessing the stimulation index of the protein.
  • stimulation index refers to the measure of the ability of the modified or non-modified bouganin protein to activate human T cells.
  • the modified or non-modified bouganin protein, or peptides thereof can be tested for their ability to evoke a proliferative response in human T-cells cultured in vitro.
  • a stimulation index equal to or greater than 2.0 is a useful measure of induced proliferation.
  • the stimulation index is conventionally derived by division of the proliferation score (e.g. counts per minute of radioactivity if using 3 H-thymidine incorporation) measured to the test peptide by the score measured in cells not contacted with a test peptide.
  • the invention provides a modified bouganin protein, wherein the modified bouganin protein has biological activity and has reduced propensity to activate human T cells compared to a non-modified bouganin protein.
  • the invention provides a modified bouganin protein, wherein the modified bouganin protein has reduced propensity to activate human T cells compared to a non-modified bouganin protein and has biological activity that is lower than the non-modified bouganin protein.
  • the invention provides a modified bouganin protein wherein the modified bouganin protein has reduced propensity to activate human T cells and no biological activity.
  • modified proteins could, for instance, be used as controls, in assays or to tolerize subjects.
  • biological activity is the ability of the modified or non-modified bouganin protein to inhibit protein synthesis on ribosomes, which can be assessed in a number of ways. It should be noted that a modified bouganin protein will still have biological activity even if such activity is lower than that of the non-modified protein, however it would need to have some level of detectable activity. For example, the biological activity of the modified or non-modified bouganin protein can be assessed by identifying their N-glycosidase activity, and in particular with sufficient activity to provide significant inhibition of protein translation. One such suitable assay involves testing the activity of the variant bouganin proteins in comparison to non-modified bouganin in a cell-free protein synthesis assay.
  • a coupled transcription/translation mix containing methionine, DNA encoding the reporter protein luciferase and serial dilutions of non-modified and modified bouganin protein are co-incubated.
  • the levels of translated luciferase are readily detected using a luminescence counter following addition of a substrate reagent.
  • the measured luminescence is inversely proportional to the bouganin N-glycosidase activity present in the reaction. It is usual to provide a negative control such as an in-active bouganin protein, for example containing a Y70A substitution.
  • the modified bouganin peptide is modified at one or more T-cell epitopes in the bouganin protein sequence.
  • T-cell epitope means an amino acid sequence which is able to bind major histocompatibility complex (MHC) class II, able to stimulate T-cells and/or also able to bind (without necessarily measurably activating) T-cells in complex with MHC class II.
  • MHC major histocompatibility complex
  • a general method that can be used in the present invention leading to the modified bouganin proteins comprising modified T-cell epitopes comprises the following steps: (i) determining the amino acid sequence of the protein or part thereof; (ii) identifying one or more potential T-cell epitopes within the amino acid sequence of the protein by methods such as determination of the binding of the peptides to MHC molecules using in vitro or in silico techniques or biological assays; (iii) designing new sequence variants with one or more amino acids within the identified potential T-cell epitopes modified in such a way to substantially reduce or eliminate the activity of the T-cell epitope as determined by the binding of the peptides to MHC molecules using in vitro or in silico techniques or biological assays.
  • sequence variants are created in such a way to avoid creation of new potential T-cell epitopes by the sequence variations unless such new potential T-cell epitopes are, in turn, modified in such a way to substantially reduce or eliminate the activity of the T-cell epitope; (iv) constructing such sequence variants by recombinant DNA techniques and testing said variants in order to identify one or more variants with desirable properties according to well-known recombinant techniques; and (v) optionally repeating steps (ii) to (iv).
  • step (iii) is carried out by substitution, addition or deletion of amino acid residues in any of the T-cell epitopes in the non-modified bouganin protein.
  • the method to make the modified bouganin protein is made with reference to the homologous protein sequence and/or in silico modeling.
  • step (ii) can be carried out according to methods described previously in the art. Suitable methods are disclosed in WO 98/59244; WO 98/52976; WO 00/34317; WO 02/069232 and may be used to identify binding propensity of bouganin derived peptides to an MHC class II molecule.
  • the inventors have developed an approach exploiting ex vivo human T-cell proliferation assays. This approach has proven to be a particularly effective method and has involved the testing of overlapping bouganin derived peptide sequences in a scheme so as to scan and test the entire bouganin sequence.
  • the synthetic peptides are tested for their ability to evoke a proliferative response in human T-cells cultured in vitro.
  • a stimulation index equal to or greater than 2.0 is a useful measure of induced proliferation.
  • the stimulation index is conventionally derived by division of the proliferation score (e.g. counts per minute of radioactivity if using 3 H-thymidine incorporation) measured to the test peptide by the score measured in cells not contacted with a test peptide.
  • PBMCs peripheral blood mononuclear cells
  • PBMC samples were selected to achieve an optimal coverage of MHC class II allotypes.
  • PBMCs peripheral blood mononuclear cells
  • All peptides were diluted at two different concentrations: 1 ⁇ M and 5 ⁇ M.
  • the stimulation indices (SI) were calculated as the amount of 3 H incorporated into the cells, divided by the amount of 3 H incorporated in mock-stimulated controls.
  • the modified bouganin protein is modified at one or more amino acid residues in a T-cell epitope selected from the group consisting of:
  • LGVYKLEFSIEAIHG termed herein epitope region R2;
  • T-cell epitopes have been identified on the basis of giving SI>2 in two or more donor PBMC samples.
  • the above disclosed peptide sequences represent the critical information required for the construction of modified bouganin proteins in which one or more of these epitopes is compromised.
  • the modified bouganin protein of the invention has at least one T-cell epitope removed. In another embodiment, the modified bouganin protein of the invention has one, two or three T-cell epitopes removed.
  • the invention also contemplates a modified bouganin protein wherein 1 to 9 amino acid residues are modified, preferably in the T-cell epitope. In another embodiment, 1 to 5 amino acid residues are modified.
  • modified as used herein means the amino acid residues are modified by substitution, addition or deletion, preferably by substitution, but the bouganin protein has reduced propensity to activate human T cells.
  • the modified protein has biological activity. More preferably the modified bouganin protein of the invention is modified by substitution at a position corresponding to any of the amino acids specified within sequences (a), (b) or (c) above.
  • One embodiment of the present invention comprises bouganin proteins for which the MHC class II ligands identified within any of the epitopes R1-R3 are modified such as to eliminate binding or otherwise reduce the numbers of MHC allotypes to which the peptide can bind.
  • Amino acids in the R1 to R3 regions to eliminate binding or otherwise reduce the numbers of MHC allotypes to which the peptide can bind can be modified by substitution, addition or deletion.
  • amino acid substitutions are made at appropriate points within the peptide sequence predicted to achieve substantial reduction or elimination of the activity of the T-cell epitope.
  • an appropriate point will in one embodiment equate to an amino acid residue binding within one of the pockets provided within the MHC class II binding groove.
  • the binding within the first pocket of the cleft at the so-called P1 or P1 anchor position of the peptide is modified.
  • the quality of binding interaction between the P1 anchor residue of the peptide and the first pocket of the MHC class II binding groove is recognized as being a major determinant of overall binding affinity for the whole peptide.
  • An appropriate substitution at this position of the peptide will be for a residue less readily accommodated within the pocket, for example, substitution to a more hydrophilic residue.
  • Amino acid residues in the peptide at positions equating to binding within other pocket regions within the MHC binding cleft are also considered and fall under the scope of the present.
  • single amino acid substitutions, deletions or additions within a given potential T-cell epitope are a preferred route by which the epitope may be eliminated.
  • Combinations of modifications (i.e. substitutions, deletions and additions) within a single epitope may be contemplated and for example can be particularly appropriate where individually defined epitopes are in overlap with each other as is the present case where epitope regions R1 and R2 overlap by 5 residues.
  • either single amino acid modifications within a given epitope or in combination within a single epitope may be made at positions not equating to the “pocket residues” with respect to the MHC class II binding groove, but at any point within the peptide sequence. Modifications may be made with reference to an homologue structure or structural method produced using in silico techniques known in the art and may be based on known structural features of the molecule according to this invention. All such modifications fall within the scope of the present invention.
  • the epitope regions R1-R3 of bouganin were analyzed for indication of MHC class II ligands encompassed within their respective sequences.
  • a software tool exploiting the schemes outlined in WO 98/59244 and WO 02/069232 was used for this analysis.
  • the software simulates the process of antigen presentation at the level of the peptide MHC class II binding interaction to provide a binding score for any given peptide sequence. Such a score is determined for many of the predominant MHC class II allotypes existent in the population.
  • this scheme is able to test any peptide sequence, the consequences of amino acid substitutions, additions or deletions with respect to the ability of a peptide to interact with a MHC class II binding groove can be predicted. Consequently new sequence compositions can be designed which contain reduced numbers of peptides able to interact with the MHC class II and thereby function as immunogenic T-cell epitopes.
  • substitutions within epitope region R1 comprise changes at positions V123, D127 and/or E129.
  • the substitution is at position Y133. This residue falls into the region of overlap between R1 and R2 but substitution at Y133 is sufficient to eliminate the R2 related MHC class II ligand and is not sufficient of itself to eliminate R1 related MHC class II ligands.
  • substitutions are to residues E151, and/or 1152.
  • substitutions are to one or more alternative amino acid residues.
  • Residue 123 is a preferred site for mutation of the R1 region because it is at the surface of the molecule, away from the active site and is variable in RIP sequence alignment. Nevertheless, not all substitution yield an active molecule hence the need to validate mutations in the bioactivity assay. Thus for example within R1, substitutions V123T, V123A and V123Q are examples of preferred alternative substitutions.
  • Residue 131 was found to be absolutely conserved in RIP and hence is unlikely suitable for mutation.
  • Residue 127 and 129 are not highly conserved but only a restricted number of residues were found to have an impact on MHC II binding.
  • the substitution sets: D127G, D127A, E129Q and E129G are also preferred substitutions.
  • residue 133 was shown to be a likely candidate to abolish MHC II binding and its apparent surface localization (as determined by modeling) combined to the fact that it is not highly conserved across RIP make it a good candidate for mutation.
  • Preferred alternative substitutions were found to be Y133N, Y133T, Y133A, Y133R, Y133D, Y133E, Y133Q, Y133G, Y133K, Y133H and Y133S.
  • amino acid residues 152, 155 and 158 were identified as key residues for MHC II binding. However, residues 155 and 158 are part of a highly conserved hydrophobic stretch thus suggesting that their mutation would not yield bioactive molecules. Residue poorly conserved was found to be a more likely candidate. For R3, the substitution sets: I152Q and I152A are also preferred substitutions.
  • the invention provides a modified bouganin protein wherein the bouganin is modified at one or more of X 1 , X 2 , X 3 , X 4 or X 5 as follows:
  • epipe region R1, SEQ ID NO:5 epitopope region R1, SEQ ID NO:5
  • epipe region R2 epitopope region R2, SEQ ID NO:6
  • epipe region R3, SEQ ID NO:7 epitopope region R3, SEQ ID NO:7
  • X 1 through X 5 can be any amino acid.
  • X 1 is T or A or Q
  • X 2 is G or A
  • X 3 is Q or G
  • X 4 is N or D or T or A or R or Q or E or G or H or K or S
  • X 5 is Q or A (epitope region R1, SEQ ID NO:8; epitope region R2, SEQ ID NO:9; epitope region R3, SEQ ID NO:10).
  • the invention provides a modified bouganin peptide, comprising the amino acid sequence:
  • X 1 is T or A or Q
  • X 2 is G or A
  • X 3 is Q or G
  • X 4 is N or D or T or A or R or Q or E or G or H or K or S
  • X 5 is Q or A (SEQ ID NO: 12).
  • the modified bouganin protein comprises the amino acid sequence:
  • the modified bouganin protein comprises the amino acid sequence:
  • the modified bouganin protein of the invention has 1, 2, 3, 4, 5 or more amino acid modifications in the T-cell epitopes of the protein.
  • the modified bouganin protein of the invention when tested in a T-cell assay evokes a reduced stimulation index in comparison to the non-modified bouganin protein.
  • the T-cell epitopes of the bouganin protein are mapped using a T-cell assay and then modified such that upon re-testing in the T-cell assay the modified bouganin protein evokes a stimulation index less than the non-modified bouganin protein, preferably the stimulation index is less than 2.0.
  • modified bouganin protein has substantially reduced or no biological activity, it may need further modification by substitution, addition or deletion of amino acid residues to restore the biological activity of the modified bouganin protein.
  • modified bouganin proteins that have substantially reduced or no biological activity are still encompassed within the scope of the invention and have utility as controls in assays, or for tolerization.
  • the modified bouganin is mutated at the tyrosine residue at position 70 to yield an inactive bouganin.
  • the tyrosine at position 70 is replaced with alanine.
  • the modified bouganin has the sequence:
  • the epitopes are compromised by mutation to result in sequences no longer able to function as T-cell epitopes. It is possible to use recombinant DNA methods to achieve directed mutagenesis of the target sequences and many such techniques are available and well known in the art. In practice a number of modified bouganin proteins will be produced and tested for the desired immune and functional characteristic. It is particularly important when conducting modifications to the protein sequence that the contemplated changes do not introduce new immunogenic epitopes. This event is avoided in practice by re-testing the contemplated sequence for the presence of epitopes and/or of MHC class II ligands by any suitable means.
  • the modified bouganin proteins of the invention may also contain or be used to obtain or design “peptide mimetics”.
  • “Peptide mimetics” are structures which serve as substitutes for peptides in interactions between molecules (See Morgan et al (1989), Ann. Reports Med. Chem . 24:243-252 for a review). Peptide mimetics include synthetic structures which may or may not contain amino acids and/or peptide bonds but retain the structural and functional features protein of the invention, including biological activity and a reduced propensity to activate human T cells. Peptide mimetics also include peptoids, oligopeptoids (Simon et al (1972) Proc. Natl. Acad, Sci USA 89:9367).
  • Peptide mimetics may be designed based on information obtained by systematic replacement of L-amino acids by D-amino acids, replacement of side chains with groups having different electronic properties, and by systematic replacement of peptide bonds with amide bond replacements. Local conformational constraints can also be introduced to determine conformational requirements for activity of a candidate peptide mimetic.
  • the mimetics may include isosteric amide bonds, or D-amino acids to stabilize or promote reverse turn conformations and to help stabilize the molecule. Cyclic amino acid analogues may be used to constrain amino acid residues to particular conformational states.
  • the mimetics can also include mimics of the secondary structures of the proteins of the invention. These structures can model the 3-dimensional orientation of amino acid residues into the known secondary conformations of proteins.
  • Peptoids may also be used which are oligomers of N-substituted amino acids and can be used as motifs for the generation of chemically diverse libraries of novel molecules.
  • the molecules of this invention can be prepared in any of several ways but is most preferably conducted exploiting routine recombinant methods. It is a relatively straightforward procedure to use the protein sequences and information provided herein to deduce a polynucleotide (DNA) encoding any of the preferred protein sequences. This can be achieved for example using computer software tools such as the DNSstar software suite [DNAstar Inc, Madison, Wis., USA] or similar. Any such DNA sequence with the capability of encoding the preferred polypeptides of the present or significant homologues thereof, should be considered as embodiments of this invention.
  • DNA polynucleotide
  • genes encoding any of the preferred modified bouganin protein sequences can be made using gene synthesis and cloned into a suitable expression vector.
  • the expression vector is introduced into a host cell and cells selected and cultured.
  • the proteins of the invention are purified from the culture medium and formulated into a preparation for therapeutic administration.
  • a wild-type bouganin gene sequence can be obtained for example following a cDNA cloning strategy using RNA prepared from the root tissues of the Bougainvillea spectabilis Willd plant.
  • the wild-type gene can be used as a template for mutagenesis and construction preferred variant sequences.
  • modified bouganin molecules are identified with N-glycosidase activity, and in particular with sufficient activity to provide significant inhibition of protein translation.
  • One such suitable assay involves testing the activity of the modified bouganin proteins in comparison to non-modified bouganin in a cell-free protein synthesis assay.
  • a coupled transcription/translation mix containing methionine, DNA encoding the reporter protein luciferase and serial dilutions of non-modified and modified bouganin proteins are co-incubated.
  • the levels of translated luciferase are readily detected using a luminescence counter following addition of a substrate reagent.
  • the measured luminescence is inversely proportional to the bouganin N-glycosidase activity present in the reaction. It is usual to provide a negative control such as an in-active bouganin protein for example containing a Y70A substitution.
  • bouganin molecules may be achieved by recombinant DNA techniques and this includes bouganin molecules fused with desired antibody or other targeting moieties.
  • Methods for purifying and manipulating recombinant proteins including fusion proteins are well known in the art. Necessary techniques are explained fully in the literature, such as, “Molecular Cloning: A Laboratory Manual”, second edition (Sambrook et al., 1989); “Oligonucleotide Synthesis” (M. J. Gait, ed., 1984); “Animal Cell Culture” (R. I. Freshney, ed., 1987); “Methods in Enzymology” (Academic Press, Inc.); “Handbook of Experimental Immunology” (D. M.
  • the proteins and peptides of the invention can be prepared using recombinant DNA methods.
  • the proteins of the invention may also be prepared by chemical synthesis using techniques well known in the chemistry of proteins such as solid phase synthesis (Merrifield, 1964 , J. Am. Chem. Assoc . 85:2149-2154) or synthesis in homogenous solution (Houbenweyl, 1987, Methods of Organic Chemistry, ed. E. Wansch, Vol. 15 I and II, Thieme, Stuttgart).
  • the present invention also provides a purified and isolated nucleic acid molecule comprising a sequence encoding the modified bouganin proteins or peptides of the invention, preferably a sequence encoding the protein described herein as SEQ ID NO:13 or SEQ ID NO:14.
  • isolated and purified refers to a nucleic acid substantially free of cellular material or culture medium when produced by recombinant DNA techniques, or chemical precursors, or other chemicals when chemically synthesized.
  • An “isolated and purified” nucleic acid is also substantially free of sequences which naturally flank the nucleic acid (i.e. sequences located at the 5′ and 3′ ends of the nucleic acid) from which the nucleic acid is derived.
  • nucleic acid refers to a sequence of nucleotide or nucleoside monomers consisting of naturally occurring bases, sugars and intersugar (backbone) linkages. The term also includes modified or substituted sequences comprising non-naturally occurring monomers or portions thereof, which function similarly.
  • the nucleic acid sequences of the present invention may be ribonucleic (RNA) or deoxyribonucleic acids (DNA) and may contain naturally occurring bases including adenine, guanine, cytosine, thymidine and uracil.
  • the sequences may also contain modified bases such as xanthine, hypoxanthine, 2-aminoadenine, 6-methyl, 2-propyl, and other alkyl adenines, 5-halo uracil, 5-halo cytosine, 6-aza uracil, 6-aza cytosine and 6-aza thymine, pseudo uracil, 4-thiouracil, 8-halo adenine, 8-amino adenine, 8-thiol adenine, 8-thio-alkyl adenines, 8-hydroxyl adenine and other 8-substituted adenines, 8-halo guanines, 8-amino guanine, 8-thiol guanine, 8-thioalkyl guanines, 8-hydroxyl guanine and other 8-substituted guanines, other aza and deaza uracils, thymidines, cytosines, adenines, or gu
  • the purified and isolated nucleic acid molecule comprises a sequence encoding the proteins or peptides, preferably SEQ ID NO: 13 or SEQ ID NO: 14, of the invention, comprising (a) the nucleic acid sequence, wherein T can also be U; (b) nucleic acid sequences complementary to (a); (c) nucleic acid sequences which are homologous to (a) or (b); (d) a fragment of (a) to (c) that is at least 15 bases, preferably 20 to 30 bases, and which will hybridize to (a) to (c) under stringent hybridization conditions; or (e) a nucleic acid molecule differing from any of the nucleic acids of (a) to (c) in codon sequences due to the degeneracy of the genetic code.
  • nucleic acid molecules comprising nucleic acid sequences having substantial sequence homology with the nucleic acid sequences encoding the proteins and peptides of the invention, and fragments thereof.
  • sequences having substantial sequence homology means those nucleic acid sequences which have slight or inconsequential sequence variations from these sequences, i.e., the sequences function in substantially the same manner to produce functionally equivalent proteins. The variations may be attributable to local mutations or structural modifications.
  • Nucleic acid sequences having substantial homology include nucleic acid sequences having at least 80%, preferably 90% identity with the nucleic acid sequence encoding the proteins and peptides of the invention.
  • Another aspect of the invention provides a nucleic acid molecule, and fragments thereof having at least 15 bases, which hybridize to nucleic acid molecules of the invention under hybridization conditions, preferably stringent hybridization conditions. Appropriate stringency conditions which promote DNA hybridization are known to those skilled in the art, or may be found in Current Protocols in Molecular Biology, John Wiley & Sons, N.Y. (1989), 6.3.1-6.3.6.
  • the following may be employed: 6.0 x sodium chloride/sodium citrate (SSC) at about 45° C., followed by a wash of 2.0 ⁇ SSC at 50° C.
  • the stringency may be selected based on the conditions used in the wash step.
  • the salt concentration in the wash step can be selected from a high stringency of about 0.2 ⁇ SSC at 50° C.
  • the temperature in the wash step can be at high stringency conditions, at about 65° C.
  • nucleic acid molecules of the present invention having a sequence which encodes a protein or peptide of the invention may be incorporated according to procedures known in the art into an appropriate expression vector which ensures good expression of the protein or peptide.
  • Possible expression vectors include but are not limited to cosmids, plasmids, or modified viruses (e.g., replication defective retroviruses, adenoviruses and adeno associated viruses), so long as the vector is compatible with the host cell used.
  • the expression “vectors suitable for transformation of a host cell”, means that the expression vectors contain a nucleic acid molecule of the invention and regulatory sequences, selected on the basis of the host cells to be used for expression, which are operatively linked to the nucleic acid molecule. “Operatively linked” is intended to mean that the nucleic acid is linked to regulatory sequences in a manner which allows expression of the nucleic acid.
  • the invention therefore contemplates a recombinant expression vector of the invention containing a nucleic acid molecule of the invention, or a fragment thereof, and the necessary regulatory sequences for the transcription and translation of the inserted protein-sequence.
  • Suitable regulatory sequences may be derived from a variety of sources, including bacterial, fungal, or viral genes (For example, see the regulatory sequences described in Goeddel, Gene Expression Technology: Methods in Enzymology 185, Academic Press, San Diego, Calif. (1990). Selection of appropriate regulatory sequences is dependent on the host cell chosen, and may be readily accomplished by one of ordinary skill in the art.
  • regulatory sequences include: a transcriptional promoter and enhancer or RNA polymerase binding sequence, a ribosomal binding sequence, including a translation initiation signal. Additionally, depending on the host cell chosen and the vector employed, other sequences, such as an origin of replication, additional DNA restriction sites, enhancers, and sequences conferring inducibility of transcription may be incorporated into the expression vector. It will also be appreciated that the necessary regulatory sequences may be supplied by the native protein and/or its flanking regions.
  • the recombinant expression vectors of the invention may also contain a selectable marker gene which facilitates the selection of host cells transformed or transfected with a recombinant molecule of the invention.
  • selectable marker genes are genes encoding a protein such as G418 and hygromycin which confer resistance to certain drugs, ⁇ -galactosidase, chloramphenicol acetyltransferase, or firefly luciferase. Transcription of the selectable marker gene is monitored by changes in the concentration of the selectable marker protein such as ⁇ -galactosidase, chloramphenicol acetyltransferase, or firefly luciferase.
  • selectable marker gene encodes a protein conferring antibiotic resistance such as neomycin resistance transformant cells can be selected with G418. Cells that have incorporated the selectable marker gene will survive, while the other cells die. This makes it possible to visualize and assay for expression of recombinant expression vectors of the invention and in particular to determine the effect of a mutation on expression and phenotype. It will be appreciated that selectable markers can be introduced on a separate vector from the nucleic acid of interest.
  • the recombinant expression vectors may also contain genes which encode a fusion moiety which provides increased expression of the recombinant protein; increased solubility of the recombinant protein; and aid in the purification of a target recombinant protein by acting as a ligand in affinity purification.
  • a proteolytic cleavage site may be added to the target recombinant protein to allow separation of the recombinant protein from the fusion moiety subsequent to purification of the fusion protein.
  • Recombinant expression vectors can be introduced into host cells to produce a transformed host cell.
  • the term “transformed host cell” is intended to include prokaryotic and eukaryotic cells which have been transformed or transfected with a recombinant expression vector of the invention.
  • the terms “transformed with”, “transfected with”, “transformation” and “transfection” are intended to encompass introduction of nucleic acid (e.g. a vector) into a cell by one of many possible techniques known in the art.
  • Prokaryotic cells can be transformed with nucleic acid by, for example, electroporation or calcium-chloride mediated transformation.
  • Nucleic acid can be introduced into mammalian cells via conventional techniques such as calcium phosphate or calcium chloride co-precipitation, DEAE-dextran mediated transfection, lipofectin, electroporation or microinjection. Suitable methods for transforming and transfecting host cells can be found in Sambrook et al. (Molecular Cloning: A Laboratory Manual, 2nd Edition, Cold Spring Harbor Laboratory press (1989)), and other such laboratory textbooks.
  • Suitable host cells include a wide variety of prokaryotic and eukaryotic host cells.
  • the proteins of the invention may be expressed in bacterial cells such as E. coli , insect cells (using baculovirus), yeast cells or mammalian cells.
  • Other suitable host cells can be found in Goeddel, Gene Expression Technology Methods in Enzymology 185, Academic Press, San Diego, Calif. (1991).
  • Nucleic acid is “operably linked” when it is placed into a functional relationship with another nucleic acid sequence.
  • DNA for a presequence or secretory leader is operably linked to DNA for a polypeptide if it is expressed as a preprotein that participates in the secretion of the polypeptide;
  • a promoter or enhancer is operably linked to a coding sequence if it affects the transcription of the sequence; or
  • a ribosome binding site is operably linked to a coding sequence if it is positioned so as to facilitate translation.
  • “operably linked” means that the DNA sequences being linked are contiguous, and, in the case of a secretory leader, contiguous and in reading frame. However, enhancers do not have to be contiguous. Linking is accomplished by ligation at convenient restriction sites. If such sites do not exist, the synthetic oligonucleotide adaptors or linkers are used in accordance with conventional practice.
  • the expression vector comprises a nucleic acid sequence encoding a modified bouganin with a reduced number of potential T cell epitopes, operably linked to an expression control sequence.
  • the expression vector comprises a nucleic acid sequence encoding the proteins or peptides of the invention, or a degenerate variant thereof and will comprise at least the RIP encoding domain of the said nucleic acids operably linked with suitable expression control and selection sequences.
  • Degeneracy in relation to polynucleotides refers to the fact well recognized that in the genetic code many amino acids are specified by more than one codon. The degeneracy of the code accounts for 20 different amino acids encoded by 64 possible triplet sequences of the four different bases comprising DNA.
  • RIP encoding domain or “Ribosome Inactivating Protein encoding domain” as used here in means the functional domain which gives bouganin its biological activity.
  • the nucleic acid molecules of the invention may also be chemically synthesized using standard techniques.
  • Various methods of chemically synthesizing polydeoxynucleotides are known, including solid-phase synthesis which, like peptide synthesis, has been fully automated in commercially available DNA synthesizers (See e.g., Itakura et al. U.S. Pat. No. 4,598,049; Caruthers et al. U.S. Pat. No. 4,458,066; and Itakura U.S. Pat. Nos. 4,401,796 and 4,373,071).
  • the invention also provides nucleic acids encoding fusion proteins comprising a novel protein of the invention and a selected protein, or a selectable marker protein.
  • Another aspect of the present invention is a cultured cell comprising at least one of the above-mentioned vectors.
  • a further aspect of the present invention is a method for preparing the modified bouganin comprising culturing the above mentioned cell under conditions permitting expression of the modified bouganin from the expression vector and purifying the bouganin from the cell.
  • bouganin is a type 1 ribosome inactivating protein (RIP) that depurinates the major ribosomal RNA of cells leading to cessation of protein synthesis and cell death.
  • the modified bouganins of the invention can be used to prepare cytotoxins. Cytotoxins containing a modified bouganin protein are preferred over cytotoxins containing a non-modified bouganin protein as the former is less immunogenic and will be less likely to be destroyed by the immune system before it reaches its target.
  • the present invention also provides a cytotoxin comprising (a) a targeting moiety attached to (b) a modified bouganin protein of the invention.
  • modified bouganin protein of the invention is used for ease of referral and includes any and all of the modified bouganin proteins described herein such as the modified bouganin proteins described above in Section (A) as well as in the figures and examples.
  • targeting moiety refers to a substance, means, or technique of delivering the modified bouganin protein to a target cell.
  • the targeting moiety is an antibody.
  • the targeting moiety could be a liposome.
  • the liposome can be linked to an antibody.
  • the targeting moiety is a protein able to direct a specific binding interaction to a particular target cell.
  • Such protein moieties include a variety of polypeptide ligands for which there are specific cell surface receptors and include therefore numerous cytokines, peptide and polypeptide hormones and other biological response modifiers.
  • Prominent examples include such proteins as vascular epithelial growth factor, epidermal growth factor, heregulin, the interleukins, interferons, tumour necrosis factor and other protein and glycoprotein molecules. Fusion proteins of these and other molecules with bouganin of the present invention may be contemplated and may comprise the modified bouganin moiety in either the N-terminal or C-terminal orientation with respect to the protein ligand domain.
  • the targeting moiety may be jointed directly to the proteins of the invention or through a linker.
  • the linker is a peptide linker or a chemical linker. Equally, chemical cross-linking of the purified ligand to the modified bouganin protein may be contemplated and within the scope of the present invention.
  • the present invention provides a cytotoxin comprising (a) a ligand that binds to a cancer cell attached to; (b) a modified bouganin protein of the invention.
  • the ligand can be any molecule that can bind to a cancer cell including, but not limited to, proteins.
  • the ligand is an antibody or antibody fragment that recognizes the surface of a cancer cell.
  • the cytotoxins of the present invention may be used to treat various forms of cancer such as colorectal cancer, breast cancer, ovarian cancer, pancreatic cancer, head and neck cancer, bladder cancer, gastrointestinal cancer, prostate cancer, small cell and non small cell lung cancer, sarcomas, gliomas, T- and B-cell lymphomas.
  • cancer such as colorectal cancer, breast cancer, ovarian cancer, pancreatic cancer, head and neck cancer, bladder cancer, gastrointestinal cancer, prostate cancer, small cell and non small cell lung cancer, sarcomas, gliomas, T- and B-cell lymphomas.
  • the cancer cell binding ligand comprises a complete immunoglobulin molecule that binds to the cancer cell.
  • cytotoxin can be referred to as immunotoxin.
  • the cancer cell-binding ligand is a dimer of Fab, Fab′, scFv, single-domain antibody fragments, or disulfide stabilized Fv fragments.
  • the cancer antibody comprises a variable heavy chain, variable light chain, Fab, Fab′, scFv, single-domain antibody fragment, or disulfide-stabilized Fv fragment.
  • Portions of the cancer cell-binding ligand may be derived from one or more species, preferably comprising portions derived from the human species, and most preferably are completely human or humanized. Regions designed to facilitate purification or for conjugation to toxin may also be included in or added to the cancer cell-binding portion.
  • the cancer cell binding ligand recognizes Ep-CAM.
  • Ep-CAM for Epithelial Cell Adhesion Molecule, which is also known as 17-1A, KSA, EGP-2 and GA733-2
  • 17-1A, KSA, EGP-2 and GA733-2 is a transmembrane protein that is highly expressed in many solid tumors, including carcinomas of the lung, breast, ovary, colorectum, and squamous cell carcinoma of the head and neck, but weakly expressed in most normal epithelial tissues.
  • the invention provides an Ep-CAM-targeted-modified bouganin cytotoxin comprising (a) a ligand (such as an antibody or antibody fragment) that binds to Ep-CAM on the cancer cell attached to; (b) a modified bouganin protein having a reduced propensity to activate T-cells as compared to a non-modified bouganin protein.
  • a ligand such as an antibody or antibody fragment
  • the cytotoxin comprises (a) a humanized antibody or antibody fragment that binds to the extracellular domain of human Ep-CAM and comprises complementarity determining region (CDR) sequences derived from a MOC-31 antibody attached to: (b) a modified bouganin protein having a reduced propensity to activate T-cells as compared to a non-modified bouganin protein.
  • CDR complementarity determining region
  • Suitable Ep-CAM-targeted-modified bouganins include, without limitation, VB6-845 and variants thereof, other cytotoxins that comprises other single or double chain immunoglobulins that selectively bind Ep-CAM, or variants thereof.
  • VB6-845 as used herein means a cytotoxin that comprises a Fab version of an anti-Ep-CAM scFv antibody linked to a modified form of bouganin, Bou 156 (SEQ ID NO:13).
  • the amino acid sequence and nucleotide sequence of VB6-845 is shown in FIG. 3B (SEQ ID NO:16 and SEQ ID NO:15, respectively).
  • the cancer cell binding ligand recognizes a tumor-associated antigen that is found specifically on neoplastic cells and not on normal cells.
  • the ligand is an antibody that binds tumor-associated antigen.
  • the anti-tumor-associated-antigen antibody specifically recognizes cancer cells from a wide variety of cancers but does not recognize normal, non-cancerous cells.
  • the invention provides a cytotoxin comprising (a) ligand (such as an antibody or antibody fragment) that binds to tumor-associated antigen on the cancer cell attached to; (b) a modified bouganin protein having a reduced propensity to activate T-cells as compared to a non-modified bouganin protein.
  • ligand such as an antibody or antibody fragment
  • Suitable tumor-associated-antigen-targeted-modified bouganins include, without limitation, VB6-011 and variants thereof, other cytotoxins that comprises other single or double chain immunoglobulins that selectively bind tumor-associated-antigen, or variants thereof.
  • VB6-011 as used herein means a cytotoxin that comprises a Fab version of the H11 human monoclonal antibody genetically linked to a modified form of bouganin, BOU 156 (SEQ ID No. 13).
  • the H11 antibody was obtained by the fusion of peripheral blood lymphocytes of a 64 year old male cancer patient fused with a human myeloma cell line to produce hybridomas.
  • the hybridoma NBGM1/H11 produces an IgM k that was re-engineered into a Fab format to make VB6-011 (see U.S. Pat. No. 6,207,153 or WO 97/44461 for detail on the preparation of the H11 antibody-secreting hybridoma).
  • the amino acid sequence and nucleotide sequence of VB6-011 is shown in FIG. 15 (SEQ ID NO:28 and SEQ ID NO:27, respectively).
  • the cytotoxin comprises VB6-845 ( FIG. 3B , SEQ ID No. 16) or VB6-011 ( FIG. 15 , SEQ ID NO: 28). In other non-limiting embodiments, the cytotoxin comprises a variant of VB6-845 or VB6-011.
  • a VB6-845 variant binds to the same Ep-CAM epitope or to a substantially similar Ep-CAM epitope that is bound by VB6-845, and the variant may competitively inhibit VB6-845 binding to Ep-CAM, under physiologic conditions, by at least 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, or 95%.
  • a VB6-845 variant may comprise the same modified bouganin as VB6-845, or may comprise a different modified bouganin of the invention.
  • the cytotoxin comprises an Ep-CAM-binding portion comprising the variable region of MOC31, or a variant thereof.
  • the cytotoxin comprises an Ep-CAM-binding portion comprising 4D5MOCB, or a variant thereof. Binding of any of these cytotoxins to Ep-CAM may be reduced by at least 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, or 95% by competition with the reference MOC31 or 4D5MOCB antibody under physiologic conditions.
  • a VB6-011 variant binds to the same tumor-associated-antigen epitope or to a substantially similar tumor-associated-antigen epitope that is bound by VB6-011, and the variant may competitively inhibit VB6-011 binding to tumor-associated-antigen, under physiologic conditions, by at least 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, or 95%.
  • a VB6-011 variant may comprise the same modified bouganin as VB6-011, or may comprise a different modified bouganin of the invention.
  • the cytotoxin comprises a tumor-associated-antigen binding portion comprising the H11 monoclonal antibody, H11 antigen binding fragments, or variants thereof. Binding of any of these cytotoxins to VB6-011 may be reduced by at least 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, or 95% by competition with the reference H11 antibody under physiologic conditions.
  • the binding affinity of the Ep-CAM-binding portion or the tumor-associated-antigen-binding portion is at least four orders of magnitude, preferably at least three orders of magnitude, more preferably less than two orders of magnitude of the binding affinity of VB6-845 or VB6-011 respectively as measured by standard laboratory techniques.
  • the Ep-CAM-binding portion may competitively block the binding of a known anti-Ep-CAM antibody, such as, but not limited to, PANOREX® or MT201, to Ep-CAM, under physiologic conditions, by at least 0.1%, 1%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, or 95%.
  • a known anti-Ep-CAM antibody such as, but not limited to, PANOREX® or MT201
  • the tumor-associated-antigen-binding portion may competitively block the binding of a known anti-tumor-associated-antigen antibody, such as, but not limited to, H11, to tumor-associated antigen, under physiologic conditions, by at least 0.1%, 1%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, or 95%.
  • a known anti-tumor-associated-antigen antibody such as, but not limited to, H11
  • specificity determining residues can be identified.
  • SDR serum-derived resemiconductor
  • CDR residues the individual substitution of which by alanine, independently of any other mutations, diminishes the affinity of the antibody for the epitope by at least 10 fold, preferably by at least 100 fold, more preferably by at least 1000 fold. This loss in affinity underscores that residue's importance in the ability of the antibody to bind the epitope.
  • the effect of single or multiple mutations on binding activity, particularly on binding affinity, may be evaluated contemporaneously to assess the importance of a particular series of amino acids on the binding interaction (e.g., the contribution of the light or heavy chain CDR2 to binding). Effects of an amino acid mutation may also be evaluated sequentially to assess the contribution of a single amino acid when assessed individually. Such evaluations can be performed, for example, by in vitro saturation scanning (see, e.g., U.S. Pat. No. 6,180,341; Hilton et al., 1996, “Saturation mutagenesis of the WSXWS motif of the erythropoietin receptor,” J Biol. Chem.
  • Sites of ligand-receptor or other biological interaction can also be identified by physical analysis of structure as determined by, for example, nuclear magnetic resonance, crystallography, electron diffraction, or photoaffinity labeling, in conjunction with mutation of putative contact site amino acids (see, e.g., de Vos et al., 1992, “Human growth hormone and extracellular domain of its receptor: crystal structure of the complex,” Science 255:306-312; Smith et al., 1992, “Human interleukin 4 The solution structure of a four-helix bundle protein,” J Mol Biol.
  • the avidity of a cytotoxin for a cancer cell receptor is a measure of the strength of the Ep-CAM-binding portion's binding of Ep-CAM, which has multiple binding sites.
  • the functional binding strength between Ep-CAM and the Ep-CAM-binding portion represents the sum strength of all the affinity bonds, and thus an individual component may bind with relatively low affinity, but a multimer of such components may demonstrate potent biological effect.
  • the multiple interactions between Ep-CAM-binding sites and Ep-CAM epitopes may demonstrate much greater than additive biological effect, i.e., the advantage of multivalence can be many orders of magnitude with respect to the equilibrium constant.
  • the avidity of a cytotoxin for a cancer cell receptor is a measure of the strength of the tumor-associated antigen-binding portion's binding of tumor-associated antigen, which may have multiple binding sites.
  • the functional binding strength between tumor-associated antigen and the tumor-associated antigen-binding portion represents the sum strength of all the affinity bonds, and thus an individual component may bind with relatively low affinity, but a multimer of such components may demonstrate potent biological effect.
  • the multiple interactions between tumor-associated antigen-binding sites and tumor-associated antigen epitopes may demonstrate much greater than additive biological effect, i.e., the advantage of multivalence can be many orders of magnitude with respect to the equilibrium constant.
  • the Ep-CAM-binding portion has a structure substantially similar to that of 4D5MOCB.
  • the substantially similar structure can be characterized by reference to epitope maps that reflect the binding points of the cytotoxin's Ep-CAM-binding portion to an Ep-CAM molecule.
  • epitope maps can be generated for the tumor-associated antigen binding portion and a substantially similar structure can be characterized by reference to epitope maps that reflect the binding points of the cytotoxin's tumor-associated antigen binding portion to a tumor-associated antigen molecule.
  • the cytotoxins of the present invention may be prepared by chemical synthesis using techniques well known in the chemistry of proteins such as solid phase synthesis (Merrifield, J. Am. Chem. Assoc . 85:2149-2154 (1964)) or synthesis in homogenous solution (Houbenweyl, Methods of Organic Chemistry, ed. E. Wansch, Vol. 15 I and II, Thieme, Stuttgart (1987)).
  • the cancer-binding ligand and modified bouganin are both proteins and can be conjugated using techniques well known in the art.
  • crosslinkers available that can conjugate two proteins. See for example “Chemistry of Protein Conjugation and Crosslinking”. 1991, Shans Wong, CRC Press, Ann Arbor).
  • the crosslinker is generally chosen based on the reactive functional groups available or inserted on the ligand or toxin. In addition, if there are no reactive groups a photoactivatible crosslinker can be used. In certain instances, it may be desirable to include a spacer between the ligand and the toxin.
  • Crosslinking agents known to the art include the homobifunctional agents: glutaraldehyde, dimethyladipimidate and Bis(diazobenzidine) and the heterobifunctional agents: m Maleimidobenzoyl-N-Hydroxysuccinimide and Sulfo-m Maleimidobenzoyl-N-Hydroxysuccinimide.
  • a ligand-bouganin toxin fusion protein may also be prepared using recombinant DNA techniques.
  • a DNA sequence encoding the cancer-binding ligand is fused to a DNA sequence encoding the modified bouganin protein, resulting in a chimeric DNA molecule.
  • the chimeric DNA sequence is transfected into a host cell that expresses the ligand-bouganin fusion protein.
  • the fusion protein can be recovered from the cell culture and purified using techniques known in the art.
  • Antibodies having specificity for cell surface proteins such as Ep-CAM and tumor-associated antigen may be prepared by conventional methods.
  • a mammal e.g. a mouse, hamster, or rabbit
  • an immunogenic form of the peptide which elicits an antibody response in the mammal.
  • Techniques for conferring immunogenicity on a peptide include conjugation to carriers or other techniques well known in the art.
  • the peptide can be administered in the presence of adjuvant.
  • the progress of immunization can be monitored by detection of antibody titers in plasma or serum. Standard ELISA or other immunoassay procedures can be used with the immunogen as antigen to assess the levels of antibodies.
  • antisera can be obtained and, if desired, polyclonal antibodies isolated from the sera.
  • antibody-producing cells can be harvested from an immunized animal and fused with myeloma cells by standard somatic cell fusion procedures thus immortalizing these cells and yielding hybridoma cells.
  • myeloma cells can be harvested from an immunized animal and fused with myeloma cells by standard somatic cell fusion procedures thus immortalizing these cells and yielding hybridoma cells.
  • somatic cell fusion procedures thus immortalizing these cells and yielding hybridoma cells.
  • Such techniques are well known in the art, (e.g. the hybridoma technique originally developed by Kohler and Milstein ( Nature 256:495-497 (1975)) as well as other techniques such as the human B-cell hybridoma technique (Kozbor et al., Immunol.
  • Hybridoma cells can be screened immunochemically for production of antibodies specifically reactive with the peptide and the monoclonal antibodies can be isolated.
  • antibody as used herein is intended to include monoclonal antibodies and polyclonal antibodies, antibody fragments (e.g. Fab and F(ab′) 2 , and single chain antibodies (scFv)), and chimeric antibodies which also specifically react with a cell surface component.
  • Antibodies can be fragmented using conventional techniques and the fragments screened for utility in the same manner as described above. For example, F(ab′) 2 fragments can be generated by treating antibody with pepsin. The resulting F(ab′) 2 fragment can be treated to reduce disulfide bridges to produce Fab′ fragments.
  • Single chain antibodies combine the antigen-binding regions of an antibody on a single stably folded polypeptide chain. Single chain antibodies can be generated by recombinant technology.
  • Chimeric antibody derivatives i.e., antibody molecules that combine a non-human animal variable region and a human constant region are also contemplated within the scope of the invention.
  • Chimeric antibody molecules can include, for example, the antigen binding domain from an antibody of a mouse, rat, or other species, with human constant regions.
  • Conventional methods may be used to make chimeric antibodies containing the immunoglobulin variable region which recognizes a cell surface antigen (See, for example, Morrison et al., Proc. Natl Acad. Sci. U.S.A . 81:6851 (1985); Takeda et al., Nature 314:452 (1985), Cabilly et al., U.S. Pat. No.
  • Monoclonal or chimeric antibodies specifically reactive against cell surface components can be further humanized by producing human constant region chimeras, in which parts of the variable regions, particularly the conserved framework regions of the antigen-binding domain, are of human origin and only the hypervariable regions are of non-human origin.
  • Such immunoglobulin molecules may be made by techniques known in the art, (e.g. Teng et al., Proc. Natl. Acad. Sci. U.S.A ., 80:7308-7312 (1983); Kozbor et al., Immunology Today 4:7279 (1983); Olsson et al., Meth.
  • Humanized antibodies can also be commercially produced (Scotgen Limited, 2 Holly Road, Twickenham, Middlesex, Great Britain.)
  • monoclonal or chimeric antibodies specifically reactive against cell surface components can be made less immunogenic by reducing their number of potential T-cell epitopes.
  • Specific antibodies, or antibody fragments, reactive against cell surface components may also be generated by screening expression libraries encoding immunoglobulin genes, or portions thereof, expressed in bacteria with cell surface components.
  • complete Fab fragments, VH regions and Fv regions can be expressed in bacteria using phage expression libraries (See for example Ward et al., Nature 341:544-546 (1989); Huse et al., Science 246:1275-1281 (1989); and McCafferty et al., Nature 348:552-554 (1990)).
  • phage expression libraries See for example Ward et al., Nature 341:544-546 (1989); Huse et al., Science 246:1275-1281 (1989); and McCafferty et al., Nature 348:552-554 (1990)).
  • SCID-hu mouse for example the model developed by Genpharm, can be used to produce antibodies, or fragments thereof.
  • a modified bouganin protein is made in fusion with an antibody sequence it is most desired to use antibody sequences in which T cell epitopes or sequences able to bind MHC class II molecules or stimulate T cells or bind to T cells in association with MHC class II molecules have been removed.
  • the modified bouganin protein may be linked to a non-antibody protein yet a protein able to direct a specific binding interaction to a particular target cell.
  • protein moieties include a variety of polypeptide ligands for which there are specific cell surface receptors and include therefore numerous cytokines, peptide and polypeptide hormones and other biological response modifiers.
  • Prominent examples include such proteins as vascular epithelial growth factor, epidermal growth factor, heregulin, the interleukins, interferons, tumour necrosis factor and other protein and glycoprotein molecules.
  • Fusion proteins of these and other molecules with bouganin of the present invention may be contemplated and may comprise the modified bouganin moiety in either the N-terminal or C-terminal orientation with respect to the protein ligand domain. Equally, chemical cross-linking of the purified ligand to the modified bouganin protein may be contemplated and within the scope of the present invention.
  • the modified bouganin protein of the present invention may be used as a complex containing a water soluble polymer such as hydroxypropylmethacrylamide or other polymers where the modified bouganin protein is in covalent attachment to the polymer or in a non-covalent binding interaction with the polymer.
  • a water soluble polymer such as hydroxypropylmethacrylamide or other polymers
  • Such an embodiment may additionally include an antigen binding domain such as an antibody or a fragment of an antibody in combination with the polymer bouganin complex.
  • the modified bouganin proteins of the invention may be used to specifically inhibit or destroy mammalian cells affected by cancer. It is an advantage of the cytotoxins of the invention that they have less immunogenicity, allowing the RIP to enter the cell and effectively kill the cancer cell. Thus, the cytotoxin may be used to specifically target cancer cells.
  • the bouganin once in the cancer cell, depurinates the major ribosomal RNA, thereby damaging the ribosomes and leading to a cessation of protein synthesis and cell death.
  • the invention provides a method of inhibiting or destroying a cancer cell comprising administering a cytotoxin of the invention to an animal in need thereof.
  • the present invention also includes a use of a cytotoxin of the invention to inhibit or destroy a cancer cell.
  • the present invention further includes a use of a cytotoxin of the invention in the manufacture of a medicament to inhibit or destroy a cancer cell.
  • the type of cancer cells that are inhibited or destroyed by a cytotoxin will be determined by the antigen specificity of its antibody portion.
  • the invention provides a method of inhibiting or destroying cancer cells comprising the steps of preparing a cytotoxin of the invention and administering the cytotoxin to the cells.
  • the cancer can be any type of cancer, including, but not limited to, colorectal cancer, breast cancer, ovarian cancer, pancreatic cancer, head and neck cancer, bladder cancer, liver cancer, renal cancer, melanomas, gastrointestinal cancer, prostate cancer, small cell and non small cell lung cancer, sarcomas, gliomas, T- and B-cell lymphomas.
  • the ability of the cytotoxins of the invention to selectively inhibit or destroy animal cancer cells may be readily tested in vitro using animal cancer cell lines.
  • the selective inhibitory effect of the cytotoxins of the invention may be determined, for example, by demonstrating the selective inhibition of cellular proliferation in cancer cells.
  • Toxicity may be measured based on cell viability, for example the viability of normal and cancerous cell cultures exposed to the cytotoxins may be compared. Cell viability may be assessed by known techniques, such as trypan blue exclusion assays.
  • a number of models may be used to test the cytotoxicity of cytotoxins.
  • Thompson, E. W. et al. Breast Cancer Res. Treatment 31:357-370 (1994)
  • Other applicable cancer cell models include cultured ovarian adenocarcinoma cells (Young, T. N. et al. Gynecol. Oncol. 62:89-99 (1996); Moore, D. H. et al. Gynecol. Oncol.
  • the present invention also relates to a method of treating cancer comprising administering an effective amount of one or more cytotoxins of the present invention to an animal in need thereof.
  • the invention includes a use of a cytotoxin of the invention to treat cancer.
  • the invention further includes a use of a cytotoxin of the invention in the manufacture of a medicament for treating cancer.
  • animal includes all members of the animal kingdom, including humans.
  • treating cancer refers to inhibition of cancer cell replication, inhibition of cancer spread (metastasis), inhibition of tumor growth, reduction of cancer cell number or tumor growth, decrease in the malignant grade of a cancer or improvement of cancer related symptoms.
  • the animal is human.
  • the cancer is selected from the group consisting of colorectal cancer, breast cancer, ovarian cancer, pancreatic cancer, head and neck cancer, bladder cancer, liver cancer, renal cancer, melanomas, gastrointestinal cancer, prostate cancer, small cell and non small cell lung cancer, sarcomas, gliomas and T- and B-cell lymphomas.
  • Clinical outcomes of cancer treatments using a cytotoxin of the invention are readily discernible by one of skill in the relevant art, such as a physician.
  • standard medical tests to measure clinical markers of cancer may be strong indicators of the treatment's efficacy. Such tests may include, without limitation, physical examination, performance scales, disease markers, 12-lead ECG, tumor measurements, tissue biopsy, cytoscopy, cytology, longest diameter of tumor calculations, radiography, digital imaging of the tumor, vital signs, weight, recordation of adverse events, assessment of infectious episodes, assessment of concomitant medications, pain assessment, blood or serum chemistry, urinalysis, CT scan, and pharmacokinetic analysis.
  • synergistic effects of a combination therapy comprising the cytotoxin and another cancer therapeutic may be determined by comparative studies with patients undergoing monotherapy.
  • Remission malignant tumors may be evaluated using criteria accepted by the skilled artisan. See, e.g., Therasse et al., 2000, “New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada,” J Natl Cancer Inst. Feb 2; 92(3):205-16.
  • the effective dose of a specific cytotoxin construct may depend on various factors, including the type of cancer, the size of the tumour, the stage of the cancer, the cytotoxin's toxicity to the patient, the specificity of targeting to cancer cells, as well as the age, weight, and health of the patient.
  • Cytotoxins comprising the modified bouganin can be administered by i.v. infusion over a period of minutes to hours, depending on the dose and the concentration of the cytotoxin in the infusate.
  • the cytotoxin is infused over a period of 3 hours.
  • the effective dose by i.v. administration of cytotoxin may range from about 1 to 100 mg/kg/dose. In other embodiments, the dose may range from approximately 2 to 50 mg/kg/dose. In specific embodiments, the dose may be at least approximately 2, 4, 8, 13, 20, 28, 40, 50 mg/kg/dose.
  • the single dose is administered approximately every week for approximately 1, 2, 3, 4, 5, or 6 weeks.
  • the single dose can be administered in consecutive weeks or, alternatively, one or more weeks can be skipped. After this cycle, a subsequent cycle may begin approximately 1, 2, 4, 6, or 12 weeks later.
  • the treatment regime may include 1, 2, 3, 4, 5, 6 or more cycles, each cycle being spaced apart by approximately 1, 2, 4, 6, or 12 weeks.
  • the single dose is administered every month for approximately 1, 2, 3, 4, 5, or 6 consecutive months. After this cycle, a subsequent cycle may begin approximately 1, 2, 4, 6, or 12 months later.
  • the treatment regime may include 1, 2, 3, 4, 5, 6 or more cycles, each cycle being spaced apart by approximately 1, 2, 4, 6, or 12 months.
  • the effective dose of the cytotoxin is between about 1 and 50 mg/kg/tumor/day, wherein the patient is administered a single dose per day.
  • the single dose is administered approximately every day (one or more days may optionally be skipped) for approximately 1, 2, 3, 4, 5, 6 or 7 consecutive days. After this cycle, a subsequent cycle may begin approximately 1, 2, 3, 4, 5, or 6 weeks later.
  • the treatment regime may include 1, 2, 3, 4, 5, 6 or more cycles, each cycle being spaced apart by approximately 1, 2, 3, 4, 5, or 6 weeks.
  • the injection volume preferably is at least an effective amount, which is appropriate to the type and/or location of the tumor.
  • the maximum injection volume in a single dose may be between about 25% and 75% of tumor volume, for example approximately one-quarter, one-third, or three-quarters of the estimated target tumor volume. In a specific, non-limiting embodiment, the maximum injection volume in a single dose is approximately 30% of the tumor volume.
  • the cytotoxin is infused for 3 hours at a rate of 100 cc per hour with a solution containing from 1 to 10 mg cytotoxin/mL.
  • the cytotoxin will be diluted in a suitable physiologically compatible solution.
  • the effective dose of another cancer therapeutic to be administered together with a cytotoxin during a cycle also varies according to the mode of administration.
  • the one or more cancer therapeutics may be delivered intratumorally, or by other modes of administration.
  • chemotherapeutic agents are administered systemically. Standard dosage and treatment regimens are known in the art (see, e.g., the latest editions of the Merck Index and the Physician's Desk Reference; NCCN Practice Guidelines in Oncology)).
  • Combination therapy with a cytotoxin may sensitize the cancer or tumor to administration of an additional cancer therapeutic.
  • the present invention contemplates combination therapies for preventing, treating, and/or preventing recurrence of cancer comprising administering an effective amount of a cytotoxin prior to, subsequently, or concurrently with a reduced dose of a cancer therapeutic.
  • initial treatment with a cytotoxin may increase the sensitivity of a cancer or tumor to subsequent challenge with a dose of cancer therapeutic. This dose is near, or below, the low range of standard dosages when the cancer therapeutic is administered alone, or in the absence of a cytotoxin.
  • the cytotoxin may be administered separately from the cancer therapeutic, and optionally, via a different mode of administration.
  • a cytotoxin is administered in combination with at least one other immunotherapeutic.
  • a cytotoxin is administered in combination with a regimen of radiation therapy.
  • the therapy may also comprise surgery and/or chemotherapy.
  • the cytotoxin may be administered in combination with radiation therapy and cisplatin (Platinol), fluorouracil (5-FU, Adrucil), carboplatin (Paraplatin), and/or paclitaxel (Taxol).
  • Treatment with the cytotoxin may allow use of lower doses of radiation and/or less frequent radiation treatments, which may for example, reduce the incidence of severe sore throat that impedes swallowing function potentially resulting in undesired weight loss or dehydration.
  • a cytotoxin is administered in combination with one or more cytokines which include, without limitation, a lymphokine, tumor necrosis factors, tumor necrosis factor-like cytokine, lymphotoxin, interferon, macrophage inflammatory protein, granulocyte monocyte colony stimulating factor, interleukin (including, without limitation, interleukin-1, interleukin-2, interleukin-6, interleukin-12, interleukin-15, interleukin-18), and a variant thereof, including a pharmaceutically acceptable salt thereof
  • a cytotoxin is administered in combination with a cancer vaccine including, without limitation, autologous cells or tissues, non-autologous cells or tissues, carcinoembryonic antigen, alpha-fetoprotein, human chorionic gonadotropin, BCG live vaccine, melanocyte lineage proteins, and mutated, tumor-specific antigens.
  • a cancer vaccine including, without limitation, autologous cells or tissues, non-autologous cells or tissues, carcinoembryonic antigen, alpha-fetoprotein, human chorionic gonadotropin, BCG live vaccine, melanocyte lineage proteins, and mutated, tumor-specific antigens.
  • a cytotoxin is administered in association with hormonal therapy.
  • Hormonal therapeutics include, without limitation, a hormonal agonist, hormonal antagonist (e.g., flutamide, tamoxifen, leuprolide acetate (LUPRON)), and steroid (e.g., dexamethasone, retinoid, betamethasone, cortisol, cortisone, prednisone, dehydrotestosterone, glucocorticoid, mineralocorticoid, estrogen, testosterone, progestin).
  • a hormonal agonist e.g., flutamide, tamoxifen, leuprolide acetate (LUPRON)
  • steroid e.g., dexamethasone, retinoid, betamethasone, cortisol, cortisone, prednisone, dehydrotestosterone, glucocorticoid, mineralocorticoid, estrogen, testosterone, progest
  • a cytotoxin is administered in association with a gene therapy program to treat or prevent cancer.
  • an Ep-CAM-targeted cytotoxin is administered in combination with one or more agents that increase expression of Ep-CAM in the tumor cells of interest.
  • Ep-CAM expression preferably is increased so that a greater number of Ep-CAM molecules are expressed on the tumor cell surface.
  • the agent may inhibit the normal cycles of Ep-CAM antigen endocytosis.
  • Such combination treatment may improve the clinical efficacy of the Ep-CAM-targeted cytotoxin alone, or with other cancer therapeutics or radiation therapy.
  • the agent which increases Ep-CAM expression in the tumor cells is vinorelbine tartrate (Navelbine) and/or paclitax (Taxol).
  • Combination therapy may thus increase the sensitivity of the cancer or tumor to the administered cytotoxin and/or additional cancer therapeutic. In this manner, shorter treatment cycles may be possible thereby reducing toxic events.
  • the invention provides a method for treating or preventing cancer comprising administering to a patient in need thereof an effective amount of a cytotoxin and at least one other cancer therapeutic for a short treatment cycle.
  • the cycle duration may vary according to the specific cancer therapeutic in use.
  • the invention also contemplates continuous or discontinuous administration, or daily doses divided into several partial administrations.
  • An appropriate cycle duration for a specific cancer therapeutic will be appreciated by the skilled artisan, and the invention contemplates the continued assessment of optimal treatment schedules for each cancer therapeutic. Specific guidelines for the skilled artisan are known in the art.
  • the cycle duration may range from approximately 10 to 56, 12 to 48, 14 to 28, 16 to 24, or 18 to 20 days.
  • the cycle duration may vary according to the specific cancer therapeutic in use.
  • the present invention contemplates at least one cycle, preferably more than one cycle during which a single cancer therapeutic or series of therapeutics is administered.
  • An appropriate total number of cycles, and the interval between cycles, will be appreciated by the skilled artisan.
  • the number of cycles may be 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13,14, 15, 16, 17, 18, 19, 20, or 21 cycles.
  • the interval between cycles may be 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13,14, 15, 16, 17, 18, 19, 20, or 21 days.
  • the invention contemplates the continued assessment of optimal treatment schedules for each cytotoxin and additional cancer therapeutic.
  • a process for preparing a pharmaceutical for treating a mammal with cancer comprising the steps of identifying T-cell epitopes of bouganin having reduced propensity for activated T-cells; preparing a cytotoxin of the invention having one or more of the T-cell epitopes and suspending the protein in a pharmaceutically acceptable carrier, diluent or excipient.
  • the invention also provides a pharmaceutical composition for treating a mammal with cancer comprising a cytotoxin of the invention and a pharmaceutically acceptable carrier, diluent or excipient.
  • the cytotoxins of the invention may be formulated into pharmaceutical compositions for administration to subjects in a biologically compatible form suitable for administration in vivo.
  • biologically compatible form suitable for administration in vivo is meant a form of the substance to be administered in which any toxic effects are outweighed by the therapeutic effects.
  • the substances may be administered to living organisms including humans, and animals.
  • Administration of a therapeutically active amount of the pharmaceutical compositions of the present invention is defined as an amount effective, at dosages and for periods of time necessary to achieve the desired result.
  • a therapeutically active amount of a substance may vary according to factors such as the disease state, age, sex, and weight of the individual, and the ability of antibody to elicit a desired response in the individual. Dosage regime may be adjusted to provide the optimum therapeutic response. For example, several divided doses may be administered daily or the dose may be proportionally reduced as indicated by the exigencies of the therapeutic situation.
  • the active substance may be administered in a convenient manner such as by injection (subcutaneous, intravenous, intramuscular, etc.), oral administration, inhalation, transdermal administration (such as topical cream or ointment, etc.), or suppository applications.
  • the active substance may be coated in a material to protect the compound from the action of enzymes, acids and other natural conditions which may inactivate the compound.
  • compositions described herein can be prepared by per se known methods for the preparation of pharmaceutically acceptable compositions which can be administered to subjects, such that an effective quantity of the active substance is combined in a mixture with a pharmaceutically acceptable vehicle.
  • Suitable vehicles are described, for example, in Remington's Pharmaceutical Sciences (Remington's Pharmaceutical Sciences, Mack Publishing Company, Easton, Pa., USA 1985).
  • the compositions include, albeit not exclusively, solutions of the substances in association with one or more pharmaceutically acceptable vehicles or diluents, and contained in buffered solutions with a suitable pH and iso-osmotic with the physiological fluids.
  • compositions may be used in methods for treating animals, including mammals, preferably humans, with cancer. It is anticipated that the compositions will be particularly useful for treating patients with colorectal cancer, breast cancer, ovarian cancer, pancreatic cancer, head and neck cancer, bladder cancer, gastrointestinal cancer, prostate cancer, small cell and non small cell lung cancer, sarcomas, gliomas, T- and B-cell lymphomas.
  • the dosage and type of cytotoxin to be administered will depend on a variety of factors which may be readily monitored in human subjects. Such factors include the etiology and severity (grade and stage) of neoplasia.
  • compositions adapted for direct administration include, without limitation, lyophilized powders or aqueous or non-aqueous sterile injectable solutions or suspensions, which may further contain antioxidants, buffers, bacteriostats and solutes that render the compositions substantially isotonic with the blood of an intended recipient.
  • Other components that may be present in such compositions include water, alcohols, polyols, glycerin and vegetable oils, for example.
  • Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules and tablets.
  • Cytotoxin may be supplied, for example but not by way of limitation, as a lyophilized powder which is reconstituted with sterile water or saline prior to administration to the patient.
  • compositions of the invention may comprise a pharmaceutically acceptable carrier.
  • suitable pharmaceutically acceptable carriers include essentially chemically inert and nontoxic compositions that do not interfere with the effectiveness of the biological activity of the pharmaceutical composition.
  • suitable pharmaceutical carriers include, but are not limited to, water, saline solutions, glycerol solutions, ethanol, N-(1(2,3-dioleyloxy)propyl)N,N,N-trimethylammonium chloride (DOTMA), diolesylphosphotidyl-ethanolamine (DOPE), and liposomes.
  • DOTMA N-(1(2,3-dioleyloxy)propyl)N,N,N-trimethylammonium chloride
  • DOPE diolesylphosphotidyl-ethanolamine
  • liposomes Such compositions should contain a therapeutically effective amount of the compound, together with a suitable amount of carrier so as to provide the form for direct administration to the patient.
  • a pharmaceutical composition comprises a cytotoxin and one or more additional cancer therapeutics, optionally in a pharmaceutically acceptable carrier.
  • composition may be in the form of a pharmaceutically acceptable salt which includes, without limitation, those formed with free amino groups such as those derived from hydrochloric, phosphoric, acetic, oxalic, tartaric acids, etc., and those formed with free carboxyl groups such as those derived from sodium, potassium, ammonium, calcium, ferric hydroxides, isopropylamine, triethylamine, 2-ethylarnino ethanol, histidine, procaine, etc.
  • a pharmaceutically acceptable salt which includes, without limitation, those formed with free amino groups such as those derived from hydrochloric, phosphoric, acetic, oxalic, tartaric acids, etc.
  • free carboxyl groups such as those derived from sodium, potassium, ammonium, calcium, ferric hydroxides, isopropylamine, triethylamine, 2-ethylarnino ethanol, histidine, procaine, etc.
  • compositions containing such modified bouganin proteins or fragments of modified bouganin proteins and related compositions should be considered within the scope of the invention.
  • a pertinent example in this respect could be development of peptide mediated tolerance induction strategies wherein one or more of the disclosed peptides is administered to a patient with immunotherapeutic intent.
  • synthetic peptides molecules for example one of more of comprising all or part of any of the epitope regions R1-R3 as defined above. Such peptides are considered embodiments of the invention.
  • any of the modified compositions would be produced to be preferably at least 80% pure and free of pyrogens and other contaminants.
  • the present invention also provides a kit comprising an effective amount of a cytotoxin, optionally, in combination with one or more other cancer therapeutics, together with instructions for the use thereof to treat the cancer.
  • An additional embodiment of the invention is a T-cell epitope peptide.
  • the T-cell epitope peptide is able to evoke a stimulation index of greater than 1.8 in a T-cell assay, more preferably greater than 2.0.
  • the T-cell epitope peptide of the invention is able to bind MHC class II.
  • the T-cell epitope peptide comprises at least 9 consecutive amino acid residues from any of the sequences of R1, R2 or R3 (above).
  • the T-cell epitope peptide sequence has greater than 90% amino acid identity with any one of the peptide sequences R1, R2 or R3; more preferably the T-cell epitope peptide has greater than 80% amino acid identity with any one of the peptide sequences R1, R2 or R3.
  • peptide as used herein is a compound that includes two or more amino acids.
  • the amino acids are linked together by a peptide bond (defined herein below).
  • There are 20 different naturally occurring amino acids involved in the biological production of peptides and any number of them may be linked in any order to form a peptide chain or ring.
  • the naturally occurring amino acids employed in the biological production of peptides all have the L-configuration.
  • Synthetic peptides can be prepared employing conventional synthetic methods, utilizing L-amino acids, D-amino acids, or various combinations of amino acids of the two different configurations. Some peptides contain only a few amino acid units.
  • Short peptides e.g., having less than ten amino acid units, are sometimes referred to as “oligopeptides”.
  • Other peptides contain a large number of amino acid residues, e.g. up to 100 or more, and are referred to as “polypeptides”.
  • a “polypeptide” may be considered as any peptide chain containing three or more amino acids, whereas an “oligopeptide” is usually considered as a particular type of “short” polypeptide.
  • any reference to a “polypeptide” also includes an oligopeptide.
  • any reference to a “peptide” includes polypeptides, oligopeptides, and proteins. Each different arrangement of amino acids forms different polypeptides or proteins. The number of polypeptides—and hence the number of different proteins—that can be formed is practically unlimited.
  • Another embodiment of the invention is the use of the T-cell epitope peptides of the invention to make the modified bouganin proteins of the invention and modified T-cell epitope peptides.
  • a further embodiment of the invention is a modified T-cell epitope peptide that is modified such that the modified T-cell epitope peptide has reduced propensity to activate human T cells than the non-modified T-cell epitope peptide.
  • the modified T-cell epitope peptides of the invention contains modifications such that when tested in a T-cell assay evokes a reduced stimulation index in comparison to the non-modified T-cell epitope peptide.
  • AK X 1 DRK X 2 L X 3 LGV X 4 KL wherein at least one of X 1 , X 2 , X 3 , and X 4 is modified from the non-modified sequence, as follows:
  • X 1 is T or A or Q
  • X 2 is G or A
  • X 3 is Q or G
  • X 4 is N or D or T or A or R or Q or E or G or H or K or S (SEQ ID NO:8).
  • LGV X 4 KLEFSIEAIHG wherein X 4 is N or D or T or A or R or Q or E or G or H or K or S (SEQ ID NO:9).
  • the invention also provides nucleic acid molecules encoding the T-cell epitope peptides or modified T-cell epitope peptides of the invention.
  • the peptides were used in T-cell proliferation assays with PBMCs (peripheral blood mononuclear cells) from na ⁇ ve donors (i.e. no known sensitization to bouganin) 20 donor PBMC were selected to get an optimal coverage of MHC class II allotypes.
  • the allotypic coverage is in excess of 85%.
  • the HLA-DR allotypes are shown in TABLE 2.
  • PBMCs were stimulated with individual peptides in triplicate cultures for 7 days before proliferation was assessed by 3 H-thymidine ( 3 H-Thy) incorporation. All peptides were tested at two different concentrations (1 ⁇ M and 5 ⁇ M). Stimulation indices (S.I.) were calculated as the amount of 3 H incorporated, divided by the amount of 3 H incorporated in mock-stimulated control cells.
  • Buffy coats from human blood stored for less than 12 hours were obtained from the National Blood Service (Addenbrooks Hospital, Cambridge, UK). Ficoll-paque was obtained from Amersham Pharmacia Biotech (Amersham, UK). Serum free AIM V media for the culture of primary human lymphocytes and containing L-glutamine, 50 ⁇ g/ml streptomycin, 10 ⁇ g/m gentomycin and 0.1% human serum albumin was from Gibco-BRL (Paisley, UK). Synthetic peptides were obtained from Eurosequence (Groningen, The Netherlands) and Babraham Technix (Cambridge, UK).
  • Erythrocytes and leukocytes were separated from plasma and platelets by gentle centrifugation of buffy coats. The top phase (containing plasma and platelets) was removed and discarded. Erythrocytes and leukocytes were diluted 1:1 in phosphate buffered saline (PBS) before layering onto 15 ml ficoll-paque (Amersham Pharmacia, Amersham UK). Centrifugation was done according to the manufacturers recommended conditions and PBMCs were harvested from the serum+PBS/ficoll paque interface. PBMCs were mixed with PBS (1:1) and collected by centrifugation. The supernatant was removed and discarded and the PBMC pellet resuspended in 50 ml PBS.
  • PBS phosphate buffered saline
  • Cells were again pelleted by centrifugation and the PBS supernatant discarded. Cells were resuspended using 50 ml AIM V media and at this point counted and viability assessed using trypan blue dye exclusion. Cells were again collected by centrifugation and the supernatant discarded. Cells were resuspended for cryogenic storage at a density of 3 ⁇ 10 7 per ml. The storage medium was 90% (v/v) heat inactivated AB human serum (Sigma, Poole, UK) and 10% (v/v) DMSO (Sigma, Poole, UK). Cells were transferred to a regulated freezing container (Sigma) and placed at ⁇ 70° C. overnight. When required for use, cells were thawed rapidly in a water bath at 37° C. before transferring to 10 ml pre-warmed AIM V medium.
  • PBMC peripheral blood mononuclear cells
  • Peptides were dissolved in DMSO to a final concentration of 10 mM, these stock solutions were then diluted 1/500 in AIM V media (final concentration 20 ⁇ M). Peptides were added to a flat bottom 96 well plate to give a final concentration of 1 and 5 ⁇ M in 100 ⁇ l. The viability of thawed PBMC's was assessed by trypan blue dye exclusion, cells were then resuspended at a density of 2 ⁇ 10 6 cells/ml, and 100 ⁇ l (2 ⁇ 10 5 PBMC/well) was transferred to each well containing peptides. Triplicate well cultures were assayed at each peptide concentration. Plates were incubated for 7 days in a humidified atmosphere of 5% CO 2 at 37° C.
  • Results were expressed as stimulation indices, derived by division of the proliferation score (e.g. counts per minute of radioactivity) measured to the test peptide by the score measured in cells not contacted with a test peptide.
  • Compilation of the results of the above assay indicates the presence of four T cell epitopes, corresponding to peptides 41, 44 and 50 in the mature, processed region of the protein and peptide 88 in the unprocessed form. Since the epitope in peptide 88 is not part of the mature protein, it is ignored under the scheme of the present invention.
  • peptide 41 (termed epitope region R1) there were four responsive donors to this peptide; donors 4, 5, 10 and 11.
  • the S.I.s for these at 5 ⁇ M are 3.6, 4.9, 2.1 and 2.0 respectively.
  • tissue types for all PBMC samples were assayed using a commercially available reagent system (Dynal, Wirral, UK). Assays were conducted in accordance with the suppliers recommended protocols and standard ancillary reagents and agarose electrophoresis systems. The allotypic specificities of each of the responsive donor samples is given in TABLE 2.
  • the bouganin gene was transferred into the pET21a (Novagen, Nottingham, UK) by PCR cloning using the pBoul plasmid as a template.
  • a pelB (pectate lyase) leader sequence was added to the 5′ end, and a sequence encoding a 6 ⁇ histidine tag was added to the 3′ end of the bouganin coding sequence.
  • the pelB leader was amplified from vector pPMI-his [Molloy, P. et al, (1995) J. Applied Bacteriology, 78: 359-365] using primer OL1322 (incorporating an Nde1 site) and primer OL1067.
  • the bouganin-his fragment was amplified from pBoul using OL1068 and OL1323 (incorporating a Not1 site).
  • the pelB leader was fused in frame to the bouganin-his fragment using overlap PCR, and the resulting fragment cloned into pGEM-T Easy (Promega).
  • the pelB-bouganin-his fragment was cloned as a Nde1-Not1 fragment into Nde1-Not1 digested pET21a. This clone was designated pBou32.
  • modified (mutant) bouganin proteins were designed using data provided by the T-cell epitope mapping procedure and use of software able to simulate the binding of peptides with human MHC class II binding groove. This latter approach is described in detail elsewhere [WO 02/069232]. Variant genes were constructed and the mutant proteins tested for functional activity. In general, “single mutant” proteins containing one amino acid substitution each were first constructed and tested, then genes for active modified proteins combined to produce multiply substituted modified proteins.
  • Mutant genes were constructed using an overlap PCR procedure in which the mutant amino acid codon becomes introduced into the gene by use of a mutant in “overlap primer”. The scheme is well understood in the art and is described in detail elsewhere [Higuchi, et al (1900) Nucl. Acids Res. 16:7351]. A total of 37 single mutant modified proteins were constructed and tested for retained functional activity. In addition, a negative control modified protein containing a substitution Y70A was also constructed and tested in all assays. One of the 37 “single mutant” modified proteins in fact contained two directly adjacent substitutions (E151T and I152E) and is counted herein as a single mutant. The substitutions tested and the corresponding activity values are given in TABLE 4.
  • proteins were purified and tested according to the procedures outlined in examples 4 and 5 below.
  • the cell pellet was resuspended in 1 ml of PEB2 (50 mM Tris-HCl pH8, 20% sucrose, 1 mg/ml lysozyme, 1 ⁇ Complete Protease Inhibitor Tablet (Roche, Lewes, UK), and incubated on ice for 1 hour with gentle mixing.
  • the cell debris was centrifuged at 14,000 rpm at 4° C. and the pellet discarded.
  • the resulting supernatant is now referred to as the ‘periplasmic fraction’.
  • Bouganin protein was purified from the periplasmic fraction by nickel affinity column chromatography using commercially available “spin column” and the manufacturer's instructions (Qiagen, Crawley, UK).
  • the resulting material was dialyzed against 4 liters of phosphate buffered saline (0.138M NaCl, 0.0027M KCl, pH 7.4) overnight at 4° C. using a 10000 molecular weight cut-off ‘Slide-A-Lyzer’ (Pierce, Chester, UK). Following dialysis, the protein concentration was estimated using the Micro BCA Assay Kit (Pierce), and samples stored at ⁇ 20° C.
  • Bouganin protein concentration was further determined using an ELISA based assay system. Briefly, antiserum against bouganin was generated (Genovac, Freiburg, Germany), through the genetic immunization of two rats with a plasmid expressing bouganin. For the ELISA, recombinant bouganin is captured onto Ni-agarose coated plates via its His-tag and subsequently detected with the rat antiserum and a secondary HRP-conjugated anti-rat Fc antibody (Sigma, Poole, UK). As a standard, a large preparation of the wild-type bouganin expressed in E. coli and quantitated using the total protein assay was used in each determination.
  • the activity of the wild-type and modified (mutant) bouganin proteins was tested by measuring their ability to inhibit protein synthesis in a cell-free protein synthesis assay.
  • results for single mutant proteins are shown in TABLE 4.
  • Results for multiple mutant modified bouganin proteins are shown in TABLE 5.
  • results are expressed relative to wild-type protein activity. All assays were conducted with the inclusion of an inactive mutant bouganin protein with a Y70A substitution.
  • luciferase assay results may be plotted showing % luciferase activity relative to control versus protein concentration of added bouganin. Examples of such plots are shown in FIG. 1 depicting the results as determined for two different multiple mutant bouganin proteins.
  • the multiple modified protein designated Bou156 was selected for further testing using an immunogenicity assay.
  • This variant contains the substitutions V123A, D127A, Y133N and I152A.
  • Immunogenicity testing involves use of live cells that may be damaged by testing using whole bouganin protein, therefore these assays were conducted using synthetic peptides comprising the substitutions incorporated into variant Bou156.
  • the peptides tested are listed in TABLE 8.
  • the assays were conducted according to the procedures described in example 1 (above) using a PBMC donor pool of 20 individuals. Peptides were tested in triplicate for each donor sample at a two different final peptide concentrations (1 ⁇ M and 5 ⁇ M).
  • DeI-41 is peptide sequence AK A DRK A LELGV N KL (SEQ ID NO:29).
  • Del-44 is peptide sequence LGV N KLEFSIEAIHG (SEQ ID NO:30).
  • DeI-50 is peptide sequence NGQE A AKFFLIVIQM (SEQ ID NO:31). None of the modified peptides induced a T cell response in any of the donors (S.I. ⁇ 2). In contrast an immunogenic control peptide stimulated T cells of 6 donors (S.I.>2).
  • VB6-845 Recombinant Engineering of an Ep-CAM-specific Fab Antibody for Optimal Delivery of De-Immunized Bouganin (De-Bouganin)
  • the de-immunized bouganin used is Bou156.
  • Tumor-targeting cytotoxins are composed of the variable region of an antibody linked to a bacterial, fungal or plant toxin.
  • the present study illustrates that the deimmunized bouganin constructs of the invention, comprising deimmunized bouganin linked to a targeting moiety have reduced immunogenicity, while still retaining their biological activity.
  • TABLE 12 demonstrates the binding of the Ep-CAM antibody to several types of tumours and thus shows that it can be used to treat these types of cancers.
  • FIG. 3 illustrates the construct VB6-845.
  • FIG. 3A illustrates dicistronic unit of the pro-VB6-845, with pelB leader sequences.
  • the amino acid sequence (SEQ ID NO:16) and nucleic acid coding sequence (SEQ ID NO:15) are provided in FIG. 3B .
  • FIG. 3C illustrates the assembled VB6-845 protein, which is described below in more detail. Testing of this construct, illustrate that the construct retained its biological activity (cytoxicity) and the specificity of the targeting moiety (Ep-CAM antibody).
  • the dicistronic unit was cloned into the pING3302 vector ( FIG. 4 ) under the control of the arabinose-inducible araBAD promoter and transformed in E104 E. coli .
  • the presence of the pelB leader sequence directed the secretion of the Fab-de-bouganin fusion protein into the culture supernatant.
  • the cleavable linker enabled the de-bouganin to cleave from the targeting moiety and exert its biological activity.
  • the linker is a furin linker, although a person skilled in the art would appreciate that other cleavable linkers could be suitable.
  • Preferred linkers could be selected based on target specificity, and environment.
  • FIG. 3 VB6-845, wherein the de-bouganin (Bou156) is linked to the C-terminus of the CH domain via a furin linker.
  • FIG. 3A illustrates the dicistronic unit of the pro-sequences
  • FIG. 3B illustrates the nucleic acid coding sequence (SEQ ID NO:15) and the amino acid sequence of the pro-sequences (SEQ ID NO:16)
  • FIG. 3C illustrates the assembled VB6-845 protein without the pelB sequences.
  • FIG. 5 illustrates the control Fab anti-Ep-CAM construct without the plant toxin, de-bouganin (VB5-845).
  • FIG. 5A illustrates the dicistronic unit of the pro-sequences
  • FIG. 5B illustrates the nucleic acid coding sequence (SEQ ID NO:17) and the amino acid sequence of the pro-sequences (SEQ ID NO:18)
  • FIG. 5C illustrates the assembled VB6-845 protein without the pelB sequences.
  • FIG. 6 illustrates the Fab anti-Ep-CAM de-bouganin construct, VB6-845-C L -de-bouganin, wherein the Bou156 is linked at the C-terminus of the C L domain.
  • FIG. 6A illustrates the dicistronic unit of the pro-sequences
  • FIG. 6B illustrates the nucleic acid coding sequence (SEQ ID NO:19) and the amino acid sequence of the pro-sequences (SEQ ID NO:20)
  • FIG. 6C illustrates the assembled VB6-845-C L -de-bouganin protein without the pelB sequences.
  • FIG. 7 illustrates the Fab anti Ep-CAM, de-bouganin construct, VB6-845-NV H -de-bouganin, wherein Bou156 is linked to the N terminus of the V H domain.
  • FIG. 7A illustrates the dicistronic units of the pro-sequences
  • FIG. 7B illustrates the nucleic acid coding sequence (SEQ ID NO:21) and the amino acid sequence of the pro-sequences (SEQ ID NO:22)
  • FIG. 7C illustrates the assembled VB6-845-NV H -de-bouganin protein without the pelB sequences.
  • FIG. 8 illustrates the Fab anti-Ep-CAM construct VB6-845-NV L -de-bouganin, wherein Bou156 is linked to the N-terminus of the V L domain.
  • FIG. 8A illustrates the dicistronic unit of the pro-sequences
  • FIG. 8B illustrates the nucleic acid coding sequence (SEQ ID NO:23) and the amino acid sequence of the pro-sequences (SEQ ID NO:24)
  • FIG. 8C illustrates the assembled VB6-845-NV L -de-bouganin protein without the pelB sequences.
  • the de-bouganin molecule is linked to the C-terminal end of the heavy or light chains.
  • the optimal configuration comprised a pelB leader sequence adjacent to V H -C H domain with an N-terminal histidine affinity tag as the first unit.
  • the second unit comprising the pe1B-V L -C L domain linked to de-bouganin by a protease-sensitive linker.
  • FIG. 6 For constructs where de-bouganin was re-positioned to the N-terminal end, Western-blot analysis showed no detectable product and only C-terminal linked de-bouganin (constructs of FIGS. 3 and 6 ) yielded an intact soluble protein ( FIG.
  • FIG. 9 illustrates the expression of VB6-845 and VB6-845 CL-de-bouganin in the supernatant of induced E104 cells at lab scale. An aliquot of the supernatant, 16 microlitres, under non-reducing conditions, was loaded on a SDS-PAGE acrylamide gel and analysed by Western Blot using either a rabbit polyclonal anti-4D5 antibody, followed by a goat anti-rabbit (1/2000), or a goat anti-human Kappa-light chain-HRP antibody (1/1000), to confirm the identity and size of the recombinant protein.
  • the arrow indicates the full-length VB6-845 (construct of FIG. 3 ) and VB6-845-CL-de-bouganin (construct of FIG. 6 ).
  • Western blotting of non-induced E104 culture supernatant revealed no corresponding bands demonstrating the specificity of the antibodies (not shown).
  • FIG. 10A The results of the reactivity tests with VB6-845 ( FIG. 3 ) and VB6-845-CL-de-bouganin ( FIG. 6 ) to Ep-CAM positive cell lines CAL 27 and NIH:OVCAR-3 as compared to a control (Ep-CAM-negative cell line, A-375) is illustrated in FIG. 10A .
  • the results were comparable to the same reactivity tests conducted with another anti-Ep-CAM construct, VB6-845-gelonin, wherein the de-bouganin is replaced with another plant toxin, gelonin (See FIG.
  • the flow cytometry tests were conducted by incubating the constructs or control with 0.45 ⁇ 10 6 cells for an hour on ice. After washing, cell surface bound constructs were detected with a rabbit anti-bouganin (for FIG. 10A ) or mouse anti-His tag ( FIG. 10B ) for an hour on ice. The cells were washed and incubated with FITC-conjugated sheep anti-rabbit IgG ( FIG. 10A ) and FITC-conjugated sheep anti-mouse (IgG) ( FIG. 10B ) for 30 minutes on ice.
  • FIG. 11 illustrates the flow cytometry results of the competition assay, with VB6-845 at 1 and 10 ⁇ g/mL and increased concentration of ProxiniumTM, ranging from 0 to 100 ⁇ g/mL, were incubated with NIH:OVCAR-3 cells (Ep-CAM positive tumour cell line). After 1 hour incubation at 4° C., cells were washed and bound VB6-845 was detected with a biotinylated rabbit anti-bouganin followed by streptavidin-cychrome. The same experiment was performed with 4B5-PE which is used as a negative control. The reaction conditions were as indicated on FIG. 11 .
  • FIG. 12 cell-free ( FIG. 12 ) and MTS ( FIG. 13 A and B) assays demonstrated that de-bouganin retained its potency when conjugated to the Fab fragment.
  • FIG. 12 the purified VB6-845 and de-bouganin proteins, at various concentrations, were incubated at 30° C. for 90 minutes with the following mixture:
  • Flexi rabbit reticulocyte lysate 35 ⁇ L Amino acid mixture, minus leucine 1 ⁇ L 3 H-leucine 5 ⁇ L Potassium chloride 1.4 ⁇ L RNasin 1 ⁇ L Luciferase control RNA, 1 mg/mL 1 ⁇ L To a final volume of 50 ⁇ L
  • the MTS assay used to measure potency was conducted using standard technique known in the art, and as more fully described below in Example 8.
  • the IC 50 of VB6-845 was 3 to 4 nM and 2 to 3 nM, respectively.
  • the potency was measured at 1 to 2 nM for CAL 27 and 0.6 to 0.7 nM versus NIH:OVCAR-3.
  • Fab anti-Ep-CAM construct comprising a human tumor targeting antibody fragment linked to a de-immunized bouganin should permit repeat systemic administration of this drug and hence yield greater clinical benefit.
  • the constructs can be isolated from the cell cultures by techniques known in the art. For instance, if a His tag is placed at the N-terminal of the peptide construct, the Fab-bouganin protein can be purified using a Ni 2+ -chelating capture method. As an example the following protocol can be used. Conducting fed batch fermentation of VB6-845 variants performed in a 15L CHEMAP fermenter using TB medium. At an OD 600 of 20 (mid-log), the culture is induced with a mixture of feed and inducer containing 50% glycerol and 200 g/1 L-arabinose.
  • the culture is harvested, centrifuged at 8000 rpm for 30 min and VB6-845 variants purified using CM sepharose and Metal-Charged Chelating sepharose columns followed by a size exclusion column. Briefly, the supernatant is concentrated and diafiltered against 20 mM sodium phosphate pH 6.9 ⁇ 0.1. The diafiltered concentrated supernatant is then applied onto a CM sepharose column equilibrated with 20 mM sodium phosphate, 25 mM NaCl pH 6.9 ⁇ 0.1.
  • the column is washed with 20 mM sodium phosphate, 25 mM NaCl pH 6.9 ⁇ 0.1, bound VB6-845 is subsequently eluted with 20 mM sodium phosphate, 150 mM NaCl pH 7.5 ⁇ 0.1.
  • the CM sepharose eluate is adjusted to contain a final concentration of 0.25% Triton-X100 and applied to a charged chelating sepharose column.
  • the chelating sepharose column is then washed with 3 different wash buffers starting with 20 mM sodium phosphate, 150 mM NaCl, 0.25% triton-X100 pH 7.5 ⁇ 0.1 followed by 20 mM sodium phosphate, 150 mM NaCl pH 7.5 ⁇ 0.1 and followed by 20 mM sodium phosphate, 150 mM NaCl, 10 mM imidazole pH 7.5 ⁇ 0.1.
  • the bound VB6-845 is then eluted with 20 mM sodium phosphate, 150 mM NaCl, 250 mM imidazole pH 7.5 ⁇ 0.1 and collected in 2 mL fractions.
  • the absorbance at A 280 is determined for each fraction and the fractions with material pooled are applied onto a size exclusion column 5200 in order to obtain a purity of >80%.
  • the pooled SEC fraction is diluted 5-fold with 20 mM NaPO 4 , pH 7.5 and passed though a Q-sepharose 15 ml fast flow column equilibrated with 20 mM NaPO 4 , 25 mM NaCl pH 7.5 at a flow rate of about 5 ml/min. After application of the sample through the column, the column is washed with 10CV of equilibration buffer and the wash is pooled with the initial Q-sepharose flow through.
  • the effluent is concentrated to ⁇ 10-fold through the use of a 30 kDa MWCO membrane (Sartorius hydrosart membrane] to achieve a final concentration of 7.5 mg/ml. Tween-80 is then added to a final concentration of 0.1%. The final product is sterile filtered and stored at ⁇ 80° C. Samples at each steps of the process are analyzed by Western blot after immunoblotting with the anti-4D5 antibody. Purity is confirmed by colloidal blue staining. The level of expression of VB6-845 variants is determined by Western Blot analysis and ELISA.
  • VB6-845 is a Fab antibody linked to a de-immunized form of the plant-derived toxin bouganin. Unlike chemotherapeutics which lack defined tumor-target specificity, VB6-845 restricts its cytolytic effect to Ep-CAM-positive tumor targets alone. In this study, flow cytometry analysis and cytotoxicity were measured to assess the potency and selectivity of VB6-845.
  • the tumor cell lines used in this study were purchase from ATCC and were propagated following ATCC's recommendations except for the cell lines C-4I, TOV-112D which were grown in RPMI 1640 or DMEM supplemented with 10% FCS, respectively. Tumor cells were harvested at 60-70% confluence with viability over 90%.
  • the human normal mammary epithelial cells (HMEC) were purchased from CAMBREX and maintained in specified media according to the procedure provided by CAMBREX. The cells were harvested at 70% confluence with viability over 90%.
  • the gynecological cell lines from endometrial ovarian and cervical cancer indications were tested for VB6-845 binding on flow cytometry (Table 9).
  • Ten microgram/mL of VB6-845 was added to each cell line (3 ⁇ 10 5 cells) and incubated for 2h at 4° C.
  • A-375 and CAL 27 were used as negative and positive cell line controls, respectively.
  • a mouse monoclonal anti-Histidine antibody (Amersham Pharmacia, Cat #27471001) diluted 1/800 in PBS containing 10% FCS was added and incubated for a further 1 hr at 4° C.
  • FITC-labeled anti-mouse IgG (The Binding Site, Cat# AF271) diluted 1/100 in PBS-10% FCS was added and incubated for 30 min. at 4° C. Finally, the cells were analyzed on a FACS Calibur following propidium iodide staining to gate out the dead cells.
  • FIG. 14 A compares the cytotoxicity of gelonin, Fab anti-Ep-CAM-gelonin construct (VB6-845-Gelonin) and the Fab anti-Ep-CAM-de-bouganin (Bou156) construct (VB6-845) in CAL 27 ( FIG. 14A ) and NIH:OVCAR-3 cells ( FIG. 14B ).
  • the nucleic acid and amino acid sequence of the VB6-845-gelonin construct is illustrate in FIG. 14C .
  • VB6-845 construct of FIG. 3
  • cytotoxic activity of VB6-845 (90% pure) was tested against Ep-CAM-positive (NIH:OVCAR-3) and Ep-CAM-negative (HMEC, DAUDI, A-375) cell lines (Table 11) along with 17 chemotherapeutic drugs (LKB Laboratories Inc.).
  • the MTS assay was performed using standard techniques known in the art. More particularly, 50 microlitres of cells (2 ⁇ 10 4 cells/ml) were seeded per well and plates were incubated at 37° C. under 5% CO 2 for 2 hr. Then 50 microlitres of spiked drug (i.e. construct to be tested or control) was added to the culture medium at increasing concentrations. Culture medium, with or without cells, was used as positive and negative controls, respectively. The plates were left at 37° C. under 5% CO 2 for 5 days. At day 5, the inhibition of cell proliferation was evaluated by adding 20 microlitres of MTS reagent (Promega, Cat# G5430). The plates were further incubated at 37° C.
  • MTS reagent Promega, Cat# G5430
  • VB6-845 demonstrated highly potent cytolytic activity in the range of 1 to 2 nM, the potent killing was restricted exclusively to the Ep-CAM-positive tumor cell line NIH:OVCAR-3. Although some killing of Ep-CAM-negative cell lines was exhibited with VB6-845, the cytotoxic effect was at least 220-fold and at most >1000-fold less toxic. VB6-845 thus represents a potent antibody-directed treatment alternative to chemotherapeutics that when combined with the lower toxicity profile, holds much promise in the treatment of many different types of solid tumors.
  • VB6-011 Recombinant Engineering of a Tumor-Associated Antigen-Specific Fab Antibody for Optimal Delivery of De-Immunized Bouganin (De-Bouganin)
  • Tumor-targeting cytotoxins are composed of the variable region of an antibody linked to a bacterial, fungal or plant toxin.
  • the present study illustrates that the deimmunized bouganin constructs of the invention, comprising deimmunized bouganin linked to a targeting moiety have reduced immunogenicity, while still retaining their biological activity.
  • TABLE 13 demonstrates the binding of the tumor-associated antigen antibody to several types of tumors and thus shows that it can be used to treat these types of cancers.
  • the H11 antibody a monoclonal antibody recognizing tumor-associated antigen, was genetically linked to a de-immunized form of bouganin (de-bouganin), Bou 156, a potent, plant-derived, type I ribosome-inactivating protein (RIP), to create the antibody-toxin construct VB6-011.
  • FIG. 15 illustrates the nucleic acid coding sequence and amino acid sequence. Testing of this construct, illustrates that the construct retained its biological activity (cytoxicity).
  • MTS assay demonstrated that de-bouganin retained its potency when conjugated to the Fab fragment ( FIG. 16 ).
  • the MTS assay used to measure potency was conducted using standard technique known in the art, and as more fully described in Example 8.
  • the MTS assay was performed using standard techniques known in the art. More particularly, 50 microlitres of cells (2 ⁇ 10 4 cells/ml) were seeded per well and plates were incubated at 37° C. under 5% CO 2 for 2 hr. Then 50 microlitres of spiked drug (i.e. construct to be tested or control) was added to the culture medium at increasing concentrations. Culture medium, with or without cells, was used as positive and negative controls, respectively. The plates were left at 37° C. under 5% CO 2 for 5 days. At day 5, the inhibition of cell proliferation was evaluated by adding 20 microlitres of MTS reagent (Promega, Cat# G5430).
  • the plates were further incubated at 37° C. under 5% CO 2 for 2 hr and ODs were read at 490 nm using the plate reader spectrophotometer. Background values were subtracted from the sample values obtained for each concentration and the results were expressed as a percent of viable cells. Results show that the 1050 value of VB6-011 is 350 nM.
  • N indicates the number of cell lines tested per indication. 2 Values indicate the mean calculated from the sum of the mean fold increase in median fluorescence over the control antibody from all cell lines in each indication. A zero value would mean no measurable reactivity relative to the control activity

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Botany (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

The invention provides modified forms of bouganin protein having biological activity and a reduced propensity to activate human T cells as compared to the non-modified bouganin protein. The invention also provides T-cell epitope peptides of bouganin, and modified T-cell epitope peptides of bouganin which have a reduced propensity to activate human T cells as compared to the non-modified T-cell epitope peptide. The invention also provides cytotoxins having the having a ligand that binds to a cancer cells attached to the modified bouganin proteins. Also provided are methods of inhibiting or destroying mammalian cancer cells using the cytotoxins of the invention and pharmaceutical compositions for treating human cancer.

Description

    CROSS-REFERENCE TO RELATED APPLICATIONS
  • This application is a divisional application of U.S. patent application Ser. No. 12/784,820 filed on May 21, 2010, which is a divisional application of U.S. patent application Ser. No. 11/971,660, filed on Jan. 9, 2008, now U.S. Pat. No. 7,750,136, which is a divisional application of U.S. patent application Ser. No. 11/084,080, filed on Mar. 18, 2005, now U.S. Pat. No. 7,339,031, which claims priority under 35 USC 119(e) from U.S. Provisional Application No. 60/554,580, filed on Mar. 19, 2004 and U.S. Provisional Application No. 60/630,571, filed on Nov. 26, 2004, each of which are incorporated by reference herein in their entirety.
    • FIELD OF THE INVENTION
  • The invention relates to modified bouganin proteins and cytotoxins containing the modified proteins useful as therapeutics against cancer. Specifically, T-cell epitopes are removed or altered to reduce immunogenicity of the bouganin toxins.
    • BACKGROUND OF THE INVENTION
  • There are many instances whereby the efficacy of a therapeutic protein is limited by an unwanted immune reaction to the therapeutic protein. Several mouse monoclonal antibodies have shown promise as therapies in a number of human disease settings but in certain cases have failed due to the induction of significant degrees of a human anti-murine antibody (HAMA) response [Schroff, R. W. et al (1985) Cancer Res. 45: 879-885; Shawler, D. L. et al (1985) J. Immunol. 135: 1530-1535]. For monoclonal antibodies, a number of techniques have been developed in attempt to reduce the HAMA response [WO 89/09622; EP 0239400; EP 0438310; WO 91/06667]. These recombinant DNA approaches have generally reduced the mouse genetic information in the final antibody construct whilst increasing the human genetic information in the final construct. Notwithstanding, the resultant “humanised” antibodies have, in several cases, still elicited an immune response in patients [Issacs J. D. (1990) Sem. Immunol. 2: 449, 456; Rebello, P. R. et al (1999) Transplantation 68: 1417-1420].
  • The key to the induction of an immune response is the presence within the protein of peptides that can stimulate the activity of T-cells via presentation on MHC class II molecules, so-called “T-cell epitopes”. Such T-cell epitopes are commonly defined as any amino acid residue sequence with the ability to bind to MHC Class II molecules. Implicitly, a “T-cell epitope” means an epitope which when bound to MHC molecules can be recognized by a T-cell receptor (TCR), and which can, at least in principle, cause the activation of these T-cells by engaging a TCR to promote a T-cell response.
  • MHC Class II molecules are a group of highly polymorphic proteins which play a central role in helper T-cell selection and activation. The human leukocyte antigen group DR (HLA-DR) are the predominant isotype of this group of proteins; however, isotypes HLA-DQ and HLA-DP perform similar functions. In the human population, individuals bear two to four DR alleles, two DQ and two DP alleles. The structure of a number of DR molecules has been solved and these appear as an open-ended peptide binding groove with a number of hydrophobic pockets which engage hydrophobic residues (pocket residues) of the peptide [Brown et al (1993) Nature 364: 33; Stern et al (1994) Nature 368: 215]. Polymorphism identifying the different allotypes of class II molecule contributes to a wide diversity of different binding surfaces for peptides within the peptide binding groove and at the population level ensures maximal flexibility with regard to the ability to recognize foreign proteins and mount an immune response to pathogenic organisms.
  • An immune response to a therapeutic protein proceeds via the MHC class II peptide presentation pathway. Here exogenous proteins are engulfed and processed for presentation in association with MHC class II molecules of the DR, DQ or DP type. MHC Class II molecules are expressed by professional antigen presenting cells (APCs), such as macrophages and dendritic cells amongst others. Engagement of a MHC class II peptide complex by a cognate T-cell receptor on the surface of the T-cell, together with the cross-binding of certain other co-receptors such as the CD4 molecule, can induce an activated state within the T-cell. Activation leads to the release of cytokines further activating other lymphocytes such as B cells to produce antibodies or activating T-killer cells as a full cellular immune response.
  • T-cell epitope identification is the first step to epitope elimination as recognized in WO98/52976; WO00/34317; WO02/069232; WO02/079232; and WO02/079415. In these teachings, predicted T-cell epitopes are removed by the use of judicious amino acid substitution within the protein of interest. Besides computational techniques, there are in vitro methods for measuring the ability of synthetic peptides to bind MHC class II molecules. An exemplary method uses B-cell lines of defined MHC allotype as a source of MHC class II binding surface and may be applied to MHC class II ligand identification [Marshall K. W. et al. (1994) J. Immunol. 152:4946-4956; O′Sullivan et al (1990) J. Immunol. 145: 1799-1808; Robadey C. et al (1997) J. Immunol 159: 3238-3246]. However, such techniques are not adapted for the screening of multiple potential epitopes to a wide diversity of MHC allotypes, nor can they confirm the ability of a binding peptide to function as a T-cell epitope.
  • Techniques exploiting soluble complexes of recombinant MHC molecules in combination with synthetic peptides have also come into use [Kern, F. et al (1998) Nature Medicine 4:975-978; Kwok, W. W. et al (2001) TRENDS in Immunol. 22:583-588]. These reagents and procedures are used to identify the presence of T-cell clones from peripheral blood samples from human or experimental animal subjects that are able to bind particular MHC-peptide complexes and are not adapted for screening multiple potential epitopes to a wide diversity of MHC allotypes.
  • Biological assays of T-cell activation offer a practical option to providing a reading of the ability of a test peptide/protein sequence to evoke an immune response. Examples of this kind of approach include the work of Petra et al using T-cell proliferation assays to the bacterial protein staphylokinase, followed by epitope mapping using synthetic peptides to stimulate T-cell lines [Petra, A. M. et al (2002) J. Immunol. 168: 155-161]. Similarly, T-cell proliferation assays using synthetic peptides of the tetanus toxin protein have resulted in definition of immunodominant epitope regions of the toxin [Reece J. C. et al (1993) J. Immunol. 151: 6175-6184]. WO99/53038 discloses an approach whereby T-cell epitopes in a test protein may be determined using isolated sub-sets of human immune cells, promoting their differentiation in vitro and culture of the cells in the presence of synthetic peptides of interest and measurement of any induced proliferation in the cultured T-cells. The same technique is also described by Stickler et al. [Stickler, M. M. et al (2000) J. Immunotherapy 23:654-660], where in both instances the method is applied to the detection of T-cell epitopes within bacterial subtilisin. Such a technique requires careful application of cell isolation techniques and cell culture with multiple cytokine supplements to obtain the desired immune cell sub-sets (dendritic cells, CD4+ and or CD8+T-cells) and is not conducive to rapid through-put screening using multiple donor samples.
  • Recently a combination approach using population based T-cell proliferation assays and in silico simulation of peptide MHC binding in the design of epitope depleted proteins has also been advanced [WO 03/104803].
  • As depicted above and as consequence thereof, it would be desirable to identify and to remove or at least to reduce T-cell epitopes from a principal therapeutically valuable but originally immunogenic peptide, polypeptide or protein.
    • SUMMARY OF THE INVENTION
  • The invention is conceived to overcome the practical reality that soluble proteins introduced with therapeutic intent in humans can trigger an immune response resulting in development of host antibodies that bind to the soluble protein. The present invention seeks to address this by providing bouganin proteins with reduced propensity to elicit an immune response. According to the methods described herein, the inventors have identified the regions of the bouganin molecule comprising the critical T-cell epitopes driving the immune responses to this protein.
  • The present invention relates to a modified bouganin protein wherein the modified bouganin has a reduced propensity to elicit an immune response. In a preferred embodiment, the modified bouganin has a reduced propensity to activate T-cells and the modified bouganin is modified at one or more amino acid residues in a T-cell epitope. The T-cell epitopes are selected preferably from the group consisting of:
  • a) AKVDRKDLELGVYKL (epitope region R1, SEQ ID NO: 2)
  • b) LGVYKLEFSIEAIHG (epitope region R2, SEQ ID NO: 3) and
  • c) NGQEIAKFFLIVIQM (epitope region R3, SEQ ID NO: 4).
  • The present invention also relates to a cytotoxin comprising a targeting moiety attached to a modified bouganin protein of the invention. In one embodiment, the targeting moiety is a ligand that binds to a cancer cell. In a further embodiment, the ligand is an antibody or antibody fragment that binds to a cancer cell. In a particular embodiment, the antibody recognizes Ep-CAM or tumor-associated antigen. In a most particular embodiment, the present invention provides a cytotoxin comprising VB6-845 or VB6-011.
  • In another aspect, the invention provides a method of inhibiting or destroying cancer cells comprising administering a cytotoxin of the invention to the cancer cells.
  • The present invention also relates to a method of treating cancer by administering a cytotoxin of the invention to an animal in need thereof.
  • Still further, a process is provided for preparing a pharmaceutical for treating an animal with cancer comprising the steps of identifying T-cell epitopes of bouganin, modifying one or more amino acid residues in a T-cell epitope to prepare a modified bouganin having reduced propensity to activate T-cells; preparing a cytotoxin have a cancer-binding ligand attached to a modified bouganin; and suspending the cytotoxin in a pharmaceutically acceptable carrier, diluent or excipient.
  • In a further aspect, the invention provides a pharmaceutical composition for treating an animal with cancer comprising the cytotoxin of the invention and a pharmaceutically acceptable carrier, diluent or excipient.
  • The cytotoxins, compositions and methods of the present invention may be used to treat various forms of cancer such as colorectal cancer, breast cancer, ovarian cancer, pancreatic cancer, head and neck cancer, bladder cancer, gastrointestinal cancer, prostate cancer, small cell and non small cell lung cancer, sarcomas, gliomas, T- and B-cell lymphomas.
  • The invention also provides the T-cell epitope peptides of the bouganin protein and the modified T-cell epitope peptides of the invention.
  • Other features and advantages of the present invention will become apparent from the following detailed description. It should be understood, however, that the detailed description and the specific examples while indicating preferred embodiments of the invention are given by way of illustration only, since various changes and modifications within the spirit and scope of the invention will become apparent to those skilled in the art from this detailed description.
    • BRIEF DESCRIPTION OF THE DRAWINGS
  • The invention will now be described in relation to the drawings in which:
  • FIG. 1 shows results of activity assays of the T-cell epitope depleted modified bouganin proteins Bou156 (panel A) and Bou157 (panel B). Bou156 comprises the substitutions V123A, D127A, Y133N and I152A. Bou157 comprises the substitutions V123A, D127A, Y133Q and I152A. Both assay sets are conducted using wild type protein and a disabled modified bouganin (Y70A) as controls. Activity is expressed as % measured luciferase activity versus concentration of bouganin protein in the assay.
  • FIG. 2 shows T-cell proliferation assay results for three synthetic peptides and 2 different PBMC donor samples. The peptides designated DeI-41, DeI-44 and DeI-50 were tested at 1 μM final concentration (panel A) and 5 μM final concentration (panel B). These peptides are derived from the immunogenic regions of the bouganin molecule and contain substitutions designed to eliminate their immunogenicity.
  • FIGS. 3A-C_illustrates VB6-845, a modified bouganin cytotoxin having a Fab anti-Ep-CAM, wherein the de-bouganin (Bou156) is linked to the C-terminus of the CH domain via a furin linker. FIG. 3A illustrates the dicistronic unit encoding the pro-sequences, FIG. 3B illustrates the nucleic acid coding sequence (SEQ ID NO:15) and the amino acid sequence (SEQ ID NO:16) of the pro-sequences and FIG. 3C illustrates the assembled VB6-845 protein without the pelB sequences.
  • FIG. 4 illustrates the map of the expression vector pING3302. Inserts of the examples were ligated in 3302 vector using EcoRI and XhoI restriction sites.
  • FIGS. 5A-C illustrates the control Fab anti-Ep-CAM construct without the plant toxin, de-bouganin (VB5-845). FIG. 5A illustrates the dicistronic unit encoding the pro-sequences, FIG. 5B illustrates the nucleic acid coding sequence (SEQ ID NO:17) and the amino acid sequence (SEQ ID NO:18) of the pro-sequences and FIG. 5C illustrates the assembled VB5-845 protein without the pelB sequences.
  • FIGS. 6A-C illustrates the Fab anti-Ep-CAM de-bouganin construct VB6-845-CL-de-bouganin, wherein the Bou156 is linked at the C-terminus of the CL domain. FIG. 6A illustrates the dicistronic units encoding the pro-sequences, FIG. 6B illustrates the nucleic acid coding sequence (SEQ ID NO:19) and the amino acid sequence (SEQ ID NO:20) of the pro-sequences and FIG. 6C illustrates the assembled VB6-845-CL-de-bouganin protein without the pelB sequences.
  • FIGS. 7A-C illustrates the Fab anti Ep-CAM, de-bouganin construct, VB6-845-NVH-de-bouganin, wherein Bou156 is linked to the N-terminus of the VH domain. FIG. 7A illustrates the dicistronic units encoding the pro-sequences, FIG. 7B illustrates the nucleic acid coding sequence (SEQ ID NO:21) and the amino acid sequence (SEQ ID NO:22) of the pro-sequences and FIG. 7C illustrates the assembled VB6-845-NVH-de-bouganin protein without the pelB sequences.
  • FIGS. 8A-C illustrates the Fab anti-Ep-CAM de-bouganin construct, VB6-845-NVL-de-bouganin, wherein Bou156 is linked to the N-terminus of the VL domain. FIG. 8A illustrates the dicistronic units encoding the pro-sequences, FIG. 8B illustrates the nucleic acid coding sequence (SEQ ID NO:23) and the amino acid sequence (SEQ ID NO:24) of the pro-sequences and FIG. 8C illustrates the assembled VB6-845-NVL-de-bouganin protein without the pelB sequences.
  • FIG. 9 is a Western Blot illustrating the expression of VB6-845 (construct of FIG. 3) and VB6-845-CL-de-bouganin (Bou156) (construct of FIG. 6) in the supernatant of induced E104 cells at lab-scale.
  • FIGS. 10A-B illustrates the results of the flow cytometry reactivity studies. FIG. 10A illustrates the reactivity of VB6-845 (construct of FIG. 3) and VB6-845-CL-de-bouganin (construct of FIG. 6) in Ep-CAM-positive cell lines CAL 27 and OVCAR-3 and Ep-CAM-negative cell line A-375, while FIG. 10 B, illustrates the results of the same tests conducted with VB6-845 (construct of FIG. 3) and VB6-845-gelonin (construct of FIG. 14C) and control (PBS).
  • FIG. 11 is a graph illustrating the flow cytometry results of the competition assay with VB6-845 at 1 and 10 μg/mL and increased concentration of Proxinium™ in NIH:OVCAR-3 cells as described in Example 7. The same experiment was performed with 4B5-PE which is used as a negative control.
  • FIG. 12 is a graph illustrating the results of the cell free translation assay comprising purified VB6-845 or de-bouganin proteins at various concentrations as described in Example 7.
  • FIGS. 13A-C illustrates the results of the MTS cytotoxicity assay of Example 8 comparing the cytoxocity of VB6-845 (construct of FIG. 3), VB6-845-CL-de-bouganin (construct of FIG. 6) and de-bouganin (Bou156) in CAL 27 (FIG. 13A) and NIH:OVCAR3 (FIG. 13B) cells.
  • FIGS. 14A-B illustrate the results of the MTS cytotoxicity assay of Example 8 comparing the cytoxocity of VB6-845 (construct of FIG. 3), VB6-845-gelonin (construct of FIG. 14C) and gelonin in CAL 27 (FIG. 14A) and NIH:OVCAR3 (FIG. 14B) cells. FIG. 14C illustrates the nucleic acid coding sequence (SEQ ID NO:25) and the amino acid sequence (SEQ ID NO:26) of the VB6-845-gelonin construct.
  • FIG. 15 illustrates the nucleic acid coding sequence (SEQ ID NO: 27) and the amino acid sequence (SEQ ID NO:28) of the pro-sequences of VB6-011.
  • FIG. 16 illustrates the results of the MTS cytotoxicity assay of Example 9 showing the cytotoxicity of VB6-011 in MB-435S cells.
    •  DETAILED DESCRIPTION OF THE INVENTION
  • The inventors have identified T-cell epitopes in bouganin, and have designed and made modified bouganin proteins that have reduced propensity to activate human T cells compared to the non-modified bouganin protein.
    • (A) Modified Bouganin Proteins
  • The present invention relates to a modified bouganin protein wherein bouganin has been modified in order to have a reduced propensity to elicit an immune response, preferably a T-cell response, as compared to a non-modified bouganin protein. Mature bouganin protein is a single polypeptide of 250 amino acids with a molecular weight of approximately 26,200 Da [Den Hartog et al (2002) Eur. J. Biochem. 269: 1772-1779; U.S. Pat. No. 6,680,296]. Bouganin is a type 1 ribosome inactivating protein (RIP) originally isolated from the plant Bougainvillea spectabilis Willd [Bolognesi et al (1997) Planta 203: 422-429]. The RIPs from plants are RNA N-glycosidases that depurinate the major ribosomal RNA of cells, thereby damaging the ribosomes and leading to a cessation of protein synthesis and cell death.
  • The amino acid sequence of the mature bouganin protein (depicted in single-letter code) is:
  • [SEQ ID NO. 1]
    YNTVSFNLGEAYEYPTFIQDLRNELAKGTPVCQLPVTLQTIADDKRFV
    LVDITTTSKKTVKVAIDVTDVYVVGYQDKWDGKDRAVFLDKVPTVATS
    KLFPGVTNRVTLTFDGSYQKLVNAAKVDRKDLELGVYKLEFSIEAIHG
    KTINGQEIAKFFLIVIQMVSEAARFKYIETEVVDRGLYGSFKPNFKVL
    NLENNWGDISDAIHKSSPQCTTINPALQLISPSNDPWVVNKVSQISPD
    MGILKFKSSK.
  • The term “non-modified bouganin protein” means a bouganin protein that has not been modified in order to reduce its propensity to elicit an immune response. The sequence of wild-type or a non-modified bouganin is shown in SEQ ID NO:1. However, one of skill in the art will appreciate that the term “non-modified bouganin” also includes modifications to SEQ ID NO:1 as long as such modifications do not reduce the propensity to elicit an immune response. Examples of modifications that can be made to SEQ ID NO:1 include peptide fragments and conservative amino acid substitutions that do not reduce the immunogenicity of the protein.
  • The term “modified bouganin protein” means a bouganin protein that has been modified as compared to the non-modified bouganin protein (described above) wherein said modification reduces the propensity of the bouganin to elicit an immune response. Modified bouganin protein can also be referred to as deimmunized bouganin. The “modified bouganin protein” can be a modified full length sequence or a modified fragment of the non-modified bouganin protein. The “modified bouganin protein” may also contain other changes as compared to the wild-type bouganin sequence which do not alter immunogenicity of the peptide. The modified bouganin protein will preferably have the same biological activity as the non-modified bouganin.
  • The term “reduced propensity to elicit an immune response” as used herein means that the modified bouganin protein is less immunogenic than non-modified bouganin.
  • The term “immune response” includes both cellular and humoral immune responses. In a preferred embodiment, the modified bouganin has a reduced propensity to activate T-cells.
  • The term “reduced propensity to activate human T-cells” as used herein means the modified bouganin protein has a reduced propensity to activate human T-cells as compared to the non-modified bouganin protein. One of skill in the art can test whether or not a modified bouganin has a reduced propensity to activate T-cells using assays known in the art including assessing the stimulation index of the protein.
  • The term “stimulation index” as used herein refers to the measure of the ability of the modified or non-modified bouganin protein to activate human T cells. For example, the modified or non-modified bouganin protein, or peptides thereof, can be tested for their ability to evoke a proliferative response in human T-cells cultured in vitro. Where this type of approach is conducted using naïve human T-cells taken from healthy donors, the inventors have established that in the operation of such an assay, a stimulation index equal to or greater than 2.0 is a useful measure of induced proliferation. The stimulation index is conventionally derived by division of the proliferation score (e.g. counts per minute of radioactivity if using 3H-thymidine incorporation) measured to the test peptide by the score measured in cells not contacted with a test peptide.
  • In one embodiment, the invention provides a modified bouganin protein, wherein the modified bouganin protein has biological activity and has reduced propensity to activate human T cells compared to a non-modified bouganin protein.
  • In another embodiment, the invention provides a modified bouganin protein, wherein the modified bouganin protein has reduced propensity to activate human T cells compared to a non-modified bouganin protein and has biological activity that is lower than the non-modified bouganin protein. In yet another embodiment, the invention provides a modified bouganin protein wherein the modified bouganin protein has reduced propensity to activate human T cells and no biological activity. Such modified proteins could, for instance, be used as controls, in assays or to tolerize subjects.
  • The term “biological activity” as used herein is the ability of the modified or non-modified bouganin protein to inhibit protein synthesis on ribosomes, which can be assessed in a number of ways. It should be noted that a modified bouganin protein will still have biological activity even if such activity is lower than that of the non-modified protein, however it would need to have some level of detectable activity. For example, the biological activity of the modified or non-modified bouganin protein can be assessed by identifying their N-glycosidase activity, and in particular with sufficient activity to provide significant inhibition of protein translation. One such suitable assay involves testing the activity of the variant bouganin proteins in comparison to non-modified bouganin in a cell-free protein synthesis assay. A coupled transcription/translation mix containing methionine, DNA encoding the reporter protein luciferase and serial dilutions of non-modified and modified bouganin protein are co-incubated. The levels of translated luciferase are readily detected using a luminescence counter following addition of a substrate reagent. The measured luminescence is inversely proportional to the bouganin N-glycosidase activity present in the reaction. It is usual to provide a negative control such as an in-active bouganin protein, for example containing a Y70A substitution.
  • In a preferred embodiment, the modified bouganin peptide is modified at one or more T-cell epitopes in the bouganin protein sequence.
  • The term “T-cell epitope” means an amino acid sequence which is able to bind major histocompatibility complex (MHC) class II, able to stimulate T-cells and/or also able to bind (without necessarily measurably activating) T-cells in complex with MHC class II.
  • In one aspect, a general method that can be used in the present invention leading to the modified bouganin proteins comprising modified T-cell epitopes comprises the following steps: (i) determining the amino acid sequence of the protein or part thereof; (ii) identifying one or more potential T-cell epitopes within the amino acid sequence of the protein by methods such as determination of the binding of the peptides to MHC molecules using in vitro or in silico techniques or biological assays; (iii) designing new sequence variants with one or more amino acids within the identified potential T-cell epitopes modified in such a way to substantially reduce or eliminate the activity of the T-cell epitope as determined by the binding of the peptides to MHC molecules using in vitro or in silico techniques or biological assays. Such sequence variants are created in such a way to avoid creation of new potential T-cell epitopes by the sequence variations unless such new potential T-cell epitopes are, in turn, modified in such a way to substantially reduce or eliminate the activity of the T-cell epitope; (iv) constructing such sequence variants by recombinant DNA techniques and testing said variants in order to identify one or more variants with desirable properties according to well-known recombinant techniques; and (v) optionally repeating steps (ii) to (iv).
  • In an example, step (iii) is carried out by substitution, addition or deletion of amino acid residues in any of the T-cell epitopes in the non-modified bouganin protein. In another example, the method to make the modified bouganin protein is made with reference to the homologous protein sequence and/or in silico modeling.
  • The identification of potential T-cell epitopes according to step (ii) can be carried out according to methods described previously in the art. Suitable methods are disclosed in WO 98/59244; WO 98/52976; WO 00/34317; WO 02/069232 and may be used to identify binding propensity of bouganin derived peptides to an MHC class II molecule. In order to identify biologically relevant peptides, the inventors have developed an approach exploiting ex vivo human T-cell proliferation assays. This approach has proven to be a particularly effective method and has involved the testing of overlapping bouganin derived peptide sequences in a scheme so as to scan and test the entire bouganin sequence. The synthetic peptides are tested for their ability to evoke a proliferative response in human T-cells cultured in vitro. Where this type of approach is conducted using naïve human T-cells taken from healthy donors, the inventors have established that in the operation of such an assay, a stimulation index equal to or greater than 2.0 is a useful measure of induced proliferation. The stimulation index is conventionally derived by division of the proliferation score (e.g. counts per minute of radioactivity if using 3H-thymidine incorporation) measured to the test peptide by the score measured in cells not contacted with a test peptide.
  • Accordingly, in the present studies, 89 synthetic 15-mer peptides (as listed in Table 1) were used in T-cell proliferation assays with PBMCs (peripheral blood mononuclear cells) from naïve donors (i.e. no known sensitization to bouganin) 20 donor PBMC samples were selected to achieve an optimal coverage of MHC class II allotypes. PBMCs were stimulated with individual peptides in triplicate cultures for 7 days before proliferation was assessed by 3H-thymidine incorporation. All peptides were diluted at two different concentrations: 1 μM and 5 μM. The stimulation indices (SI) were calculated as the amount of 3H incorporated into the cells, divided by the amount of 3H incorporated in mock-stimulated controls.
  • This method has identified the most immunogenic regions of the bouganin molecule in humans. Accordingly, in a specific embodiment, the modified bouganin protein is modified at one or more amino acid residues in a T-cell epitope selected from the group consisting of:
    • (SEQ ID NO:2);
  • a) AKVDRKDLELGVYKL, termed herein epitope region R1
    • (SEQ ID NO:3)
  • b) LGVYKLEFSIEAIHG, termed herein epitope region R2; and
    • (SEQ ID NO:4)
  • c) NGQEIAKFFLIVIQM, termed herein epitope region R3.
  • These T-cell epitopes have been identified on the basis of giving SI>2 in two or more donor PBMC samples. The above disclosed peptide sequences represent the critical information required for the construction of modified bouganin proteins in which one or more of these epitopes is compromised.
  • In an embodiment of the invention, the modified bouganin protein of the invention has at least one T-cell epitope removed. In another embodiment, the modified bouganin protein of the invention has one, two or three T-cell epitopes removed. The invention also contemplates a modified bouganin protein wherein 1 to 9 amino acid residues are modified, preferably in the T-cell epitope. In another embodiment, 1 to 5 amino acid residues are modified. The term “modified” as used herein means the amino acid residues are modified by substitution, addition or deletion, preferably by substitution, but the bouganin protein has reduced propensity to activate human T cells. In another embodiment the modified protein has biological activity. More preferably the modified bouganin protein of the invention is modified by substitution at a position corresponding to any of the amino acids specified within sequences (a), (b) or (c) above.
  • One embodiment of the present invention comprises bouganin proteins for which the MHC class II ligands identified within any of the epitopes R1-R3 are modified such as to eliminate binding or otherwise reduce the numbers of MHC allotypes to which the peptide can bind. Amino acids in the R1 to R3 regions to eliminate binding or otherwise reduce the numbers of MHC allotypes to which the peptide can bind can be modified by substitution, addition or deletion.
  • For the elimination of T-cell epitopes, amino acid substitutions are made at appropriate points within the peptide sequence predicted to achieve substantial reduction or elimination of the activity of the T-cell epitope. In practice an appropriate point will in one embodiment equate to an amino acid residue binding within one of the pockets provided within the MHC class II binding groove.
  • In one embodiment, the binding within the first pocket of the cleft at the so-called P1 or P1 anchor position of the peptide is modified. The quality of binding interaction between the P1 anchor residue of the peptide and the first pocket of the MHC class II binding groove is recognized as being a major determinant of overall binding affinity for the whole peptide. An appropriate substitution at this position of the peptide will be for a residue less readily accommodated within the pocket, for example, substitution to a more hydrophilic residue. Amino acid residues in the peptide at positions equating to binding within other pocket regions within the MHC binding cleft are also considered and fall under the scope of the present.
  • It is understood that single amino acid substitutions, deletions or additions within a given potential T-cell epitope are a preferred route by which the epitope may be eliminated. Combinations of modifications (i.e. substitutions, deletions and additions) within a single epitope may be contemplated and for example can be particularly appropriate where individually defined epitopes are in overlap with each other as is the present case where epitope regions R1 and R2 overlap by 5 residues. Moreover, either single amino acid modifications within a given epitope or in combination within a single epitope may be made at positions not equating to the “pocket residues” with respect to the MHC class II binding groove, but at any point within the peptide sequence. Modifications may be made with reference to an homologue structure or structural method produced using in silico techniques known in the art and may be based on known structural features of the molecule according to this invention. All such modifications fall within the scope of the present invention.
  • The epitope regions R1-R3 of bouganin were analyzed for indication of MHC class II ligands encompassed within their respective sequences. A software tool exploiting the schemes outlined in WO 98/59244 and WO 02/069232 was used for this analysis. The software simulates the process of antigen presentation at the level of the peptide MHC class II binding interaction to provide a binding score for any given peptide sequence. Such a score is determined for many of the predominant MHC class II allotypes existent in the population. As this scheme is able to test any peptide sequence, the consequences of amino acid substitutions, additions or deletions with respect to the ability of a peptide to interact with a MHC class II binding groove can be predicted. Consequently new sequence compositions can be designed which contain reduced numbers of peptides able to interact with the MHC class II and thereby function as immunogenic T-cell epitopes.
  • Under this scheme in one embodiment of the invention substitutions within epitope region R1 comprise changes at positions V123, D127 and/or E129. Similarly for epitope region R2, in one embodiment the substitution is at position Y133. This residue falls into the region of overlap between R1 and R2 but substitution at Y133 is sufficient to eliminate the R2 related MHC class II ligand and is not sufficient of itself to eliminate R1 related MHC class II ligands. For epitope region R3, in one embodiment of the invention substitutions are to residues E151, and/or 1152.
  • In all instances the substitutions are to one or more alternative amino acid residues. Analysis of R1 with the MHC II stimulation software indicated that amino acid residues 123, 127, 129 and 131 were key residues in this epitope for binding to MHC II molecules. Residue 123 is a preferred site for mutation of the R1 region because it is at the surface of the molecule, away from the active site and is variable in RIP sequence alignment. Nevertheless, not all substitution yield an active molecule hence the need to validate mutations in the bioactivity assay. Thus for example within R1, substitutions V123T, V123A and V123Q are examples of preferred alternative substitutions. Residue 131 was found to be absolutely conserved in RIP and hence is unlikely suitable for mutation. Residue 127 and 129 are not highly conserved but only a restricted number of residues were found to have an impact on MHC II binding. The substitution sets: D127G, D127A, E129Q and E129G are also preferred substitutions. For R2, residue 133 was shown to be a likely candidate to abolish MHC II binding and its apparent surface localization (as determined by modeling) combined to the fact that it is not highly conserved across RIP make it a good candidate for mutation. Preferred alternative substitutions were found to be Y133N, Y133T, Y133A, Y133R, Y133D, Y133E, Y133Q, Y133G, Y133K, Y133H and Y133S. For R3, amino acid residues 152, 155 and 158 were identified as key residues for MHC II binding. However, residues 155 and 158 are part of a highly conserved hydrophobic stretch thus suggesting that their mutation would not yield bioactive molecules. Residue poorly conserved was found to be a more likely candidate. For R3, the substitution sets: I152Q and I152A are also preferred substitutions.
  • Accordingly, the invention provides a modified bouganin protein wherein the bouganin is modified at one or more of X1, X2, X3, X4 or X5 as follows:
  • (epitope region R1, SEQ ID NO:5)
    • a) AKX1DRKX2LX3LGVX4KL;
  • (epitope region R2, SEQ ID NO:6)
    • b) LGVX4KLEFSIEAIHG; and
  • (epitope region R3, SEQ ID NO:7)
    • c) NGQEX5AKFFLIVIQM
  • wherein X1 through X5 can be any amino acid.
  • In a specific embodiment, X1 is T or A or Q; X2 is G or A; X3 is Q or G; X4 is N or D or T or A or R or Q or E or G or H or K or S; and X5 is Q or A (epitope region R1, SEQ ID NO:8; epitope region R2, SEQ ID NO:9; epitope region R3, SEQ ID NO:10).
  • Taken together a most preferred substitution set may be compiled based on immunogenic epitope mapping studies using ex vivo T-cell assays, in silico MHC peptide binding simulations and structural considerations from sequence homology analysis. Finally, if a bioactive protein is preferred, in vitro activity assay can then be performed on the modified protein that may comprise one or multiple mutations.
  • Accordingly, in another embodiment, the invention provides a modified bouganin peptide, comprising the amino acid sequence:
  • YNTVSFNLGEAYEYPTFIQDLRNELAKGTPVCQLPVTLQTIADDKRFV
    LVDITTTSKKTVKVAIDVTDVYVVGYQDKWDGKDRAVFLDKVPTVATS
    KLFPGVTNRVTLTFDGSYQKLVNAAKX 1DRKX 2LX 3LGVX 4KLEFSIEA
    IHGKTINGQEX 5AKFFLIVIQMVSEAARFKYIETEVVDRGLYGSFKPN
    FKVLNLENNWGDISDAIHKSSPQCTTINPALQLISPSNDPWVVNKVSQ
    ISPDMGILKFKSSK

    wherein X1 through X5 can be any amino acid (SEQ ID NO:11).
  • In a preferred embodiment, X1 is T or A or Q; X2 is G or A; X3 is Q or G; X4 is N or D or T or A or R or Q or E or G or H or K or S; and X5 is Q or A (SEQ ID NO: 12).
  • In a specific embodiment, the modified bouganin protein comprises the amino acid sequence:
  • (SEQ ID NO: 13)
    YNTVSFNLGEAYEYPTFIQDLRNELAKGTPVCQLPVTLOTIADDKRFV
    LVDITTTSKKTVKVAIDVTDVYVVGYQDKWDGKDRAVFLDKVPTVATS
    KLFPGVTNRVTLTFDGSYQKLVNAAK A DRK A LELGV N KLEFSIEAIHG
    KTINGQE A AKFFLIVIQMVSEAARFKYIETEVVDRGLYGSFKPNFKVL
    NLENNWGDISDAIHKSSPOCTTINPALOLISPSNDPWVVNKVSQISPD
    MGILKFKSSK.
  • In yet another embodiment, the modified bouganin protein comprises the amino acid sequence:
  • (SEQ ID NO: 14)
    YNTVSFNLGEAYEYPTFIQDLRNELAKGTPVCQLPVTLQTIADDKRFV
    LVDITTTSKKTVKVAIDVTDVYVVGYQDKWDGKDRAVFLDKVPTVATS
    KLFPGVTNRVTLTFDGSYQKLVNAAK A DRK A LELGV Q KLEFSIEAIHG
    KTINGQE A AKFFLIVIQMVSEAARFKYIETEVVDRGLYGSFKPNFKVL
    NLENNWGDISDAIHKSSPQCTTINPALQLISPSNDPWVVNKVSQISPD
    MGILKFKSSK.

    Underlined residues are substituted residues different from the non-modified bouganin protein.
  • As will be clear to the person skilled in the art, multiple alternative sets of modifications could be arrived at which achieve the objective of removing undesired epitopes. The resulting sequences would however remain broadly homologous with the specific proteins disclosed herein and therefore fall under the scope of the present invention. Obvious chemical equivalents to the sequences disclosed by the present invention are also contemplated to fall within the scope of the present invention. Such equivalents include proteins that perform substantially the same function in substantially the same way.
  • In another embodiment the modified bouganin protein of the invention has 1, 2, 3, 4, 5 or more amino acid modifications in the T-cell epitopes of the protein.
  • In an additional embodiment, the modified bouganin protein of the invention when tested in a T-cell assay evokes a reduced stimulation index in comparison to the non-modified bouganin protein.
  • In a further embodiment of the invention, the T-cell epitopes of the bouganin protein are mapped using a T-cell assay and then modified such that upon re-testing in the T-cell assay the modified bouganin protein evokes a stimulation index less than the non-modified bouganin protein, preferably the stimulation index is less than 2.0.
  • It will be clear to a person skilled in the art that if the modified bouganin protein has substantially reduced or no biological activity, it may need further modification by substitution, addition or deletion of amino acid residues to restore the biological activity of the modified bouganin protein. However, such modified bouganin proteins that have substantially reduced or no biological activity are still encompassed within the scope of the invention and have utility as controls in assays, or for tolerization.
  • In one embodiment, the modified bouganin is mutated at the tyrosine residue at position 70 to yield an inactive bouganin. In a specific embodiment, the tyrosine at position 70 is replaced with alanine. In a preferred embodiment, the modified bouganin has the sequence:
  • [SEQ ID NO. 129]
    YNTVSFNLGEAYEYPTFIQDLRNELAKGTPVCQLPVTLQTIADDKRFV
    LVDITTTSKKTVKVAIDVTDVAVVGYQDKWDGKDRAVFLDKVPTVATS
    KLFPGVTNRVTLTFDGSYQKLVNAAKVDRKDLELGVYKLEFSIEAIHG
    KTINGQEIAKFFLIVIQMVSEAARFKYIETEVVDRGLYGSFKPNFKVL
    NLENNWGDISDAIHKSSPQCTTINPALQLISPSNDPWVVNKVSQISPD
    MGILKFKSSK.
  • Under the scheme of the present invention, the epitopes are compromised by mutation to result in sequences no longer able to function as T-cell epitopes. It is possible to use recombinant DNA methods to achieve directed mutagenesis of the target sequences and many such techniques are available and well known in the art. In practice a number of modified bouganin proteins will be produced and tested for the desired immune and functional characteristic. It is particularly important when conducting modifications to the protein sequence that the contemplated changes do not introduce new immunogenic epitopes. This event is avoided in practice by re-testing the contemplated sequence for the presence of epitopes and/or of MHC class II ligands by any suitable means.
  • The modified bouganin proteins of the invention may also contain or be used to obtain or design “peptide mimetics”. “Peptide mimetics” are structures which serve as substitutes for peptides in interactions between molecules (See Morgan et al (1989), Ann. Reports Med. Chem. 24:243-252 for a review). Peptide mimetics include synthetic structures which may or may not contain amino acids and/or peptide bonds but retain the structural and functional features protein of the invention, including biological activity and a reduced propensity to activate human T cells. Peptide mimetics also include peptoids, oligopeptoids (Simon et al (1972) Proc. Natl. Acad, Sci USA 89:9367).
  • Peptide mimetics may be designed based on information obtained by systematic replacement of L-amino acids by D-amino acids, replacement of side chains with groups having different electronic properties, and by systematic replacement of peptide bonds with amide bond replacements. Local conformational constraints can also be introduced to determine conformational requirements for activity of a candidate peptide mimetic. The mimetics may include isosteric amide bonds, or D-amino acids to stabilize or promote reverse turn conformations and to help stabilize the molecule. Cyclic amino acid analogues may be used to constrain amino acid residues to particular conformational states. The mimetics can also include mimics of the secondary structures of the proteins of the invention. These structures can model the 3-dimensional orientation of amino acid residues into the known secondary conformations of proteins. Peptoids may also be used which are oligomers of N-substituted amino acids and can be used as motifs for the generation of chemically diverse libraries of novel molecules.
  • The molecules of this invention can be prepared in any of several ways but is most preferably conducted exploiting routine recombinant methods. It is a relatively straightforward procedure to use the protein sequences and information provided herein to deduce a polynucleotide (DNA) encoding any of the preferred protein sequences. This can be achieved for example using computer software tools such as the DNSstar software suite [DNAstar Inc, Madison, Wis., USA] or similar. Any such DNA sequence with the capability of encoding the preferred polypeptides of the present or significant homologues thereof, should be considered as embodiments of this invention.
  • As a general scheme, genes encoding any of the preferred modified bouganin protein sequences can be made using gene synthesis and cloned into a suitable expression vector. In turn the expression vector is introduced into a host cell and cells selected and cultured. The proteins of the invention are purified from the culture medium and formulated into a preparation for therapeutic administration. Alternatively, a wild-type bouganin gene sequence can be obtained for example following a cDNA cloning strategy using RNA prepared from the root tissues of the Bougainvillea spectabilis Willd plant. The wild-type gene can be used as a template for mutagenesis and construction preferred variant sequences. In this regard it is particularly convenient to use the strategy of “overlap extension PCR” as described by Higuchi et al [Higuchi et al (1988) Nucleic Acids Res. 16: 7351] although other methodologies and systems could be readily applied.
  • The biological activity of the proteins of the invention can equally be assessed in many ways. In one embodiment, modified bouganin molecules are identified with N-glycosidase activity, and in particular with sufficient activity to provide significant inhibition of protein translation. One such suitable assay involves testing the activity of the modified bouganin proteins in comparison to non-modified bouganin in a cell-free protein synthesis assay. A coupled transcription/translation mix containing methionine, DNA encoding the reporter protein luciferase and serial dilutions of non-modified and modified bouganin proteins are co-incubated. The levels of translated luciferase are readily detected using a luminescence counter following addition of a substrate reagent. The measured luminescence is inversely proportional to the bouganin N-glycosidase activity present in the reaction. It is usual to provide a negative control such as an in-active bouganin protein for example containing a Y70A substitution.
  • Constitution of the preferred and active bouganin molecules may be achieved by recombinant DNA techniques and this includes bouganin molecules fused with desired antibody or other targeting moieties. Methods for purifying and manipulating recombinant proteins including fusion proteins are well known in the art. Necessary techniques are explained fully in the literature, such as, “Molecular Cloning: A Laboratory Manual”, second edition (Sambrook et al., 1989); “Oligonucleotide Synthesis” (M. J. Gait, ed., 1984); “Animal Cell Culture” (R. I. Freshney, ed., 1987); “Methods in Enzymology” (Academic Press, Inc.); “Handbook of Experimental Immunology” (D. M. Weir & C. C. Blackwell, eds.); “Gene Transfer Vectors for Mammalian Cells” (J. M. Miller & M. P. Cabs, eds., 1987); “Current Protocols in Molecular Biology” (F. M. Ausubel et al., eds., 1987); “PCR: The Polymerase Chain Reaction”, (Mullis et al., eds., 1994); “Current Protocols in Immunology” (J. E. Coligan et al., eds., 1991).
  • The proteins and peptides of the invention can be prepared using recombinant DNA methods. The proteins of the invention may also be prepared by chemical synthesis using techniques well known in the chemistry of proteins such as solid phase synthesis (Merrifield, 1964, J. Am. Chem. Assoc. 85:2149-2154) or synthesis in homogenous solution (Houbenweyl, 1987, Methods of Organic Chemistry, ed. E. Wansch, Vol. 15 I and II, Thieme, Stuttgart).
  • The present invention also provides a purified and isolated nucleic acid molecule comprising a sequence encoding the modified bouganin proteins or peptides of the invention, preferably a sequence encoding the protein described herein as SEQ ID NO:13 or SEQ ID NO:14.
  • The term “isolated and purified” as used herein refers to a nucleic acid substantially free of cellular material or culture medium when produced by recombinant DNA techniques, or chemical precursors, or other chemicals when chemically synthesized. An “isolated and purified” nucleic acid is also substantially free of sequences which naturally flank the nucleic acid (i.e. sequences located at the 5′ and 3′ ends of the nucleic acid) from which the nucleic acid is derived.
  • The term “nucleic acid” as used herein refers to a sequence of nucleotide or nucleoside monomers consisting of naturally occurring bases, sugars and intersugar (backbone) linkages. The term also includes modified or substituted sequences comprising non-naturally occurring monomers or portions thereof, which function similarly. The nucleic acid sequences of the present invention may be ribonucleic (RNA) or deoxyribonucleic acids (DNA) and may contain naturally occurring bases including adenine, guanine, cytosine, thymidine and uracil. The sequences may also contain modified bases such as xanthine, hypoxanthine, 2-aminoadenine, 6-methyl, 2-propyl, and other alkyl adenines, 5-halo uracil, 5-halo cytosine, 6-aza uracil, 6-aza cytosine and 6-aza thymine, pseudo uracil, 4-thiouracil, 8-halo adenine, 8-amino adenine, 8-thiol adenine, 8-thio-alkyl adenines, 8-hydroxyl adenine and other 8-substituted adenines, 8-halo guanines, 8-amino guanine, 8-thiol guanine, 8-thioalkyl guanines, 8-hydroxyl guanine and other 8-substituted guanines, other aza and deaza uracils, thymidines, cytosines, adenines, or guanines, 5-trifluoromethyl uracil and 5-trifluoro cytosine.
  • In one embodiment, the purified and isolated nucleic acid molecule comprises a sequence encoding the proteins or peptides, preferably SEQ ID NO: 13 or SEQ ID NO: 14, of the invention, comprising (a) the nucleic acid sequence, wherein T can also be U; (b) nucleic acid sequences complementary to (a); (c) nucleic acid sequences which are homologous to (a) or (b); (d) a fragment of (a) to (c) that is at least 15 bases, preferably 20 to 30 bases, and which will hybridize to (a) to (c) under stringent hybridization conditions; or (e) a nucleic acid molecule differing from any of the nucleic acids of (a) to (c) in codon sequences due to the degeneracy of the genetic code.
  • Further, it will be appreciated that the invention includes nucleic acid molecules comprising nucleic acid sequences having substantial sequence homology with the nucleic acid sequences encoding the proteins and peptides of the invention, and fragments thereof. The term “sequences having substantial sequence homology” means those nucleic acid sequences which have slight or inconsequential sequence variations from these sequences, i.e., the sequences function in substantially the same manner to produce functionally equivalent proteins. The variations may be attributable to local mutations or structural modifications.
  • Nucleic acid sequences having substantial homology include nucleic acid sequences having at least 80%, preferably 90% identity with the nucleic acid sequence encoding the proteins and peptides of the invention. Another aspect of the invention provides a nucleic acid molecule, and fragments thereof having at least 15 bases, which hybridize to nucleic acid molecules of the invention under hybridization conditions, preferably stringent hybridization conditions. Appropriate stringency conditions which promote DNA hybridization are known to those skilled in the art, or may be found in Current Protocols in Molecular Biology, John Wiley & Sons, N.Y. (1989), 6.3.1-6.3.6. For example, the following may be employed: 6.0 x sodium chloride/sodium citrate (SSC) at about 45° C., followed by a wash of 2.0×SSC at 50° C. The stringency may be selected based on the conditions used in the wash step. For example, the salt concentration in the wash step can be selected from a high stringency of about 0.2×SSC at 50° C. In addition, the temperature in the wash step can be at high stringency conditions, at about 65° C.
  • Accordingly, nucleic acid molecules of the present invention having a sequence which encodes a protein or peptide of the invention may be incorporated according to procedures known in the art into an appropriate expression vector which ensures good expression of the protein or peptide. Possible expression vectors include but are not limited to cosmids, plasmids, or modified viruses (e.g., replication defective retroviruses, adenoviruses and adeno associated viruses), so long as the vector is compatible with the host cell used. The expression “vectors suitable for transformation of a host cell”, means that the expression vectors contain a nucleic acid molecule of the invention and regulatory sequences, selected on the basis of the host cells to be used for expression, which are operatively linked to the nucleic acid molecule. “Operatively linked” is intended to mean that the nucleic acid is linked to regulatory sequences in a manner which allows expression of the nucleic acid.
  • The invention therefore contemplates a recombinant expression vector of the invention containing a nucleic acid molecule of the invention, or a fragment thereof, and the necessary regulatory sequences for the transcription and translation of the inserted protein-sequence. Suitable regulatory sequences may be derived from a variety of sources, including bacterial, fungal, or viral genes (For example, see the regulatory sequences described in Goeddel, Gene Expression Technology: Methods in Enzymology 185, Academic Press, San Diego, Calif. (1990). Selection of appropriate regulatory sequences is dependent on the host cell chosen, and may be readily accomplished by one of ordinary skill in the art. Examples of such regulatory sequences include: a transcriptional promoter and enhancer or RNA polymerase binding sequence, a ribosomal binding sequence, including a translation initiation signal. Additionally, depending on the host cell chosen and the vector employed, other sequences, such as an origin of replication, additional DNA restriction sites, enhancers, and sequences conferring inducibility of transcription may be incorporated into the expression vector. It will also be appreciated that the necessary regulatory sequences may be supplied by the native protein and/or its flanking regions.
  • The recombinant expression vectors of the invention may also contain a selectable marker gene which facilitates the selection of host cells transformed or transfected with a recombinant molecule of the invention. Examples of selectable marker genes are genes encoding a protein such as G418 and hygromycin which confer resistance to certain drugs, β-galactosidase, chloramphenicol acetyltransferase, or firefly luciferase. Transcription of the selectable marker gene is monitored by changes in the concentration of the selectable marker protein such as β-galactosidase, chloramphenicol acetyltransferase, or firefly luciferase. If the selectable marker gene encodes a protein conferring antibiotic resistance such as neomycin resistance transformant cells can be selected with G418. Cells that have incorporated the selectable marker gene will survive, while the other cells die. This makes it possible to visualize and assay for expression of recombinant expression vectors of the invention and in particular to determine the effect of a mutation on expression and phenotype. It will be appreciated that selectable markers can be introduced on a separate vector from the nucleic acid of interest.
  • The recombinant expression vectors may also contain genes which encode a fusion moiety which provides increased expression of the recombinant protein; increased solubility of the recombinant protein; and aid in the purification of a target recombinant protein by acting as a ligand in affinity purification. For example, a proteolytic cleavage site may be added to the target recombinant protein to allow separation of the recombinant protein from the fusion moiety subsequent to purification of the fusion protein.
  • Recombinant expression vectors can be introduced into host cells to produce a transformed host cell. The term “transformed host cell” is intended to include prokaryotic and eukaryotic cells which have been transformed or transfected with a recombinant expression vector of the invention. The terms “transformed with”, “transfected with”, “transformation” and “transfection” are intended to encompass introduction of nucleic acid (e.g. a vector) into a cell by one of many possible techniques known in the art. Prokaryotic cells can be transformed with nucleic acid by, for example, electroporation or calcium-chloride mediated transformation. Nucleic acid can be introduced into mammalian cells via conventional techniques such as calcium phosphate or calcium chloride co-precipitation, DEAE-dextran mediated transfection, lipofectin, electroporation or microinjection. Suitable methods for transforming and transfecting host cells can be found in Sambrook et al. (Molecular Cloning: A Laboratory Manual, 2nd Edition, Cold Spring Harbor Laboratory press (1989)), and other such laboratory textbooks.
  • Suitable host cells include a wide variety of prokaryotic and eukaryotic host cells. For example, the proteins of the invention may be expressed in bacterial cells such as E. coli, insect cells (using baculovirus), yeast cells or mammalian cells. Other suitable host cells can be found in Goeddel, Gene Expression Technology Methods in Enzymology 185, Academic Press, San Diego, Calif. (1991).
  • Nucleic acid is “operably linked” when it is placed into a functional relationship with another nucleic acid sequence. For example, DNA for a presequence or secretory leader is operably linked to DNA for a polypeptide if it is expressed as a preprotein that participates in the secretion of the polypeptide; a promoter or enhancer is operably linked to a coding sequence if it affects the transcription of the sequence; or a ribosome binding site is operably linked to a coding sequence if it is positioned so as to facilitate translation. Generally, “operably linked” means that the DNA sequences being linked are contiguous, and, in the case of a secretory leader, contiguous and in reading frame. However, enhancers do not have to be contiguous. Linking is accomplished by ligation at convenient restriction sites. If such sites do not exist, the synthetic oligonucleotide adaptors or linkers are used in accordance with conventional practice.
  • In some embodiments the expression vector comprises a nucleic acid sequence encoding a modified bouganin with a reduced number of potential T cell epitopes, operably linked to an expression control sequence. In various embodiments the expression vector comprises a nucleic acid sequence encoding the proteins or peptides of the invention, or a degenerate variant thereof and will comprise at least the RIP encoding domain of the said nucleic acids operably linked with suitable expression control and selection sequences. Degeneracy in relation to polynucleotides refers to the fact well recognized that in the genetic code many amino acids are specified by more than one codon. The degeneracy of the code accounts for 20 different amino acids encoded by 64 possible triplet sequences of the four different bases comprising DNA.
  • The term “RIP encoding domain” or “Ribosome Inactivating Protein encoding domain” as used here in means the functional domain which gives bouganin its biological activity.
  • The nucleic acid molecules of the invention may also be chemically synthesized using standard techniques. Various methods of chemically synthesizing polydeoxynucleotides are known, including solid-phase synthesis which, like peptide synthesis, has been fully automated in commercially available DNA synthesizers (See e.g., Itakura et al. U.S. Pat. No. 4,598,049; Caruthers et al. U.S. Pat. No. 4,458,066; and Itakura U.S. Pat. Nos. 4,401,796 and 4,373,071).
  • The invention also provides nucleic acids encoding fusion proteins comprising a novel protein of the invention and a selected protein, or a selectable marker protein.
  • Another aspect of the present invention is a cultured cell comprising at least one of the above-mentioned vectors.
  • A further aspect of the present invention is a method for preparing the modified bouganin comprising culturing the above mentioned cell under conditions permitting expression of the modified bouganin from the expression vector and purifying the bouganin from the cell.
    • (B) Modified Bouganin Cytotoxins:
  • As mentioned previously, bouganin is a type 1 ribosome inactivating protein (RIP) that depurinates the major ribosomal RNA of cells leading to cessation of protein synthesis and cell death. As such, the modified bouganins of the invention can be used to prepare cytotoxins. Cytotoxins containing a modified bouganin protein are preferred over cytotoxins containing a non-modified bouganin protein as the former is less immunogenic and will be less likely to be destroyed by the immune system before it reaches its target.
  • Accordingly, the present invention also provides a cytotoxin comprising (a) a targeting moiety attached to (b) a modified bouganin protein of the invention.
  • The term “modified bouganin protein of the invention” is used for ease of referral and includes any and all of the modified bouganin proteins described herein such as the modified bouganin proteins described above in Section (A) as well as in the figures and examples.
  • The term “targeting moiety” as used herein refers to a substance, means, or technique of delivering the modified bouganin protein to a target cell. In one embodiment the targeting moiety is an antibody. In one embodiment the targeting moiety could be a liposome. In one embodiment the liposome can be linked to an antibody. In another embodiment the targeting moiety is a protein able to direct a specific binding interaction to a particular target cell. Such protein moieties include a variety of polypeptide ligands for which there are specific cell surface receptors and include therefore numerous cytokines, peptide and polypeptide hormones and other biological response modifiers. Prominent examples include such proteins as vascular epithelial growth factor, epidermal growth factor, heregulin, the interleukins, interferons, tumour necrosis factor and other protein and glycoprotein molecules. Fusion proteins of these and other molecules with bouganin of the present invention may be contemplated and may comprise the modified bouganin moiety in either the N-terminal or C-terminal orientation with respect to the protein ligand domain. The targeting moiety may be jointed directly to the proteins of the invention or through a linker. In one embodiment, the linker is a peptide linker or a chemical linker. Equally, chemical cross-linking of the purified ligand to the modified bouganin protein may be contemplated and within the scope of the present invention.
  • In a preferred embodiment, the present invention provides a cytotoxin comprising (a) a ligand that binds to a cancer cell attached to; (b) a modified bouganin protein of the invention.
  • The ligand can be any molecule that can bind to a cancer cell including, but not limited to, proteins. In one embodiment, the ligand is an antibody or antibody fragment that recognizes the surface of a cancer cell.
  • Accordingly, the cytotoxins of the present invention may be used to treat various forms of cancer such as colorectal cancer, breast cancer, ovarian cancer, pancreatic cancer, head and neck cancer, bladder cancer, gastrointestinal cancer, prostate cancer, small cell and non small cell lung cancer, sarcomas, gliomas, T- and B-cell lymphomas.
  • In one embodiment, the cancer cell binding ligand comprises a complete immunoglobulin molecule that binds to the cancer cell. When a cancer cell binding ligand is an antibody or fragment thereof, cytotoxin can be referred to as immunotoxin. In another embodiment, the cancer cell-binding ligand is a dimer of Fab, Fab′, scFv, single-domain antibody fragments, or disulfide stabilized Fv fragments. In another embodiment, the cancer antibody comprises a variable heavy chain, variable light chain, Fab, Fab′, scFv, single-domain antibody fragment, or disulfide-stabilized Fv fragment. Portions of the cancer cell-binding ligand may be derived from one or more species, preferably comprising portions derived from the human species, and most preferably are completely human or humanized. Regions designed to facilitate purification or for conjugation to toxin may also be included in or added to the cancer cell-binding portion.
  • In a particular embodiment, the cancer cell binding ligand recognizes Ep-CAM. Ep-CAM (for Epithelial Cell Adhesion Molecule, which is also known as 17-1A, KSA, EGP-2 and GA733-2) is a transmembrane protein that is highly expressed in many solid tumors, including carcinomas of the lung, breast, ovary, colorectum, and squamous cell carcinoma of the head and neck, but weakly expressed in most normal epithelial tissues.
  • Accordingly, in one embodiment, the invention provides an Ep-CAM-targeted-modified bouganin cytotoxin comprising (a) a ligand (such as an antibody or antibody fragment) that binds to Ep-CAM on the cancer cell attached to; (b) a modified bouganin protein having a reduced propensity to activate T-cells as compared to a non-modified bouganin protein.
  • In a specific embodiment, the cytotoxin comprises (a) a humanized antibody or antibody fragment that binds to the extracellular domain of human Ep-CAM and comprises complementarity determining region (CDR) sequences derived from a MOC-31 antibody attached to: (b) a modified bouganin protein having a reduced propensity to activate T-cells as compared to a non-modified bouganin protein.
  • Suitable Ep-CAM-targeted-modified bouganins according to the invention include, without limitation, VB6-845 and variants thereof, other cytotoxins that comprises other single or double chain immunoglobulins that selectively bind Ep-CAM, or variants thereof. The term “VB6-845” as used herein means a cytotoxin that comprises a Fab version of an anti-Ep-CAM scFv antibody linked to a modified form of bouganin, Bou 156 (SEQ ID NO:13). The amino acid sequence and nucleotide sequence of VB6-845 is shown in FIG. 3B (SEQ ID NO:16 and SEQ ID NO:15, respectively).
  • In another embodiment, the cancer cell binding ligand recognizes a tumor-associated antigen that is found specifically on neoplastic cells and not on normal cells. In a preferred embodiment, the ligand is an antibody that binds tumor-associated antigen. The anti-tumor-associated-antigen antibody specifically recognizes cancer cells from a wide variety of cancers but does not recognize normal, non-cancerous cells.
  • Accordingly in another embodiment, the invention provides a cytotoxin comprising (a) ligand (such as an antibody or antibody fragment) that binds to tumor-associated antigen on the cancer cell attached to; (b) a modified bouganin protein having a reduced propensity to activate T-cells as compared to a non-modified bouganin protein.
  • Suitable tumor-associated-antigen-targeted-modified bouganins according to the invention include, without limitation, VB6-011 and variants thereof, other cytotoxins that comprises other single or double chain immunoglobulins that selectively bind tumor-associated-antigen, or variants thereof. The term “VB6-011” as used herein means a cytotoxin that comprises a Fab version of the H11 human monoclonal antibody genetically linked to a modified form of bouganin, BOU 156 (SEQ ID No. 13). The H11 antibody was obtained by the fusion of peripheral blood lymphocytes of a 64 year old male cancer patient fused with a human myeloma cell line to produce hybridomas. The hybridoma NBGM1/H11 produces an IgMk that was re-engineered into a Fab format to make VB6-011 (see U.S. Pat. No. 6,207,153 or WO 97/44461 for detail on the preparation of the H11 antibody-secreting hybridoma). The amino acid sequence and nucleotide sequence of VB6-011 is shown in FIG. 15 (SEQ ID NO:28 and SEQ ID NO:27, respectively).
  • In a specific, non-limiting embodiment, the cytotoxin comprises VB6-845 (FIG. 3B, SEQ ID No. 16) or VB6-011 (FIG. 15, SEQ ID NO: 28). In other non-limiting embodiments, the cytotoxin comprises a variant of VB6-845 or VB6-011.
  • A VB6-845 variant binds to the same Ep-CAM epitope or to a substantially similar Ep-CAM epitope that is bound by VB6-845, and the variant may competitively inhibit VB6-845 binding to Ep-CAM, under physiologic conditions, by at least 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, or 95%. A VB6-845 variant may comprise the same modified bouganin as VB6-845, or may comprise a different modified bouganin of the invention. In another non-limiting embodiment, the cytotoxin comprises an Ep-CAM-binding portion comprising the variable region of MOC31, or a variant thereof. In yet another embodiment, the cytotoxin comprises an Ep-CAM-binding portion comprising 4D5MOCB, or a variant thereof. Binding of any of these cytotoxins to Ep-CAM may be reduced by at least 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, or 95% by competition with the reference MOC31 or 4D5MOCB antibody under physiologic conditions.
  • A VB6-011 variant binds to the same tumor-associated-antigen epitope or to a substantially similar tumor-associated-antigen epitope that is bound by VB6-011, and the variant may competitively inhibit VB6-011 binding to tumor-associated-antigen, under physiologic conditions, by at least 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, or 95%. A VB6-011 variant may comprise the same modified bouganin as VB6-011, or may comprise a different modified bouganin of the invention.
  • In another non-limiting embodiment, the cytotoxin comprises a tumor-associated-antigen binding portion comprising the H11 monoclonal antibody, H11 antigen binding fragments, or variants thereof. Binding of any of these cytotoxins to VB6-011 may be reduced by at least 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, or 95% by competition with the reference H11 antibody under physiologic conditions.
  • In a preferred embodiment, the binding affinity of the Ep-CAM-binding portion or the tumor-associated-antigen-binding portion is at least four orders of magnitude, preferably at least three orders of magnitude, more preferably less than two orders of magnitude of the binding affinity of VB6-845 or VB6-011 respectively as measured by standard laboratory techniques. In non-limiting embodiments, the Ep-CAM-binding portion may competitively block the binding of a known anti-Ep-CAM antibody, such as, but not limited to, PANOREX® or MT201, to Ep-CAM, under physiologic conditions, by at least 0.1%, 1%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, or 95%. In non-limiting embodiments, the tumor-associated-antigen-binding portion may competitively block the binding of a known anti-tumor-associated-antigen antibody, such as, but not limited to, H11, to tumor-associated antigen, under physiologic conditions, by at least 0.1%, 1%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, or 95%.
  • The skilled artisan would appreciate that specificity determining residues can be identified. The term “specificity determining residue,” also known as “SDR,” refers to a residue that forms part of the paratope of an antibody, particularly CDR residues, the individual substitution of which by alanine, independently of any other mutations, diminishes the affinity of the antibody for the epitope by at least 10 fold, preferably by at least 100 fold, more preferably by at least 1000 fold. This loss in affinity underscores that residue's importance in the ability of the antibody to bind the epitope. See, e.g., Tamura et al., 2000, “Structural correlates of an anticarcinoma antibody: identification of specificity-determining residues (SDRs) and development of a minimally immunogenic antibody variant by retention of SDRs only,” J. Immunol. 164(3):1432-1441.
  • The effect of single or multiple mutations on binding activity, particularly on binding affinity, may be evaluated contemporaneously to assess the importance of a particular series of amino acids on the binding interaction (e.g., the contribution of the light or heavy chain CDR2 to binding). Effects of an amino acid mutation may also be evaluated sequentially to assess the contribution of a single amino acid when assessed individually. Such evaluations can be performed, for example, by in vitro saturation scanning (see, e.g., U.S. Pat. No. 6,180,341; Hilton et al., 1996, “Saturation mutagenesis of the WSXWS motif of the erythropoietin receptor,” J Biol. Chem. 271:4699-4708) and site-directed mutagenesis (see, e.g., Cunningham and Wells, 1989, “High-resolution epitope mapping of hGH-receptor interactions by alanine-scanning mutagenesis,” Science 244:1081-1085; Bass et al., 1991, “A systematic mutational analysis of hormone-binding determinants in the human growth hormone receptor,” Proc Natl Acad Sci. USA 88:4498-4502). In the alanine-scanning mutagenesis technique, single alanine mutations are introduced at multiple residues in the molecule, and the resultant mutant molecules are tested for biological activity to identify amino acid residues that are critical to the activity of the molecule.
  • Sites of ligand-receptor or other biological interaction can also be identified by physical analysis of structure as determined by, for example, nuclear magnetic resonance, crystallography, electron diffraction, or photoaffinity labeling, in conjunction with mutation of putative contact site amino acids (see, e.g., de Vos et al., 1992, “Human growth hormone and extracellular domain of its receptor: crystal structure of the complex,” Science 255:306-312; Smith et al., 1992, “Human interleukin 4 The solution structure of a four-helix bundle protein,” J Mol Biol. 224:899-904; Wlodaver et al., 1992, “Crystal structure of human recombinant interleukin-4 at 2.25 A resolution,” FEBS Lett. 309:59-64). Additionally, the importance of particular individual amino acids, or series of amino acids, may be evaluated by comparison with the amino acid sequence of related polypeptides or analogous binding sites.
  • Furthermore, the skilled artisan would appreciate that increased avidity may compensate for lower binding affinity. The avidity of a cytotoxin for a cancer cell receptor is a measure of the strength of the Ep-CAM-binding portion's binding of Ep-CAM, which has multiple binding sites. The functional binding strength between Ep-CAM and the Ep-CAM-binding portion represents the sum strength of all the affinity bonds, and thus an individual component may bind with relatively low affinity, but a multimer of such components may demonstrate potent biological effect. In fact, the multiple interactions between Ep-CAM-binding sites and Ep-CAM epitopes may demonstrate much greater than additive biological effect, i.e., the advantage of multivalence can be many orders of magnitude with respect to the equilibrium constant.
  • Similarly, the avidity of a cytotoxin for a cancer cell receptor is a measure of the strength of the tumor-associated antigen-binding portion's binding of tumor-associated antigen, which may have multiple binding sites. The functional binding strength between tumor-associated antigen and the tumor-associated antigen-binding portion represents the sum strength of all the affinity bonds, and thus an individual component may bind with relatively low affinity, but a multimer of such components may demonstrate potent biological effect. In fact, the multiple interactions between tumor-associated antigen-binding sites and tumor-associated antigen epitopes may demonstrate much greater than additive biological effect, i.e., the advantage of multivalence can be many orders of magnitude with respect to the equilibrium constant.
  • In one non-limiting embodiment, the Ep-CAM-binding portion has a structure substantially similar to that of 4D5MOCB. The substantially similar structure can be characterized by reference to epitope maps that reflect the binding points of the cytotoxin's Ep-CAM-binding portion to an Ep-CAM molecule. In another non-limiting embodiment, epitope maps can be generated for the tumor-associated antigen binding portion and a substantially similar structure can be characterized by reference to epitope maps that reflect the binding points of the cytotoxin's tumor-associated antigen binding portion to a tumor-associated antigen molecule.
  • The cytotoxins of the present invention may be prepared by chemical synthesis using techniques well known in the chemistry of proteins such as solid phase synthesis (Merrifield, J. Am. Chem. Assoc. 85:2149-2154 (1964)) or synthesis in homogenous solution (Houbenweyl, Methods of Organic Chemistry, ed. E. Wansch, Vol. 15 I and II, Thieme, Stuttgart (1987)). In one embodiment, the cancer-binding ligand and modified bouganin are both proteins and can be conjugated using techniques well known in the art. There are several hundred crosslinkers available that can conjugate two proteins. (See for example “Chemistry of Protein Conjugation and Crosslinking”. 1991, Shans Wong, CRC Press, Ann Arbor). The crosslinker is generally chosen based on the reactive functional groups available or inserted on the ligand or toxin. In addition, if there are no reactive groups a photoactivatible crosslinker can be used. In certain instances, it may be desirable to include a spacer between the ligand and the toxin. Crosslinking agents known to the art include the homobifunctional agents: glutaraldehyde, dimethyladipimidate and Bis(diazobenzidine) and the heterobifunctional agents: m Maleimidobenzoyl-N-Hydroxysuccinimide and Sulfo-m Maleimidobenzoyl-N-Hydroxysuccinimide.
  • A ligand-bouganin toxin fusion protein may also be prepared using recombinant DNA techniques. In such a case a DNA sequence encoding the cancer-binding ligand is fused to a DNA sequence encoding the modified bouganin protein, resulting in a chimeric DNA molecule. The chimeric DNA sequence is transfected into a host cell that expresses the ligand-bouganin fusion protein. The fusion protein can be recovered from the cell culture and purified using techniques known in the art.
  • Antibodies having specificity for cell surface proteins such as Ep-CAM and tumor-associated antigen may be prepared by conventional methods. A mammal, (e.g. a mouse, hamster, or rabbit) can be immunized with an immunogenic form of the peptide which elicits an antibody response in the mammal. Techniques for conferring immunogenicity on a peptide include conjugation to carriers or other techniques well known in the art. For example, the peptide can be administered in the presence of adjuvant. The progress of immunization can be monitored by detection of antibody titers in plasma or serum. Standard ELISA or other immunoassay procedures can be used with the immunogen as antigen to assess the levels of antibodies. Following immunization, antisera can be obtained and, if desired, polyclonal antibodies isolated from the sera.
  • To produce monoclonal antibodies, antibody-producing cells (lymphocytes) can be harvested from an immunized animal and fused with myeloma cells by standard somatic cell fusion procedures thus immortalizing these cells and yielding hybridoma cells. Such techniques are well known in the art, (e.g. the hybridoma technique originally developed by Kohler and Milstein (Nature 256:495-497 (1975)) as well as other techniques such as the human B-cell hybridoma technique (Kozbor et al., Immunol. Today 4:72 (1983)), the EBV-hybridoma technique to produce human monoclonal antibodies (Cole et al., Monoclonal Antibodies in Cancer Therapy Allen R., Bliss, Inc., pages 77-96 (1985)), and screening of combinatorial antibody libraries (Huse et al., Science 246:1275 (1989)). Hybridoma cells can be screened immunochemically for production of antibodies specifically reactive with the peptide and the monoclonal antibodies can be isolated.
  • The term “antibody” as used herein is intended to include monoclonal antibodies and polyclonal antibodies, antibody fragments (e.g. Fab and F(ab′)2, and single chain antibodies (scFv)), and chimeric antibodies which also specifically react with a cell surface component. Antibodies can be fragmented using conventional techniques and the fragments screened for utility in the same manner as described above. For example, F(ab′)2 fragments can be generated by treating antibody with pepsin. The resulting F(ab′)2 fragment can be treated to reduce disulfide bridges to produce Fab′ fragments. Single chain antibodies combine the antigen-binding regions of an antibody on a single stably folded polypeptide chain. Single chain antibodies can be generated by recombinant technology.
  • Chimeric antibody derivatives, i.e., antibody molecules that combine a non-human animal variable region and a human constant region are also contemplated within the scope of the invention. Chimeric antibody molecules can include, for example, the antigen binding domain from an antibody of a mouse, rat, or other species, with human constant regions. Conventional methods may be used to make chimeric antibodies containing the immunoglobulin variable region which recognizes a cell surface antigen (See, for example, Morrison et al., Proc. Natl Acad. Sci. U.S.A. 81:6851 (1985); Takeda et al., Nature 314:452 (1985), Cabilly et al., U.S. Pat. No. 4,816,567; Boss et al., U.S. Pat. No. 4,816,397; Tanaguchi et al., E.P. Patent No. 171,496; European Patent No. 173,494, United Kingdom Patent No. GB 2177096B). It is expected that chimeric antibodies would be less immunogenic in a human subject than the corresponding non-chimeric antibody. Chimeric antibodies can be stabilized by the method described in Pluckthun et al., WO 00/61635.
  • Monoclonal or chimeric antibodies specifically reactive against cell surface components can be further humanized by producing human constant region chimeras, in which parts of the variable regions, particularly the conserved framework regions of the antigen-binding domain, are of human origin and only the hypervariable regions are of non-human origin. Such immunoglobulin molecules may be made by techniques known in the art, (e.g. Teng et al., Proc. Natl. Acad. Sci. U.S.A., 80:7308-7312 (1983); Kozbor et al., Immunology Today 4:7279 (1983); Olsson et al., Meth. Enzymol., 92:3-16 (1982), and PCT Publication WO92/06193 or EP 239,400). Humanized antibodies can also be commercially produced (Scotgen Limited, 2 Holly Road, Twickenham, Middlesex, Great Britain.) In addition, monoclonal or chimeric antibodies specifically reactive against cell surface components can be made less immunogenic by reducing their number of potential T-cell epitopes.
  • Specific antibodies, or antibody fragments, reactive against cell surface components may also be generated by screening expression libraries encoding immunoglobulin genes, or portions thereof, expressed in bacteria with cell surface components. For example, complete Fab fragments, VH regions and Fv regions can be expressed in bacteria using phage expression libraries (See for example Ward et al., Nature 341:544-546 (1989); Huse et al., Science 246:1275-1281 (1989); and McCafferty et al., Nature 348:552-554 (1990)). Alternatively, a SCID-hu mouse, for example the model developed by Genpharm, can be used to produce antibodies, or fragments thereof.
  • In all instances where a modified bouganin protein is made in fusion with an antibody sequence it is most desired to use antibody sequences in which T cell epitopes or sequences able to bind MHC class II molecules or stimulate T cells or bind to T cells in association with MHC class II molecules have been removed.
  • A further embodiment of the present invention, the modified bouganin protein may be linked to a non-antibody protein yet a protein able to direct a specific binding interaction to a particular target cell. Such protein moieties include a variety of polypeptide ligands for which there are specific cell surface receptors and include therefore numerous cytokines, peptide and polypeptide hormones and other biological response modifiers. Prominent examples include such proteins as vascular epithelial growth factor, epidermal growth factor, heregulin, the interleukins, interferons, tumour necrosis factor and other protein and glycoprotein molecules. Fusion proteins of these and other molecules with bouganin of the present invention may be contemplated and may comprise the modified bouganin moiety in either the N-terminal or C-terminal orientation with respect to the protein ligand domain. Equally, chemical cross-linking of the purified ligand to the modified bouganin protein may be contemplated and within the scope of the present invention.
  • In a further embodiment the modified bouganin protein of the present invention may be used as a complex containing a water soluble polymer such as hydroxypropylmethacrylamide or other polymers where the modified bouganin protein is in covalent attachment to the polymer or in a non-covalent binding interaction with the polymer. Such an embodiment may additionally include an antigen binding domain such as an antibody or a fragment of an antibody in combination with the polymer bouganin complex.
    • (C) Uses of the Cytotoxins
  • The modified bouganin proteins of the invention may be used to specifically inhibit or destroy mammalian cells affected by cancer. It is an advantage of the cytotoxins of the invention that they have less immunogenicity, allowing the RIP to enter the cell and effectively kill the cancer cell. Thus, the cytotoxin may be used to specifically target cancer cells. The bouganin, once in the cancer cell, depurinates the major ribosomal RNA, thereby damaging the ribosomes and leading to a cessation of protein synthesis and cell death.
  • Accordingly, in one embodiment, the invention provides a method of inhibiting or destroying a cancer cell comprising administering a cytotoxin of the invention to an animal in need thereof. The present invention also includes a use of a cytotoxin of the invention to inhibit or destroy a cancer cell. The present invention further includes a use of a cytotoxin of the invention in the manufacture of a medicament to inhibit or destroy a cancer cell. The type of cancer cells that are inhibited or destroyed by a cytotoxin will be determined by the antigen specificity of its antibody portion.
  • In another embodiment, the invention provides a method of inhibiting or destroying cancer cells comprising the steps of preparing a cytotoxin of the invention and administering the cytotoxin to the cells. The cancer can be any type of cancer, including, but not limited to, colorectal cancer, breast cancer, ovarian cancer, pancreatic cancer, head and neck cancer, bladder cancer, liver cancer, renal cancer, melanomas, gastrointestinal cancer, prostate cancer, small cell and non small cell lung cancer, sarcomas, gliomas, T- and B-cell lymphomas.
  • The ability of the cytotoxins of the invention to selectively inhibit or destroy animal cancer cells may be readily tested in vitro using animal cancer cell lines. The selective inhibitory effect of the cytotoxins of the invention may be determined, for example, by demonstrating the selective inhibition of cellular proliferation in cancer cells.
  • Toxicity may be measured based on cell viability, for example the viability of normal and cancerous cell cultures exposed to the cytotoxins may be compared. Cell viability may be assessed by known techniques, such as trypan blue exclusion assays.
  • In another example, a number of models may be used to test the cytotoxicity of cytotoxins. Thompson, E. W. et al. (Breast Cancer Res. Treatment 31:357-370 (1994)) has described a model for the determination of invasiveness of human breast cancer cells in vitro by measuring tumour cell-mediated proteolysis of extracellular matrix and tumour cell invasion of reconstituted basement membrane (collagen, laminin, fibronectin, Matrigel or gelatin). Other applicable cancer cell models include cultured ovarian adenocarcinoma cells (Young, T. N. et al. Gynecol. Oncol. 62:89-99 (1996); Moore, D. H. et al. Gynecol. Oncol. 65:78-82 (1997)), human follicular thyroid cancer cells (Demeure, M. J. et al., World J. Surg. 16:770-776 (1992)), human melanoma (A-2058) and fibrosarcoma (HT-1080) cell lines (Mackay, A. R. et al. Lab. Invest. 70:781-783 (1994)), and lung squamous (HS-24) and adenocarcinoma (SB-3) cell lines (Spiess, E. et al. J. Histochem. Cytochem. 42:917-929 (1994)). An in vivo test system involving the implantation of tumours and measurement of tumour growth and metastasis in athymic nude mice has also been described (Thompson, E. W. et al., Breast Cancer Res. Treatment 31:357-370 (1994); Shi, Y. E. et al., Cancer Res. 53:1409-1415 (1993)).
  • The present invention also relates to a method of treating cancer comprising administering an effective amount of one or more cytotoxins of the present invention to an animal in need thereof. The invention includes a use of a cytotoxin of the invention to treat cancer. The invention further includes a use of a cytotoxin of the invention in the manufacture of a medicament for treating cancer.
  • The term “animal” includes all members of the animal kingdom, including humans.
  • The term “treating cancer” or “treat cancer” refers to inhibition of cancer cell replication, inhibition of cancer spread (metastasis), inhibition of tumor growth, reduction of cancer cell number or tumor growth, decrease in the malignant grade of a cancer or improvement of cancer related symptoms.
  • In a preferred embodiment, the animal is human. In another embodiment, the cancer is selected from the group consisting of colorectal cancer, breast cancer, ovarian cancer, pancreatic cancer, head and neck cancer, bladder cancer, liver cancer, renal cancer, melanomas, gastrointestinal cancer, prostate cancer, small cell and non small cell lung cancer, sarcomas, gliomas and T- and B-cell lymphomas.
  • Clinical outcomes of cancer treatments using a cytotoxin of the invention are readily discernible by one of skill in the relevant art, such as a physician. For example, standard medical tests to measure clinical markers of cancer may be strong indicators of the treatment's efficacy. Such tests may include, without limitation, physical examination, performance scales, disease markers, 12-lead ECG, tumor measurements, tissue biopsy, cytoscopy, cytology, longest diameter of tumor calculations, radiography, digital imaging of the tumor, vital signs, weight, recordation of adverse events, assessment of infectious episodes, assessment of concomitant medications, pain assessment, blood or serum chemistry, urinalysis, CT scan, and pharmacokinetic analysis. Furthermore, synergistic effects of a combination therapy comprising the cytotoxin and another cancer therapeutic may be determined by comparative studies with patients undergoing monotherapy.
  • Remission malignant tumors may be evaluated using criteria accepted by the skilled artisan. See, e.g., Therasse et al., 2000, “New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada,” J Natl Cancer Inst. Feb 2; 92(3):205-16.
  • The effective dose of a specific cytotoxin construct may depend on various factors, including the type of cancer, the size of the tumour, the stage of the cancer, the cytotoxin's toxicity to the patient, the specificity of targeting to cancer cells, as well as the age, weight, and health of the patient.
  • Cytotoxins comprising the modified bouganin can be administered by i.v. infusion over a period of minutes to hours, depending on the dose and the concentration of the cytotoxin in the infusate.
  • In one embodiment, the cytotoxin is infused over a period of 3 hours.
  • In one embodiment, the effective dose by i.v. administration of cytotoxin may range from about 1 to 100 mg/kg/dose. In other embodiments, the dose may range from approximately 2 to 50 mg/kg/dose. In specific embodiments, the dose may be at least approximately 2, 4, 8, 13, 20, 28, 40, 50 mg/kg/dose.
  • In one embodiment, the single dose is administered approximately every week for approximately 1, 2, 3, 4, 5, or 6 weeks. The single dose can be administered in consecutive weeks or, alternatively, one or more weeks can be skipped. After this cycle, a subsequent cycle may begin approximately 1, 2, 4, 6, or 12 weeks later. The treatment regime may include 1, 2, 3, 4, 5, 6 or more cycles, each cycle being spaced apart by approximately 1, 2, 4, 6, or 12 weeks.
  • In another embodiment the single dose is administered every month for approximately 1, 2, 3, 4, 5, or 6 consecutive months. After this cycle, a subsequent cycle may begin approximately 1, 2, 4, 6, or 12 months later. The treatment regime may include 1, 2, 3, 4, 5, 6 or more cycles, each cycle being spaced apart by approximately 1, 2, 4, 6, or 12 months.
  • In a particular non-limiting embodiment, the effective dose of the cytotoxin is between about 1 and 50 mg/kg/tumor/day, wherein the patient is administered a single dose per day. The single dose is administered approximately every day (one or more days may optionally be skipped) for approximately 1, 2, 3, 4, 5, 6 or 7 consecutive days. After this cycle, a subsequent cycle may begin approximately 1, 2, 3, 4, 5, or 6 weeks later. The treatment regime may include 1, 2, 3, 4, 5, 6 or more cycles, each cycle being spaced apart by approximately 1, 2, 3, 4, 5, or 6 weeks. The injection volume preferably is at least an effective amount, which is appropriate to the type and/or location of the tumor. The maximum injection volume in a single dose may be between about 25% and 75% of tumor volume, for example approximately one-quarter, one-third, or three-quarters of the estimated target tumor volume. In a specific, non-limiting embodiment, the maximum injection volume in a single dose is approximately 30% of the tumor volume.
  • In another embodiment, the cytotoxin is infused for 3 hours at a rate of 100 cc per hour with a solution containing from 1 to 10 mg cytotoxin/mL. The cytotoxin will be diluted in a suitable physiologically compatible solution.
  • The effective dose of another cancer therapeutic to be administered together with a cytotoxin during a cycle also varies according to the mode of administration. The one or more cancer therapeutics may be delivered intratumorally, or by other modes of administration. Typically, chemotherapeutic agents are administered systemically. Standard dosage and treatment regimens are known in the art (see, e.g., the latest editions of the Merck Index and the Physician's Desk Reference; NCCN Practice Guidelines in Oncology)).
  • Combination therapy with a cytotoxin may sensitize the cancer or tumor to administration of an additional cancer therapeutic. Accordingly, the present invention contemplates combination therapies for preventing, treating, and/or preventing recurrence of cancer comprising administering an effective amount of a cytotoxin prior to, subsequently, or concurrently with a reduced dose of a cancer therapeutic. For example, initial treatment with a cytotoxin may increase the sensitivity of a cancer or tumor to subsequent challenge with a dose of cancer therapeutic. This dose is near, or below, the low range of standard dosages when the cancer therapeutic is administered alone, or in the absence of a cytotoxin. When concurrently administered, the cytotoxin may be administered separately from the cancer therapeutic, and optionally, via a different mode of administration.
  • In another embodiment, a cytotoxin is administered in combination with at least one other immunotherapeutic.
  • In another embodiment, a cytotoxin is administered in combination with a regimen of radiation therapy. The therapy may also comprise surgery and/or chemotherapy. For example, the cytotoxin may be administered in combination with radiation therapy and cisplatin (Platinol), fluorouracil (5-FU, Adrucil), carboplatin (Paraplatin), and/or paclitaxel (Taxol). Treatment with the cytotoxin may allow use of lower doses of radiation and/or less frequent radiation treatments, which may for example, reduce the incidence of severe sore throat that impedes swallowing function potentially resulting in undesired weight loss or dehydration.
  • In another embodiment, a cytotoxin is administered in combination with one or more cytokines which include, without limitation, a lymphokine, tumor necrosis factors, tumor necrosis factor-like cytokine, lymphotoxin, interferon, macrophage inflammatory protein, granulocyte monocyte colony stimulating factor, interleukin (including, without limitation, interleukin-1, interleukin-2, interleukin-6, interleukin-12, interleukin-15, interleukin-18), and a variant thereof, including a pharmaceutically acceptable salt thereof
  • In yet another embodiment, a cytotoxin is administered in combination with a cancer vaccine including, without limitation, autologous cells or tissues, non-autologous cells or tissues, carcinoembryonic antigen, alpha-fetoprotein, human chorionic gonadotropin, BCG live vaccine, melanocyte lineage proteins, and mutated, tumor-specific antigens.
  • In yet another embodiment, a cytotoxin is administered in association with hormonal therapy. Hormonal therapeutics include, without limitation, a hormonal agonist, hormonal antagonist (e.g., flutamide, tamoxifen, leuprolide acetate (LUPRON)), and steroid (e.g., dexamethasone, retinoid, betamethasone, cortisol, cortisone, prednisone, dehydrotestosterone, glucocorticoid, mineralocorticoid, estrogen, testosterone, progestin).
  • In yet another embodiment, a cytotoxin is administered in association with a gene therapy program to treat or prevent cancer.
  • In yet another embodiment, an Ep-CAM-targeted cytotoxin is administered in combination with one or more agents that increase expression of Ep-CAM in the tumor cells of interest. Ep-CAM expression preferably is increased so that a greater number of Ep-CAM molecules are expressed on the tumor cell surface. For example, the agent may inhibit the normal cycles of Ep-CAM antigen endocytosis. Such combination treatment may improve the clinical efficacy of the Ep-CAM-targeted cytotoxin alone, or with other cancer therapeutics or radiation therapy. In specific, nonlimiting embodiments, the agent which increases Ep-CAM expression in the tumor cells is vinorelbine tartrate (Navelbine) and/or paclitax (Taxol). See, e.g., Thurmond et al., 2003, “Adenocarcinoma cells exposed in vitro to Navelbine or Taxol increase Ep-CAM expression through a novel mechanism.” Cancer Immunol Immunother. July; 52(7):429-37.
  • Combination therapy may thus increase the sensitivity of the cancer or tumor to the administered cytotoxin and/or additional cancer therapeutic. In this manner, shorter treatment cycles may be possible thereby reducing toxic events. Accordingly, the invention provides a method for treating or preventing cancer comprising administering to a patient in need thereof an effective amount of a cytotoxin and at least one other cancer therapeutic for a short treatment cycle. The cycle duration may vary according to the specific cancer therapeutic in use. The invention also contemplates continuous or discontinuous administration, or daily doses divided into several partial administrations. An appropriate cycle duration for a specific cancer therapeutic will be appreciated by the skilled artisan, and the invention contemplates the continued assessment of optimal treatment schedules for each cancer therapeutic. Specific guidelines for the skilled artisan are known in the art. See, e.g., Therasse et al., 2000, “New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada,” J Natl Cancer Inst. February 2; 92(3):205-16.
  • Alternatively, longer treatment cycles may be desired. Accordingly, the cycle duration may range from approximately 10 to 56, 12 to 48, 14 to 28, 16 to 24, or 18 to 20 days. The cycle duration may vary according to the specific cancer therapeutic in use.
  • The present invention contemplates at least one cycle, preferably more than one cycle during which a single cancer therapeutic or series of therapeutics is administered. An appropriate total number of cycles, and the interval between cycles, will be appreciated by the skilled artisan. The number of cycles may be 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13,14, 15, 16, 17, 18, 19, 20, or 21 cycles. The interval between cycles may be 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13,14, 15, 16, 17, 18, 19, 20, or 21 days. The invention contemplates the continued assessment of optimal treatment schedules for each cytotoxin and additional cancer therapeutic.
  • In another embodiment, a process is provided for preparing a pharmaceutical for treating a mammal with cancer comprising the steps of identifying T-cell epitopes of bouganin having reduced propensity for activated T-cells; preparing a cytotoxin of the invention having one or more of the T-cell epitopes and suspending the protein in a pharmaceutically acceptable carrier, diluent or excipient.
  • The invention also provides a pharmaceutical composition for treating a mammal with cancer comprising a cytotoxin of the invention and a pharmaceutically acceptable carrier, diluent or excipient.
  • The cytotoxins of the invention may be formulated into pharmaceutical compositions for administration to subjects in a biologically compatible form suitable for administration in vivo. By “biologically compatible form suitable for administration in vivo” is meant a form of the substance to be administered in which any toxic effects are outweighed by the therapeutic effects. The substances may be administered to living organisms including humans, and animals. Administration of a therapeutically active amount of the pharmaceutical compositions of the present invention is defined as an amount effective, at dosages and for periods of time necessary to achieve the desired result. For example, a therapeutically active amount of a substance may vary according to factors such as the disease state, age, sex, and weight of the individual, and the ability of antibody to elicit a desired response in the individual. Dosage regime may be adjusted to provide the optimum therapeutic response. For example, several divided doses may be administered daily or the dose may be proportionally reduced as indicated by the exigencies of the therapeutic situation.
  • The active substance may be administered in a convenient manner such as by injection (subcutaneous, intravenous, intramuscular, etc.), oral administration, inhalation, transdermal administration (such as topical cream or ointment, etc.), or suppository applications. Depending on the route of administration, the active substance may be coated in a material to protect the compound from the action of enzymes, acids and other natural conditions which may inactivate the compound.
  • The compositions described herein can be prepared by per se known methods for the preparation of pharmaceutically acceptable compositions which can be administered to subjects, such that an effective quantity of the active substance is combined in a mixture with a pharmaceutically acceptable vehicle. Suitable vehicles are described, for example, in Remington's Pharmaceutical Sciences (Remington's Pharmaceutical Sciences, Mack Publishing Company, Easton, Pa., USA 1985). On this basis, the compositions include, albeit not exclusively, solutions of the substances in association with one or more pharmaceutically acceptable vehicles or diluents, and contained in buffered solutions with a suitable pH and iso-osmotic with the physiological fluids.
  • The pharmaceutical compositions may be used in methods for treating animals, including mammals, preferably humans, with cancer. It is anticipated that the compositions will be particularly useful for treating patients with colorectal cancer, breast cancer, ovarian cancer, pancreatic cancer, head and neck cancer, bladder cancer, gastrointestinal cancer, prostate cancer, small cell and non small cell lung cancer, sarcomas, gliomas, T- and B-cell lymphomas. The dosage and type of cytotoxin to be administered will depend on a variety of factors which may be readily monitored in human subjects. Such factors include the etiology and severity (grade and stage) of neoplasia.
  • Pharmaceutical compositions adapted for direct administration include, without limitation, lyophilized powders or aqueous or non-aqueous sterile injectable solutions or suspensions, which may further contain antioxidants, buffers, bacteriostats and solutes that render the compositions substantially isotonic with the blood of an intended recipient. Other components that may be present in such compositions include water, alcohols, polyols, glycerin and vegetable oils, for example. Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules and tablets. Cytotoxin may be supplied, for example but not by way of limitation, as a lyophilized powder which is reconstituted with sterile water or saline prior to administration to the patient.
  • Pharmaceutical compositions of the invention may comprise a pharmaceutically acceptable carrier. Suitable pharmaceutically acceptable carriers include essentially chemically inert and nontoxic compositions that do not interfere with the effectiveness of the biological activity of the pharmaceutical composition. Examples of suitable pharmaceutical carriers include, but are not limited to, water, saline solutions, glycerol solutions, ethanol, N-(1(2,3-dioleyloxy)propyl)N,N,N-trimethylammonium chloride (DOTMA), diolesylphosphotidyl-ethanolamine (DOPE), and liposomes. Such compositions should contain a therapeutically effective amount of the compound, together with a suitable amount of carrier so as to provide the form for direct administration to the patient.
  • In another embodiment, a pharmaceutical composition comprises a cytotoxin and one or more additional cancer therapeutics, optionally in a pharmaceutically acceptable carrier.
  • The composition may be in the form of a pharmaceutically acceptable salt which includes, without limitation, those formed with free amino groups such as those derived from hydrochloric, phosphoric, acetic, oxalic, tartaric acids, etc., and those formed with free carboxyl groups such as those derived from sodium, potassium, ammonium, calcium, ferric hydroxides, isopropylamine, triethylamine, 2-ethylarnino ethanol, histidine, procaine, etc.
  • In as far as this invention relates to modified bouganin, compositions containing such modified bouganin proteins or fragments of modified bouganin proteins and related compositions should be considered within the scope of the invention. A pertinent example in this respect could be development of peptide mediated tolerance induction strategies wherein one or more of the disclosed peptides is administered to a patient with immunotherapeutic intent. Accordingly, synthetic peptides molecules, for example one of more of comprising all or part of any of the epitope regions R1-R3 as defined above. Such peptides are considered embodiments of the invention.
  • In a further aspect of the present invention relates to methods for therapeutic treatment of humans using the modified bouganin compositions. For administration to an individual, any of the modified compositions would be produced to be preferably at least 80% pure and free of pyrogens and other contaminants.
  • The present invention also provides a kit comprising an effective amount of a cytotoxin, optionally, in combination with one or more other cancer therapeutics, together with instructions for the use thereof to treat the cancer.
    • (D) T-Cell Epitope Peptides
  • An additional embodiment of the invention is a T-cell epitope peptide. In an example, the T-cell epitope peptide is able to evoke a stimulation index of greater than 1.8 in a T-cell assay, more preferably greater than 2.0. The T-cell epitope peptide of the invention is able to bind MHC class II.
  • In an embodiment of the invention the T-cell epitope peptide comprises at least 9 consecutive amino acid residues from any of the sequences of R1, R2 or R3 (above). In another embodiment, the T-cell epitope peptide sequence has greater than 90% amino acid identity with any one of the peptide sequences R1, R2 or R3; more preferably the T-cell epitope peptide has greater than 80% amino acid identity with any one of the peptide sequences R1, R2 or R3.
  • The term “peptide” as used herein is a compound that includes two or more amino acids. The amino acids are linked together by a peptide bond (defined herein below). There are 20 different naturally occurring amino acids involved in the biological production of peptides, and any number of them may be linked in any order to form a peptide chain or ring. The naturally occurring amino acids employed in the biological production of peptides all have the L-configuration. Synthetic peptides can be prepared employing conventional synthetic methods, utilizing L-amino acids, D-amino acids, or various combinations of amino acids of the two different configurations. Some peptides contain only a few amino acid units. Short peptides, e.g., having less than ten amino acid units, are sometimes referred to as “oligopeptides”. Other peptides contain a large number of amino acid residues, e.g. up to 100 or more, and are referred to as “polypeptides”. By convention, a “polypeptide” may be considered as any peptide chain containing three or more amino acids, whereas an “oligopeptide” is usually considered as a particular type of “short” polypeptide. Thus, as used herein, it is understood that any reference to a “polypeptide” also includes an oligopeptide. Further, any reference to a “peptide” includes polypeptides, oligopeptides, and proteins. Each different arrangement of amino acids forms different polypeptides or proteins. The number of polypeptides—and hence the number of different proteins—that can be formed is practically unlimited.
  • Another embodiment of the invention is the use of the T-cell epitope peptides of the invention to make the modified bouganin proteins of the invention and modified T-cell epitope peptides.
  • A further embodiment of the invention is a modified T-cell epitope peptide that is modified such that the modified T-cell epitope peptide has reduced propensity to activate human T cells than the non-modified T-cell epitope peptide. In an example, the modified T-cell epitope peptides of the invention contains modifications such that when tested in a T-cell assay evokes a reduced stimulation index in comparison to the non-modified T-cell epitope peptide.
  • In an embodiment of the invention the modified T-cell epitope peptide has the following sequence:
  • AKX 1DRKX 2LX 3LGVX 4KL

    wherein at least one of X1, X2, X3, and X4 is modified from the non-modified sequence, as follows:
  • X1 is T or A or Q;
  • X2 is G or A;
  • X3 is Q or G; and
  • X4 is N or D or T or A or R or Q or E or G or H or K or S (SEQ ID NO:8).
  • In another embodiment of the invention the modified T-cell epitope peptide has the following sequence:
  • LGVX 4KLEFSIEAIHG

    wherein X4 is N or D or T or A or R or Q or E or G or H or K or S (SEQ ID NO:9).
  • In a further embodiment of the invention the modified T-cell epitope peptide has the following sequence:
  • NGQEX 5AKFFLIVIQM

    wherein X5 is Q or A (SEQ ID NO:10).
  • The invention also provides nucleic acid molecules encoding the T-cell epitope peptides or modified T-cell epitope peptides of the invention.
  • The following figures, sequence listings and examples are provided to aid the understanding of the present invention. It is understood that modifications can be made in the procedures set forth without departing from the spirit of the invention.
  • The following non-limiting examples are illustrative of the present invention:
    • EXAMPLES Example 1 Method of Mapping Epitopes in Bouganin Using Naïve Human T-Cell Proliferation Assays
  • Peptides covering the sequence of the mature bouganin protein, as described by Den Hartog et al [ibid] were synthesized. The length of each peptide is 15 amino acids, and successive peptides overlap by 12 residues. The sequence of these peptides and their numbering is indicated in TABLE 1.
  • The peptides were used in T-cell proliferation assays with PBMCs (peripheral blood mononuclear cells) from naïve donors (i.e. no known sensitization to bouganin) 20 donor PBMC were selected to get an optimal coverage of MHC class II allotypes. The allotypic coverage is in excess of 85%. The HLA-DR allotypes are shown in TABLE 2.
  • PBMCs were stimulated with individual peptides in triplicate cultures for 7 days before proliferation was assessed by 3H-thymidine (3H-Thy) incorporation. All peptides were tested at two different concentrations (1 μM and 5 μM). Stimulation indices (S.I.) were calculated as the amount of 3H incorporated, divided by the amount of 3H incorporated in mock-stimulated control cells.
  • Buffy coats from human blood stored for less than 12 hours were obtained from the National Blood Service (Addenbrooks Hospital, Cambridge, UK). Ficoll-paque was obtained from Amersham Pharmacia Biotech (Amersham, UK). Serum free AIM V media for the culture of primary human lymphocytes and containing L-glutamine, 50 μg/ml streptomycin, 10 μg/m gentomycin and 0.1% human serum albumin was from Gibco-BRL (Paisley, UK). Synthetic peptides were obtained from Eurosequence (Groningen, The Netherlands) and Babraham Technix (Cambridge, UK).
  • Erythrocytes and leukocytes were separated from plasma and platelets by gentle centrifugation of buffy coats. The top phase (containing plasma and platelets) was removed and discarded. Erythrocytes and leukocytes were diluted 1:1 in phosphate buffered saline (PBS) before layering onto 15 ml ficoll-paque (Amersham Pharmacia, Amersham UK). Centrifugation was done according to the manufacturers recommended conditions and PBMCs were harvested from the serum+PBS/ficoll paque interface. PBMCs were mixed with PBS (1:1) and collected by centrifugation. The supernatant was removed and discarded and the PBMC pellet resuspended in 50 ml PBS. Cells were again pelleted by centrifugation and the PBS supernatant discarded. Cells were resuspended using 50 ml AIM V media and at this point counted and viability assessed using trypan blue dye exclusion. Cells were again collected by centrifugation and the supernatant discarded. Cells were resuspended for cryogenic storage at a density of 3×107 per ml. The storage medium was 90% (v/v) heat inactivated AB human serum (Sigma, Poole, UK) and 10% (v/v) DMSO (Sigma, Poole, UK). Cells were transferred to a regulated freezing container (Sigma) and placed at −70° C. overnight. When required for use, cells were thawed rapidly in a water bath at 37° C. before transferring to 10 ml pre-warmed AIM V medium.
  • PBMC were stimulated with protein and peptide antigens in a 96 well flat bottom plate at a density of 2×105 PBMC per well. PBMC were incubated for 7 days at 37° C. before pulsing with 3H-Thy (Amersham-Pharmacia, Amersham, UK). Two control peptides termed C-32 and C-49 that have previously been shown to be immunogenic and a potent whole protein non-recall antigen Keyhole Limpet Hemocyanin (KLH) were used in each donor assay. C-32=sequence PKYVKQNTLKLAT from Flu haemagglutinin residues 307-319 (SEQ ID NO:127). C-49=sequence KVVDQIKKISKPVQH from Chlamydia HSP 60 (SEQ ID NO:128).
  • Peptides were dissolved in DMSO to a final concentration of 10 mM, these stock solutions were then diluted 1/500 in AIM V media (final concentration 20 μM). Peptides were added to a flat bottom 96 well plate to give a final concentration of 1 and 5 μM in 100 μl. The viability of thawed PBMC's was assessed by trypan blue dye exclusion, cells were then resuspended at a density of 2×106 cells/ml, and 100 μl (2×105 PBMC/well) was transferred to each well containing peptides. Triplicate well cultures were assayed at each peptide concentration. Plates were incubated for 7 days in a humidified atmosphere of 5% CO2 at 37° C. Cells were pulsed for 18-21 hours with 1 μCi 3H-Thy/well before harvesting onto filter mats. CPM values were determined using a Wallac microplate beta top plate counter (Perkin Elmer). Results were expressed as stimulation indices, derived by division of the proliferation score (e.g. counts per minute of radioactivity) measured to the test peptide by the score measured in cells not contacted with a test peptide.
  • Compilation of the results of the above assay indicates the presence of four T cell epitopes, corresponding to peptides 41, 44 and 50 in the mature, processed region of the protein and peptide 88 in the unprocessed form. Since the epitope in peptide 88 is not part of the mature protein, it is ignored under the scheme of the present invention.
  • For peptide 41 (termed epitope region R1) there were four responsive donors to this peptide; donors 4, 5, 10 and 11. The S.I.s for these at 5 μM are 3.6, 4.9, 2.1 and 2.0 respectively.
  • For peptide 44 (termed epitope region R2). There are two responsive donors to this peptide; donors 4 (S.I.=3.5) and 11 (S.I.=2.3). Neighboring peptides 43 and 45 induced lower level T cell proliferation since both these peptides overlap by 12 amino acids with peptide 44.
  • For peptide 50 there were 2 responsive donors to this peptide; donors 4 (S.I.=2.9) and 14 (S.I.=2.0). Peptide 51 induced lower level T cell proliferation in donor 14 (S.I.>1.9).
  • The tissue types for all PBMC samples were assayed using a commercially available reagent system (Dynal, Wirral, UK). Assays were conducted in accordance with the suppliers recommended protocols and standard ancillary reagents and agarose electrophoresis systems. The allotypic specificities of each of the responsive donor samples is given in TABLE 2.
    • Example 2 Cloning of Bouganin from Bougainvillea spectabilis
  • Total RNA was extracted from the leaves of Bougainvillea spectabilis using the ‘SV Total RNA Isolation System and protocols provided by the supplier (Promega, Southampton, UK). Fresh leaf tissue was ground to a fine powder under liquid nitrogen, and approximately 50 mg of ground tissue was used for the RNA isolation. RNA quality and quantity was checked by visualization on a 1% agarose gel, and the bouganin gene was amplified from the total RNA using the ‘Access RT-PCR System’ (Promega) using approximately 1 μg of RNA per reaction and with the gene specific primers OL1032 and OL1033. Primer sequences are given in TABLE 3 below. This reaction generated a 1242 bp fragment encompassing the native leader sequence and the full-length bouganin sequence. This fragment was cloned into the pGEM-T Easy vector (Promega), following kit instructions, and designated pBoul. The sequence was confirmed by DNA sequencing.
  • The bouganin gene was transferred into the pET21a (Novagen, Nottingham, UK) by PCR cloning using the pBoul plasmid as a template. A pelB (pectate lyase) leader sequence was added to the 5′ end, and a sequence encoding a 6× histidine tag was added to the 3′ end of the bouganin coding sequence. The pelB leader was amplified from vector pPMI-his [Molloy, P. et al, (1995) J. Applied Bacteriology, 78: 359-365] using primer OL1322 (incorporating an Nde1 site) and primer OL1067. The bouganin-his fragment was amplified from pBoul using OL1068 and OL1323 (incorporating a Not1 site). The pelB leader was fused in frame to the bouganin-his fragment using overlap PCR, and the resulting fragment cloned into pGEM-T Easy (Promega). Following sequence confirmation the pelB-bouganin-his fragment was cloned as a Nde1-Not1 fragment into Nde1-Not1 digested pET21a. This clone was designated pBou32.
    • Example 3 Construction of Mutant Bouganin Proteins
  • A number of modified (mutant) bouganin proteins were designed using data provided by the T-cell epitope mapping procedure and use of software able to simulate the binding of peptides with human MHC class II binding groove. This latter approach is described in detail elsewhere [WO 02/069232]. Variant genes were constructed and the mutant proteins tested for functional activity. In general, “single mutant” proteins containing one amino acid substitution each were first constructed and tested, then genes for active modified proteins combined to produce multiply substituted modified proteins.
  • Mutant genes were constructed using an overlap PCR procedure in which the mutant amino acid codon becomes introduced into the gene by use of a mutant in “overlap primer”. The scheme is well understood in the art and is described in detail elsewhere [Higuchi, et al (1900) Nucl. Acids Res. 16:7351]. A total of 37 single mutant modified proteins were constructed and tested for retained functional activity. In addition, a negative control modified protein containing a substitution Y70A was also constructed and tested in all assays. One of the 37 “single mutant” modified proteins in fact contained two directly adjacent substitutions (E151T and I152E) and is counted herein as a single mutant. The substitutions tested and the corresponding activity values are given in TABLE 4.
  • A total of 11 multiple substitution modified proteins were constructed and tested for retained activity. The substitutions tested and the corresponding activity values are given in TABLE 5.
  • TABLE 6 describes the sequences of the substitution modified proteins. TABLE 7 lists some specific sequences.
  • In all instances, proteins were purified and tested according to the procedures outlined in examples 4 and 5 below.
    • Example 4 Expression of and Purification of Bouganin Protein
  • The plasmid pBou32 was transformed into BL21(DE3) (Novagen) competent cells following manufacturers' instructions, and selected on LB (Invitrogen, Paisley, UK) plates containing 50 μg/ml carbenicillin. A fresh colony from this transformation was used to inoculate 5 ml 2xYT (Invitrogen) broth, without antibiotic, and this was grown with shaking at 250 rpm at 37° C. until OD600=1.5-2.0. The culture was then centrifuged at 2500 rpm for 15 minutes at room temperature, and the cells resuspended in 5 ml fresh 2xYT plus 1 mM IPTG. This culture was incubated at 30° C. with shaking at 300 rpm for 1.5 hours and the cells collected by centrifugation and the supernatant discarded.
  • The cell pellet was resuspended in 1 ml of PEB2 (50 mM Tris-HCl pH8, 20% sucrose, 1 mg/ml lysozyme, 1× Complete Protease Inhibitor Tablet (Roche, Lewes, UK), and incubated on ice for 1 hour with gentle mixing. The cell debris was centrifuged at 14,000 rpm at 4° C. and the pellet discarded. The resulting supernatant is now referred to as the ‘periplasmic fraction’. Bouganin protein was purified from the periplasmic fraction by nickel affinity column chromatography using commercially available “spin column” and the manufacturer's instructions (Qiagen, Crawley, UK). The resulting material was dialyzed against 4 liters of phosphate buffered saline (0.138M NaCl, 0.0027M KCl, pH 7.4) overnight at 4° C. using a 10000 molecular weight cut-off ‘Slide-A-Lyzer’ (Pierce, Chester, UK). Following dialysis, the protein concentration was estimated using the Micro BCA Assay Kit (Pierce), and samples stored at −20° C.
  • Bouganin protein concentration was further determined using an ELISA based assay system. Briefly, antiserum against bouganin was generated (Genovac, Freiburg, Germany), through the genetic immunization of two rats with a plasmid expressing bouganin. For the ELISA, recombinant bouganin is captured onto Ni-agarose coated plates via its His-tag and subsequently detected with the rat antiserum and a secondary HRP-conjugated anti-rat Fc antibody (Sigma, Poole, UK). As a standard, a large preparation of the wild-type bouganin expressed in E. coli and quantitated using the total protein assay was used in each determination.
    • Example 5 Assay of Bouganin Activity
  • The activity of the wild-type and modified (mutant) bouganin proteins was tested by measuring their ability to inhibit protein synthesis in a cell-free protein synthesis assay.
  • A mixture of 10 μl TNT Coupled Transcription/Translation mix (Promega), 20 μM methionine, 120 ng pT7 luciferase DNA (Promega) and serial dilutions of WT and mutant bouganin protein in a final volume of 12.5 μl were incubated at 30° C. for one hour, after which the reaction was stopped by addition of 100 μl ‘SteadyGlow’ luciferase assay reagent (Promega). The luciferase activity was measured using a Wallac luminescence counter. Active bouganin protein is detected as a decrease in measured luciferase activity. Each modified bouganin protein was tested in at least 5 concentrations, with each data point in duplicate. Positive and negative controls were included in each experiment.
  • Results for single mutant proteins are shown in TABLE 4. Results for multiple mutant modified bouganin proteins are shown in TABLE 5. In each instance results are expressed relative to wild-type protein activity. All assays were conducted with the inclusion of an inactive mutant bouganin protein with a Y70A substitution.
  • In addition, luciferase assay results may be plotted showing % luciferase activity relative to control versus protein concentration of added bouganin. Examples of such plots are shown in FIG. 1 depicting the results as determined for two different multiple mutant bouganin proteins.
    • Example 6 Assay of Variant Bouganin Sequences for Loss of T-Cell Epitopes
  • The multiple modified protein designated Bou156 was selected for further testing using an immunogenicity assay. This variant contains the substitutions V123A, D127A, Y133N and I152A. Immunogenicity testing involves use of live cells that may be damaged by testing using whole bouganin protein, therefore these assays were conducted using synthetic peptides comprising the substitutions incorporated into variant Bou156. The peptides tested are listed in TABLE 8. The assays were conducted according to the procedures described in example 1 (above) using a PBMC donor pool of 20 individuals. Peptides were tested in triplicate for each donor sample at a two different final peptide concentrations (1 μM and 5 μM).
  • The results are expressed as SI per peptide per donor sample and are shown in FIG. 2. DeI-41 is peptide sequence AKADRKALELGVNKL (SEQ ID NO:29). Del-44 is peptide sequence LGVNKLEFSIEAIHG (SEQ ID NO:30). DeI-50 is peptide sequence NGQEAAKFFLIVIQM (SEQ ID NO:31). None of the modified peptides induced a T cell response in any of the donors (S.I.<2). In contrast an immunogenic control peptide stimulated T cells of 6 donors (S.I.>2).
    • Example 7 VB6-845: Recombinant Engineering of an Ep-CAM-specific Fab Antibody for Optimal Delivery of De-Immunized Bouganin (De-Bouganin)
  • For this example and Example 8, the de-immunized bouganin used is Bou156.
  • Tumor-targeting cytotoxins are composed of the variable region of an antibody linked to a bacterial, fungal or plant toxin. The present study illustrates that the deimmunized bouganin constructs of the invention, comprising deimmunized bouganin linked to a targeting moiety have reduced immunogenicity, while still retaining their biological activity. TABLE 12 demonstrates the binding of the Ep-CAM antibody to several types of tumours and thus shows that it can be used to treat these types of cancers.
    • De-Immunized Bouganin Construct: Ep-CAM Directed Targeting Moiety Linked to De-Bouganin
  • VB5-845, a Fab version of an anti-Ep-CAM scFv antibody, was genetically linked to a de-immunized form of bouganin (de-bouganin), Bou 156, a potent, plant-derived, type I ribosome-inactivating protein (RIP), to create the antibody-toxin construct VB6-845. FIG. 3 illustrates the construct VB6-845. FIG. 3A illustrates dicistronic unit of the pro-VB6-845, with pelB leader sequences. The amino acid sequence (SEQ ID NO:16) and nucleic acid coding sequence (SEQ ID NO:15) are provided in FIG. 3B. FIG. 3C illustrates the assembled VB6-845 protein, which is described below in more detail. Testing of this construct, illustrate that the construct retained its biological activity (cytoxicity) and the specificity of the targeting moiety (Ep-CAM antibody).
    • Orientation of the De-Immunized Bouganin Construct
  • To determine the optimal antibody-de-bouganin orientation, several forms of a dicistronic expression unit were generated, expressed and tested for potency.
  • In each case, the dicistronic unit was cloned into the pING3302 vector (FIG. 4) under the control of the arabinose-inducible araBAD promoter and transformed in E104 E. coli. Upon induction, the presence of the pelB leader sequence directed the secretion of the Fab-de-bouganin fusion protein into the culture supernatant. The cleavable linker enabled the de-bouganin to cleave from the targeting moiety and exert its biological activity. In one embodiment the linker is a furin linker, although a person skilled in the art would appreciate that other cleavable linkers could be suitable. Preferred linkers could be selected based on target specificity, and environment. A sample of the constructs made and tested are as follows:
  • FIG. 3: VB6-845, wherein the de-bouganin (Bou156) is linked to the C-terminus of the CH domain via a furin linker. FIG. 3A illustrates the dicistronic unit of the pro-sequences, FIG. 3B illustrates the nucleic acid coding sequence (SEQ ID NO:15) and the amino acid sequence of the pro-sequences (SEQ ID NO:16) and FIG. 3C illustrates the assembled VB6-845 protein without the pelB sequences.
  • FIG. 5 illustrates the control Fab anti-Ep-CAM construct without the plant toxin, de-bouganin (VB5-845). FIG. 5A illustrates the dicistronic unit of the pro-sequences, FIG. 5B illustrates the nucleic acid coding sequence (SEQ ID NO:17) and the amino acid sequence of the pro-sequences (SEQ ID NO:18) and FIG. 5C illustrates the assembled VB6-845 protein without the pelB sequences.
  • FIG. 6 illustrates the Fab anti-Ep-CAM de-bouganin construct, VB6-845-CL-de-bouganin, wherein the Bou156 is linked at the C-terminus of the CL domain. FIG. 6A illustrates the dicistronic unit of the pro-sequences, FIG. 6B illustrates the nucleic acid coding sequence (SEQ ID NO:19) and the amino acid sequence of the pro-sequences (SEQ ID NO:20) and FIG. 6C illustrates the assembled VB6-845-CL-de-bouganin protein without the pelB sequences.
  • FIG. 7 illustrates the Fab anti Ep-CAM, de-bouganin construct, VB6-845-NVH-de-bouganin, wherein Bou156 is linked to the N terminus of the VH domain. FIG. 7A illustrates the dicistronic units of the pro-sequences, FIG. 7B illustrates the nucleic acid coding sequence (SEQ ID NO:21) and the amino acid sequence of the pro-sequences (SEQ ID NO:22) and FIG. 7C illustrates the assembled VB6-845-NVH-de-bouganin protein without the pelB sequences.
  • FIG. 8 illustrates the Fab anti-Ep-CAM construct VB6-845-NVL-de-bouganin, wherein Bou156 is linked to the N-terminus of the VL domain. FIG. 8A illustrates the dicistronic unit of the pro-sequences, FIG. 8B illustrates the nucleic acid coding sequence (SEQ ID NO:23) and the amino acid sequence of the pro-sequences (SEQ ID NO:24) and FIG. 8C illustrates the assembled VB6-845-NVL-de-bouganin protein without the pelB sequences.
  • In one embodiment, the de-bouganin molecule is linked to the C-terminal end of the heavy or light chains. The optimal configuration comprised a pelB leader sequence adjacent to VH-CH domain with an N-terminal histidine affinity tag as the first unit. Immediately following was the second unit comprising the pe1B-VL-CL domain linked to de-bouganin by a protease-sensitive linker. (FIG. 6) For constructs where de-bouganin was re-positioned to the N-terminal end, Western-blot analysis showed no detectable product and only C-terminal linked de-bouganin (constructs of FIGS. 3 and 6) yielded an intact soluble protein (FIG. 9), with good binding properties to Ep-CAM-positive cell lines, as illustrated in the reactivity tests detected by flow cytometry. In the Western Blot analysis, FIG. 9 illustrates the expression of VB6-845 and VB6-845 CL-de-bouganin in the supernatant of induced E104 cells at lab scale. An aliquot of the supernatant, 16 microlitres, under non-reducing conditions, was loaded on a SDS-PAGE acrylamide gel and analysed by Western Blot using either a rabbit polyclonal anti-4D5 antibody, followed by a goat anti-rabbit (1/2000), or a goat anti-human Kappa-light chain-HRP antibody (1/1000), to confirm the identity and size of the recombinant protein. The arrow indicates the full-length VB6-845 (construct of FIG. 3) and VB6-845-CL-de-bouganin (construct of FIG. 6). Western blotting of non-induced E104 culture supernatant revealed no corresponding bands demonstrating the specificity of the antibodies (not shown).
  • The results of the reactivity tests with VB6-845 (FIG. 3) and VB6-845-CL-de-bouganin (FIG. 6) to Ep-CAM positive cell lines CAL 27 and NIH:OVCAR-3 as compared to a control (Ep-CAM-negative cell line, A-375) is illustrated in FIG. 10A. The results were comparable to the same reactivity tests conducted with another anti-Ep-CAM construct, VB6-845-gelonin, wherein the de-bouganin is replaced with another plant toxin, gelonin (See FIG. 14C showing its amino acid sequence (SEQ ID NO:26) and nucleic acid sequence(SEQ ID NO:25) The results of the reactivity test with the gelonin construct are illustrated in FIG. 10B. The addition of a second de-bouganin domain in the molecule with the optimal orientation did not yield product.
  • The flow cytometry tests were conducted by incubating the constructs or control with 0.45×106 cells for an hour on ice. After washing, cell surface bound constructs were detected with a rabbit anti-bouganin (for FIG. 10A) or mouse anti-His tag (FIG. 10B) for an hour on ice. The cells were washed and incubated with FITC-conjugated sheep anti-rabbit IgG (FIG. 10A) and FITC-conjugated sheep anti-mouse (IgG) (FIG. 10B) for 30 minutes on ice. Subsequently the cells were washed, resuspended in PBS 5% FCS containing propidium iodide for assessment of antibody binding by flow cytometry. No shift in median fluorescence was detected following incubation with VB6-845 and VB6-845-CL-de-bouganin with A-375. In contrast, a marked shift in median fluorescence was observed with Ep-CAM positive cell lines, CAL 27 and NIH:OVCAR-3 (FIG. 10A). As stated above, the results with VB6-845 were similar with the gelonin construct (FIG. 10B).
    • Ep-CAM Specificity
  • A competition assay of VB6-845 (construct of FIG. 3) with Proxinium™, a scFv format of VB6-845, but containing Pseudomonas exotoxin A, demonstrated that the Ep-CAM specificity of VB6-845 was unaltered when engineered into a Fab format. (FIG. 11)
  • FIG. 11 illustrates the flow cytometry results of the competition assay, with VB6-845 at 1 and 10 μg/mL and increased concentration of Proxinium™, ranging from 0 to 100 μg/mL, were incubated with NIH:OVCAR-3 cells (Ep-CAM positive tumour cell line). After 1 hour incubation at 4° C., cells were washed and bound VB6-845 was detected with a biotinylated rabbit anti-bouganin followed by streptavidin-cychrome. The same experiment was performed with 4B5-PE which is used as a negative control. The reaction conditions were as indicated on FIG. 11.
    • Potency (Biological Activity)
  • In addition, cell-free (FIG. 12) and MTS (FIG. 13 A and B) assays demonstrated that de-bouganin retained its potency when conjugated to the Fab fragment. In Figure. 12, the purified VB6-845 and de-bouganin proteins, at various concentrations, were incubated at 30° C. for 90 minutes with the following mixture:
  •
    Flexi rabbit reticulocyte lysate 35 μL 
    Amino acid mixture, minus leucine 1 μL
    3H-leucine 5 μL
    Potassium chloride 1.4 μL 
    RNasin
    1 μL
    Luciferase control RNA, 1 mg/mL 1 μL
    To a final volume of 50 μL
  • After the translation reaction is completed, a sample of 2 μL is taken, mixed with 98 μL of 1 M NaOH/2% H2O2 and incubated at 37° C. for 10 minutes. The translated protein is precipitated with the addition of ice-cold 25% TCA/2% casamino acids and incubated on ice for 30 minutes. The precipitate is then collected on Whatman GF/C glass fiber filter (pre-wet with 5% cold TCA) by centrifugation at 8000 rpm 5 minutes. The filter is rinsed 3 times with ice-cold 5% TCA and once with acetone. After the filter is dry, scintillation mixture is added and counts are determined in a liquid scintillation counter. The MTS assay used to measure potency was conducted using standard technique known in the art, and as more fully described below in Example 8. Using the Ep-CAM-positive cell lines, CAL 27 and NIH:OVCAR-3, the IC50 of VB6-845 was 3 to 4 nM and 2 to 3 nM, respectively. In the case of VB6-845-CL-de-bouganin, the potency was measured at 1 to 2 nM for CAL 27 and 0.6 to 0.7 nM versus NIH:OVCAR-3. The development of Fab anti-Ep-CAM construct, comprising a human tumor targeting antibody fragment linked to a de-immunized bouganin should permit repeat systemic administration of this drug and hence yield greater clinical benefit.
    • Harvesting of the Constructs
  • The constructs can be isolated from the cell cultures by techniques known in the art. For instance, if a His tag is placed at the N-terminal of the peptide construct, the Fab-bouganin protein can be purified using a Ni2+-chelating capture method. As an example the following protocol can be used. Conducting fed batch fermentation of VB6-845 variants performed in a 15L CHEMAP fermenter using TB medium. At an OD600 of 20 (mid-log), the culture is induced with a mixture of feed and inducer containing 50% glycerol and 200 g/1 L-arabinose. At 30 hours post induction, the culture is harvested, centrifuged at 8000 rpm for 30 min and VB6-845 variants purified using CM sepharose and Metal-Charged Chelating sepharose columns followed by a size exclusion column. Briefly, the supernatant is concentrated and diafiltered against 20 mM sodium phosphate pH 6.9±0.1. The diafiltered concentrated supernatant is then applied onto a CM sepharose column equilibrated with 20 mM sodium phosphate, 25 mM NaCl pH 6.9±0.1. The column is washed with 20 mM sodium phosphate, 25 mM NaCl pH 6.9±0.1, bound VB6-845 is subsequently eluted with 20 mM sodium phosphate, 150 mM NaCl pH 7.5±0.1. The CM sepharose eluate is adjusted to contain a final concentration of 0.25% Triton-X100 and applied to a charged chelating sepharose column. The chelating sepharose column is then washed with 3 different wash buffers starting with 20 mM sodium phosphate, 150 mM NaCl, 0.25% triton-X100 pH 7.5±0.1 followed by 20 mM sodium phosphate, 150 mM NaCl pH 7.5±0.1 and followed by 20 mM sodium phosphate, 150 mM NaCl, 10 mM imidazole pH 7.5±0.1. The bound VB6-845 is then eluted with 20 mM sodium phosphate, 150 mM NaCl, 250 mM imidazole pH 7.5±0.1 and collected in 2 mL fractions. The absorbance at A280 is determined for each fraction and the fractions with material pooled are applied onto a size exclusion column 5200 in order to obtain a purity of >80%. In one embodiment, to increase the protein purity and remove endotoxin, the pooled SEC fraction is diluted 5-fold with 20 mM NaPO4, pH 7.5 and passed though a Q-sepharose 15 ml fast flow column equilibrated with 20 mM NaPO4, 25 mM NaCl pH 7.5 at a flow rate of about 5 ml/min. After application of the sample through the column, the column is washed with 10CV of equilibration buffer and the wash is pooled with the initial Q-sepharose flow through. The effluent is concentrated to −10-fold through the use of a 30 kDa MWCO membrane (Sartorius hydrosart membrane] to achieve a final concentration of 7.5 mg/ml. Tween-80 is then added to a final concentration of 0.1%. The final product is sterile filtered and stored at −80° C. Samples at each steps of the process are analyzed by Western blot after immunoblotting with the anti-4D5 antibody. Purity is confirmed by colloidal blue staining. The level of expression of VB6-845 variants is determined by Western Blot analysis and ELISA.
    • Example 8 Functional and Biological Characterization of VB6-845, a Recombinant Ep-CAM-Specific Fab Antibody Genetically-Linked With De-Immunized Bouganin (De-Bouganin)
  • Chemotherapeutics are highly cytotoxic agents that often represent the standard of care in the treatment of many of the solid tumor cancers. The cytotoxic action of these drugs targets rapidly dividing cells, both normal and tumor, thus creating a variety of adverse clinical side-effects. VB6-845 is a Fab antibody linked to a de-immunized form of the plant-derived toxin bouganin. Unlike chemotherapeutics which lack defined tumor-target specificity, VB6-845 restricts its cytolytic effect to Ep-CAM-positive tumor targets alone. In this study, flow cytometry analysis and cytotoxicity were measured to assess the potency and selectivity of VB6-845.
    • Flow Cytometry
  • The tumor cell lines used in this study were purchase from ATCC and were propagated following ATCC's recommendations except for the cell lines C-4I, TOV-112D which were grown in RPMI 1640 or DMEM supplemented with 10% FCS, respectively. Tumor cells were harvested at 60-70% confluence with viability over 90%. The human normal mammary epithelial cells (HMEC) were purchased from CAMBREX and maintained in specified media according to the procedure provided by CAMBREX. The cells were harvested at 70% confluence with viability over 90%.
  • The gynecological cell lines from endometrial ovarian and cervical cancer indications were tested for VB6-845 binding on flow cytometry (Table 9). Ten microgram/mL of VB6-845 was added to each cell line (3×105 cells) and incubated for 2h at 4° C. A-375 and CAL 27 were used as negative and positive cell line controls, respectively. After washing off the unbound material, a mouse monoclonal anti-Histidine antibody (Amersham Pharmacia, Cat #27471001) diluted 1/800 in PBS containing 10% FCS was added and incubated for a further 1 hr at 4° C. Subsequently, FITC-labeled anti-mouse IgG (The Binding Site, Cat# AF271) diluted 1/100 in PBS-10% FCS was added and incubated for 30 min. at 4° C. Finally, the cells were analyzed on a FACS Calibur following propidium iodide staining to gate out the dead cells.
    • Cytotoxicity
  • The level of killing for VB6-845 in the cells listed in the flow cytometry study is as indicated in Table 10, indicated that the construct retained its de-bouganin cytotoxicity activity against Ep-CAM-positive cell lines. The cytoxicity was comparable to another Fab VB6-845 variant containing a different plant-derived toxin, gelonin. (FIG. 14) FIG. 14 A compares the cytotoxicity of gelonin, Fab anti-Ep-CAM-gelonin construct (VB6-845-Gelonin) and the Fab anti-Ep-CAM-de-bouganin (Bou156) construct (VB6-845) in CAL 27 (FIG. 14A) and NIH:OVCAR-3 cells (FIG. 14B). The nucleic acid and amino acid sequence of the VB6-845-gelonin construct is illustrate in FIG. 14C.
  • To study the specificity and selectivity of VB6-845 (Construct of FIG. 3), the cytotoxic activity of VB6-845 (90% pure) was tested against Ep-CAM-positive (NIH:OVCAR-3) and Ep-CAM-negative (HMEC, DAUDI, A-375) cell lines (Table 11) along with 17 chemotherapeutic drugs (LKB Laboratories Inc.).
  • The MTS assay was performed using standard techniques known in the art. More particularly, 50 microlitres of cells (2×104 cells/ml) were seeded per well and plates were incubated at 37° C. under 5% CO2 for 2 hr. Then 50 microlitres of spiked drug (i.e. construct to be tested or control) was added to the culture medium at increasing concentrations. Culture medium, with or without cells, was used as positive and negative controls, respectively. The plates were left at 37° C. under 5% CO2 for 5 days. At day 5, the inhibition of cell proliferation was evaluated by adding 20 microlitres of MTS reagent (Promega, Cat# G5430). The plates were further incubated at 37° C. under 5% CO2 for 2 hr and ODs were read at 490 nm using the plate reader spetrophotometer. Background values were subtracted from the sample values obtained for each concentration and the results were expressed as a percent of viable cells. The IC50 values for each drug were calculated for each cell line.
  • When assayed for cytotoxicity against NIH:OVCAR-3, an Ep-CAM-positive ovarian carcinoma, using a panel of standard chemotherapeutic agents, VB6-845 was shown to be more potent than 12 of the 17 drugs tested. (Table 11) Though 5 chemotherapeutics were more cytotoxic, they were also shown to be far more toxic in that they lacked any cell-specific killing. Of the five recommended chemotherapeutic agents for the treatment of ovarian cancer (Paclitaxel, Carboplatin, Cisplatin, Doxorubicin and Topotecan), only two (Paclitaxel and Topotecan) were more cytotoxic. While VB6-845 demonstrated highly potent cytolytic activity in the range of 1 to 2 nM, the potent killing was restricted exclusively to the Ep-CAM-positive tumor cell line NIH:OVCAR-3. Although some killing of Ep-CAM-negative cell lines was exhibited with VB6-845, the cytotoxic effect was at least 220-fold and at most >1000-fold less toxic. VB6-845 thus represents a potent antibody-directed treatment alternative to chemotherapeutics that when combined with the lower toxicity profile, holds much promise in the treatment of many different types of solid tumors.
    • Example 9 VB6-011: Recombinant Engineering of a Tumor-Associated Antigen-Specific Fab Antibody for Optimal Delivery of De-Immunized Bouganin (De-Bouganin)
  • Tumor-targeting cytotoxins are composed of the variable region of an antibody linked to a bacterial, fungal or plant toxin. The present study illustrates that the deimmunized bouganin constructs of the invention, comprising deimmunized bouganin linked to a targeting moiety have reduced immunogenicity, while still retaining their biological activity. TABLE 13 demonstrates the binding of the tumor-associated antigen antibody to several types of tumors and thus shows that it can be used to treat these types of cancers.
    • De-immunized Bouganin Construct: Tumor-Associated Antigen Directed Targeting Moiety Linked to De-Bouganin
  • The H11 antibody, a monoclonal antibody recognizing tumor-associated antigen, was genetically linked to a de-immunized form of bouganin (de-bouganin), Bou 156, a potent, plant-derived, type I ribosome-inactivating protein (RIP), to create the antibody-toxin construct VB6-011. FIG. 15 illustrates the nucleic acid coding sequence and amino acid sequence. Testing of this construct, illustrates that the construct retained its biological activity (cytoxicity).
    • Potency (Biological Activity)
  • MTS assay demonstrated that de-bouganin retained its potency when conjugated to the Fab fragment (FIG. 16). The MTS assay used to measure potency was conducted using standard technique known in the art, and as more fully described in Example 8.
    • Cytotoxicity
  • To study the specificity and selectivity of VB6-011, the cytotoxic activity was tested against MB-435S cells. The MTS assay was performed using standard techniques known in the art. More particularly, 50 microlitres of cells (2×104 cells/ml) were seeded per well and plates were incubated at 37° C. under 5% CO2 for 2 hr. Then 50 microlitres of spiked drug (i.e. construct to be tested or control) was added to the culture medium at increasing concentrations. Culture medium, with or without cells, was used as positive and negative controls, respectively. The plates were left at 37° C. under 5% CO2 for 5 days. At day 5, the inhibition of cell proliferation was evaluated by adding 20 microlitres of MTS reagent (Promega, Cat# G5430). The plates were further incubated at 37° C. under 5% CO2 for 2 hr and ODs were read at 490 nm using the plate reader spectrophotometer. Background values were subtracted from the sample values obtained for each concentration and the results were expressed as a percent of viable cells. Results show that the 1050 value of VB6-011 is 350 nM.
  • While the present invention has been described with reference to what are presently considered to be the preferred examples, it is to be understood that the invention is not limited to the disclosed examples. To the contrary, the invention is intended to cover various modifications and equivalent arrangements included within the spirit and scope of the appended claims.
  • All publications, patents and patent applications are herein incorporated by reference in their entirety to the same extent as if each individual publication, patent or patent application was specifically and individually indicated to be incorporated by reference in its entirety.
  • TABLE 1
    Position of
    Peptide first amino SEQ ID
    # acid NO Sequence
    1 1 32 YNTVSFNLGEAYEYP
    2 4 33 VSFNLGEAYEYPTFI
    3 7 34 NLGEAYEYPTFIQDL
    4 10 35 EAYEYPTFIQDLRNE
    5 13 36 EYPTFIQDLRNELAK
    6 16 37 TFIQDLRNELAKGTP
    7 19 38 QDLRNELAKGTPVCQ
    8 22 39 RNELAKGTPVCQLPV
    9 25 40 LAKGTPVCQLPVTLQ
    10 28 41 GTPVCQLPVTLQTIA
    11 31 42 VCQLPVTLQTIADDK
    12 34 43 LPVTLQTIADDKRFV
    13 37 44 TLQTIADDKRFVLVD
    14 40 45 TIADDKRFVLVDITT
    15 43 46 DDKRFVLVDITTTSK
    16 46 47 RFVLVDITTTSKKTV
    17 49 48 LVDITTTSKKTVKVA
    18 52 49 ITTTSKKTVKVAIDV
    19 55 50 TSKKTVKVAIDVTDV
    20 58 51 KTVKVAIDVTDVYVV
    21 61 52 KVAIDVTDVYVVGYQ
    22 64 53 IDVTDVYVVGYQDKW
    23 67 54 TDVYVVGYQDKWDGK
    24 70 55 YVVGYQDKWDGKDRA
    25 73 56 GYQDKWDGKDRAVFL
    26 76 57 DKWDGKDRAVFLDKV
    27 79 58 DGKDRAVFLDKVPTV
    28 82 59 DRAVFLDKVPTVATS
    29 85 60 VFLDKVPTVATSKLF
    30 88 61 DKVPTVATSKLFPGV
    31 91 62 PTVATSKLFPGVTNR
    32 94 63 ATSKLFPGVTNRVTL
    33 97 64 KLFPGVTNRVTLTFD
    34 100 65 PGVTNRVTLTFDGSY
    35 103 66 TNRVTLTFDGSYQKL
    36 106 67 VTLTFDGSYQKLVNA
    37 109 68 TFDGSYQKLVNAAKV
    38 112 69 GSYQKLVNAAKVDRK
    39 115 70 QKLVNAAKVDRKDLE
    40 118 71 VNAAKVDRKDLELGV
    41 121 72 AKVDRKDLELGVYKL
    42 124 73 DRKDLELGVYKLEFS
    43 127 74 DLELGVYKLEFSIEA
    44 130 75 LGVYKLEFSIEAIHG
    45 133 76 YKLEFSIEAIHGKTI
    46 136 77 EFSIEAIHGKTINGQ
    47 139 78 IEAIHGKTINGQEIA
    48 142 79 IHGKTINGQEIAKFF
    49 145 80 KTINGQEIAKFFLIV
    50 148 81 NGQEIAKFFLIVIQM
    51 151 82 EIAKFFLIVIQMVSE
    52 154 83 KFFLIVIQMVSEAAR
    53 157 84 LIVIQMVSEAARFKY
    54 160 85 IQMVSEAARFKYIET
    55 163 86 VSEAARFKYIETEVV
    56 166 87 AARFKYIETEVVDRG
    57 169 88 FKYIETEVVDRGLYG
    58 172 89 IETEVVDRGLYGSFK
    59 175 90 EVVDRGLYGSFKPNF
    60 178 91 DRGLYGSFKPNFKVL
    61 181 92 LYGSFKPNFKVLNLE
    62 184 93 SFKPNFKVLNLENNW
    63 187 94 PNFKVLNLENNWGDI
    64 190 95 KVLNLENNWGDISDA
    65 193 96 NLENNWGDISDAIHK
    66 196 97 NNWGDISDAIHKSSP
    67 199 98 GDISDAIHKSSPQCT
    68 202 99 SDAIHKSSPQCTTIN
    69 205 100 IHKSSPQCTTINPAL
    70 208 101 SSPQCTTINPALQLI
    71 211 102 QCTTINPALQLISPS
    72 214 103 TINPALQLISPSNDP
    73 217 104 PALQLISPSNDPWVV
    74 220 105 QLISPSNDPWVVNKV
    75 223 106 SPSNDPWVVNKVSQI
    76 226 107 NDPWVVNKVSQISPD
    77 229 108 WVVNKVSQISPDMGI
    78 232 109 NKVSQISPDMGILKF
    79 235 110 SQISPDMGILKFKSS
    80 238 111 SPDMGILKFKSSKLT
    81 240 112 MGILKFKSSKLTQFA
    82 243 113 LKFKSSKLTQFATMI
    83 246 114 KSSKLTQFATMIRSA
    84 249 115 KLTQFATMIRSAIVE
    85 252 116 QFATMIRSAIVEDLD
    86 255 117 TMIRSAIVEDLDGDE
    87 258 118 RSAIVEDLDGDELEI
    88 261 119 IVEDLDGDELEILEP
    89 264 120 DLDGDELEILEPNIA
    Bouganin sequence peptides.
    The underlined residues are not present in the mature protein
  • TABLE 2
    Donor
    Donor storage
    No code Allotype
    1 BC63 DRB1*04, DRB1*07, DRB4*01
    2 BC86 DRB1*04, DRB1*15, DRB5
    3 BC90 DRB1*07, DRB1*15, DRB4*01, DRB5
    4 BC134 DRB1*01, DRB1*03, DRB3
    5 BC167 DRB1*01, DRB1*07 and DRB4*01
    6 BC216 DRB1*14, DRB1*15, DRB3, DRB5
    7 BC217 DRB1*04, DRB1*12, DRB3, DRB4*01
    8 BC233 DRB1*04, DRB1*11 and DRB3, DRB4*01
    9 BC241 DRB1*07, DRB1*11, DRB3, DRB4*01
    10 BC246 DRB1*01, DRB1*13 and DRB3
    11 BC262 DRB1*03, DRB1*07, DRB3, DRB4*01
    12 BC292 DRB1*07, DRB1*13, DRB3, DRB4*01
    13 BC293 DRB1*04, DRB1*10, DRB4*01
    14 BC231 DRB1*03 or DRB1*03, DRB1*13 and
    DRB3
    15 BC301 DRB1*07, DRB1*14, DRB3
    16 BC326 DRB1*03, DRB1*15, DRB3, DRB5
    17 BC316 DRB1*13, DRB1*15, DRB3, DRB5
    18 BC321 DRB1*01, DRB1*15, DRB5
    19 BC382 DRB1*04, DRB1*08, DRB4*01
    20 BC336 DRB1*01, DRB1*11, DRB3
    MHC Allotypes of PBMC donors
  • TABLE 3
    SEQ ID
    Primer NO Sequence
    OL1032 121 CATTACAAACGTCTACCAAGTTT
    OL1033 122 TTACAAAAGTAGATAAGTAATGTG
    OL1322 123 GATATACATATGAAATACCTATTGCCTACG
    OL1067 124 TGACACAGTGTTGTACGCTGGTTGGGCAGCGAGTAA
    OL1068 125 GCTGCCCAACCAGCGTACAACACTGTGTCATTTAAC
    OL1323 126 CGAGTGCGGCCGCTCAATGGTGATGGTGATGGTGT
    Sequences of primers used in the construction of the WT bouganin gene
  • TABLE 4
    Single substitution bouganin variants constructed and tested.
    Nucleotide Activity in Clone
    Mutation Mutations luciferase assay* ID**
    Negative control
    Y70A TAT - GCT −− BouY70A
    Epitope Region R1 (peptide 41)
    V123T GTG - ACG +/− Bou2
    V123A GTG - GCT ++ Bou3
    V123D GTG - GAT −− —
    V123E GTG - GAA −− —
    V123G GTG - GGC −− —
    V123H GTG - CAC −− —
    V123K GTG - AAG −− —
    V123N GTG - AAC −− —
    V123P GTG - CCT −− —
    V123Q GTG - CAA ++ Bou4
    V123R GTG - AGA −− —
    V123S GTG - TCA −− —
    D127G GAT - GGC ++ Bou5
    D127A GAT - GCT ++ Bou6
    E129K GAA - AAG −− —
    E129R GAA - AGA −− —
    E129Q GAA - CAA +/− Bou7
    E129G GAA - GGC ++ Bou8
    Epitope Region R2 (peptide 44)
    Y133P TAC - CCC −− —
    Y133N TAC - AAC ++ Bou9
    Y133T TAC - ACA ++ Bou10
    Y133A TAC - GCT ++ Bou11
    Y133R TAC - AGA ++ Bou12
    Y133D TAC - GAT ++ Bou13
    Y133E TAC - GAA +/− Bou14
    Y133Q TAC - CAA ++ Bou15
    Y133G TAC - GGC ++ Bou16
    Y133H TAC - CAC ++ Bou17
    Y133K TAC - AAG ++ Bou18
    Y133S TAC - TCA ++ Bou19
    Epitope Region R3 (peptide 50)
    E151T I152E GAGATA - ACGGAA −− —
    I152Q ATA - CAA ++ Bou20
    I152A ATA - GCA ++ Bou21
    I152E ATA - GAA −− —
    F155P TTC - CCA −− —
    F155H TTC - CAC −− —
    I158P ATT - CCA −− —
    *Activity in Luciferase assay:
    ++ = same or higher than WT protein. + = within 2-fold of WT activity. +/− = within 3-fold of WT activity. −− = less than one-third of WT activity. WT = Wild-type protein.
    **Clone ID. Designations for functionally active variants only.
  • TABLE 5
    Multiple substitution bouganin variants constructed and tested.
    Epitope Epitope Epitope Activity in
    Region R1 Region R2 Region R3 luciferase
    Clone ID (peptide 41) (peptide 44) (peptide51) assay
    Bou143 V123Q Y133Q I152Q ++
    Bou144 V123A Y133N I152A ++
    Bou145 V123A Y133Q I152A ++
    Bou146 V123A D127G ++
    Bou147 V123A D127A ++
    Bou148 V123Q D127G ++
    Bou149 V123Q D127A ++
    Bou150 V123Q E129G +
    Bou151 V123A E129G +
    Bou156 V123A D127A Y133N I152A ++
    Bou157 V123A D127A Y133Q I152A ++
    *Activity in Luciferase assay:
    ++ = same or higher than WT protein. + = within 2-fold of WT activity. +/− = within 3-fold of WT activity. −− = less than one-third of WT activity. WT = Wild-type protein.
  • TABLE 6
    Clone ID Substitution(s)* Protein
    Bou32 WT SEQ ID No 1
    Bou156 V123A, D127A, Y133N, I152A SEQ ID No 13
    Bou157 V123A, D127A, Y133Q, I152A SEQ ID No 14
    Bou143 V123Q, Y133Q, I152Q
    Bou144 V123A, Y133N, I152A
    Bou145 V123A, Y133Q, I152A
    Bou146 V123A, D127G
    Bou147 V123A, D127A
    Bou148 V123Q, D127G
    Bou149 V123Q, D127A
    Bou150 V123Q, E129G
    Bou151 V123A, E129G
    Bou2 V123T
    Bou3 V123A
    Bou4 V123Q
    Bou5 D127G
    Bou6 D127A
    Bou7 E129Q
    Bou8 E129G
    Bou9 Y133N
    Bou10 Y133T
    Bou11 Y133A
    Bou12 Y133R
    Bou13 Y133D
    Bou14 Y133E
    Bou15 Y133Q
    Bou16 Y133G
    Bou17 Y133H
    Bou18 Y133K
    Bou19 Y133S
    Bou20 I152Q
    Bou21 I152A
    *The numbering commences from residue 1 of the bouganin reading frame and therefore excludes a PelB leader sequence included in most constructs.
  • TABLE 7
    Protein
    SEQ ID No 1
    YNTVSFNLGEAYEYPTFIQDLRNELAKGTPVCQLPVTLQTIADDKRFVL
    VDITTTSKKTVKVAIDVTDVYVVGYQDKWDGKDRAVFLDKVPTVATSKL
    FPGVTNRVTLTFDGSYQKLVNAAKVDRKDLELGVYKLEFSIEAIHGKTI
    NGQEIAKFFLIVIQMVSEAARFKYIETEVVDRGLYGSFKPNFKVLNLEN
    NWGDISDAIHKSSPQCTTINPALQLISPSNDPWVVNKVSQISPDMGILK
    FKSSK
    Protein
    SEQ ID No 13
    YNTVSFNLGEAYEYPTFIQDLRNELAKGTPVCQLPVTLQTIADDKRFVL
    VDITTTSKKTVKVAIDVTDVYVVGYQDKWDGKDRAVFLDKVPTVATSKL
    FPGVTNRVTLTFDGSYQKLVNAAKADRKALELGVNKLEFSIEAIHGKTI
    NGQEAAKFFLIVIQMVSEAARFKYIETEVVDRGLYGSFKPNFKVLNLEN
    NWGDISDAIHKSSPQCTTINPALQLISPSNDPWVVNKVSQISPDMGILK
    FKSSK
  • TABLE 8
    Modified and WT peptides of Bouganin 
    further tested in T cell assays.
    Position
    of first
    Peptide amino acid SEQ ID
    number within bouganin Sequence* NO
    DeI-41 121-135 AKADRKALELGVNKL 29
    DeI-44 130-144 LGVNKLEFSIEAIHG 30
    DeI-50 149-163 NGQEAAKFFLIVIQM 31
    *Substituted (mutant) residue underlined.
  • TABLE 9
    VB6-845 binding to gynecological cell lines by flow cytometry
    VB6-845 (fold increase
    Indication Cell lines MF ± SEM)
    Endometrial HEC-1-A 42.3 ± 0.9 
    RL95-2 4.9 ± 0.7
    SK-UT-1 1.1 ± 0.1
    Ovarian NIH: OVCAR-3 33.6 ± 6.0 
    SK-OV-3 4.3 ± 1.0
    TOV-112G 1.1 ± 0.1
    Cervical HT-3 29.1 ± 1.2 
    C-4 I 6.8 ± 0.6
    C-33A 1.1 ± 0.0
    Melanoma A-375 1.1 ± 0.1
    Results are expressed as fold-increase in MF ± SEM.
  • TABLE 10
    VB6-845-mediated Cytotoxicity by MTS assay
    VB6-845 (fold increase
    Indication Cell lines MF ± SEM)
    Endometrial HEC-1-A 43
    KLE >100
    RL95-2 100
    Ovarian NIH-OVCAR-3 3.4
    Caov-3 1.3
    SK-OV-3 >100
    Cervical MS751 0.43
    HT-3 23
    ME-180 37
    C-4 I 1.7
    Melanoma A-375 >100
  • TABLE 11
    Specificity and selectivity of VB6-845 Versus Chemotherapeutics
    IC50 nM
    NIH: OVCAR-3 A-375 DAUDI HMEC
    Paclitaxel <10−6 4.9 × 10−6 <10−6 <10−6
    Docetaxel <10−6 <10−6 <10−6 <10−6
    Vincristine 4.4 × 10−6 <10−6 <10−6 <10−6
    Vinblastine Sulfate 1.1 × 10−6 <10−6 <10−6 <10−6
    Topotecan 0.071 1.5 0.009 4.1
    VB6-845 1 >1000 >1000 220
    (90% pure)
    Doxorubicin 3 2.8 16 × 10−6 16
    Mitomycin C 28 14 2.8 50
    Bleomycin Sulfate 30 170 22 600
    Bleomycin A5 150 290 130 1000
    Irinotecan 180 900 190 1000
    Etoposide 210 280 1.7 600
    Methotrexate >1000 6 3.6 41
    Chlorambucil >1000 >1000 >1000 >1000
    Fluorouracil >1000 >1000 >1000 >1000
    Cyclophosphamide >1000 >1000 >1000 >1000
    Cisplatin >1000 >1000 >1000 >1000
    Carboplatin >1000 >1000 >1000 >1000
  • TABLE 12
    VB6-845 Tumor Cell Indications
    Binding for scFv 845
    INDICATIONS N1 (IgG) 2
    Gastric 3 148.9
    Ovarian 2 84.1
    Esophageal 3 72.4
    Bladder 14 59.6
    Prostate 5 50.1
    Cervical 3 37.5
    Endometrial 1 23.8
    Lung 3 16.4
    Head and Neck 2 11.4
    Kidney 3 9.4
    Pancreas 3 5.5
    Melanoma 3 1.6
    1N indicates the number of cell lines tested per indication.
    2 Mean fold-increase in median fluorescence over the control antibody from all cell lines in each indication.
  • TABLE 13
    VB6-011 Tumor Cell Indications
    Binding for mAb 011
    INDICATIONS N1 (IgG) 2
    Breast 3 16.9
    Prostate 3 15.1
    Melanoma 3 14.0
    Lung 3 13.1
    Ovarian 2 11.1
    Colon 3 8.7
    Kidney 3 6.9
    Liver 2 6.5
    Pancreas 3 4.2
    Head and Neck 2 2.9
    1N indicates the number of cell lines tested per indication.
    2 Values indicate the mean calculated from the sum of the mean fold increase in median fluorescence over the control antibody from all cell lines in each indication. A zero value would mean no measurable reactivity relative to the control activity

Claims (8)

What is claimed is:
1. An immunotoxin comprising a first polypeptide having an amino acid sequence from amino acid 23 to amino acid 503 of SEQ ID NO: 16, and a second polypeptide having an amino acid sequence from amino acid 532 to amino acid 750 of SEQ ID NO: 16, and the first polypeptide and the second polypeptide are linked by a di-sulfide bond.
2. The immunotoxin of claim 1, wherein the immunotoxin is a modified bouganin protein linked to a Fab antibody fragment that binds to Ep-CAM.
3. An immunotoxin comprising a first polypeptide having an amino acid sequence from amino acid 29 to amino acid 247 of SEQ ID NO: 20, and a second polypeptide having an amino acid sequence from amino acid 270 to amino acid 750 of SEQ ID NO: 20, and the first polypeptide and the second polypeptide are linked by a di-sulfide bond.
4. The immunotoxin of claim 3, wherein the immunotoxin is a modified bouganin protein linked to a Fab antibody fragment that binds to Ep-CAM.
5. An immunotoxin comprising a first polypeptide having an amino acid sequence from amino acid 23 to amino acid 503 of SEQ ID NO: 22, and a second polypeptide having an amino acid sequence from amino acid 532 to amino acid 750 of SEQ ID NO: 22, and the first polypeptide and the second polypeptide are linked by a di-sulfide bond.
6. The immunotoxin of claim 5, wherein the immunotoxin is a modified bouganin protein linked to a Fab antibody fragment that binds to Ep-CAM.
7. An immunotoxin comprising a first polypeptide having an amino acid sequence from amino acid 29 to amino acid 247 of SEQ ID NO: 24, and a second polypeptide having an amino acid sequence from amino acid 270 to amino acid 750 of SEQ ID NO: 24, and the first polypeptide and the second polypeptide are linked by a di-sulfide bond.
8. The immunotoxin of claim 7, wherein the immunotoxin is a modified bouganin protein linked to a Fab antibody fragment that binds to Ep-CAM.
US14/242,181 2004-03-19 2014-04-01 Cytotoxins comprising modified bouganin toxin for the treatment of cancer Abandoned US20150018526A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US14/242,181 US20150018526A1 (en) 2004-03-19 2014-04-01 Cytotoxins comprising modified bouganin toxin for the treatment of cancer

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US55458004P 2004-03-19 2004-03-19
US63057104P 2004-11-26 2004-11-26
US11/084,080 US7339031B2 (en) 2004-03-19 2005-03-18 Modified bouganin proteins, cytotoxins and methods and uses thereof
US11/971,660 US7750136B2 (en) 2004-03-19 2008-01-09 Modified bouganin proteins, cytotoxins and methods and uses thereof
US12/784,820 US8716234B2 (en) 2004-03-19 2010-05-21 Cytotoxins comprising modified bouganin toxin for the treatment of cancer
US14/242,181 US20150018526A1 (en) 2004-03-19 2014-04-01 Cytotoxins comprising modified bouganin toxin for the treatment of cancer

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US12/784,820 Continuation US8716234B2 (en) 2004-03-19 2010-05-21 Cytotoxins comprising modified bouganin toxin for the treatment of cancer

Publications (1)

Publication Number Publication Date
US20150018526A1 true US20150018526A1 (en) 2015-01-15

Family

ID=34993709

Family Applications (4)

Application Number Title Priority Date Filing Date
US11/084,080 Active 2025-06-23 US7339031B2 (en) 2004-03-19 2005-03-18 Modified bouganin proteins, cytotoxins and methods and uses thereof
US11/971,660 Active 2025-05-08 US7750136B2 (en) 2004-03-19 2008-01-09 Modified bouganin proteins, cytotoxins and methods and uses thereof
US12/784,820 Active 2025-12-15 US8716234B2 (en) 2004-03-19 2010-05-21 Cytotoxins comprising modified bouganin toxin for the treatment of cancer
US14/242,181 Abandoned US20150018526A1 (en) 2004-03-19 2014-04-01 Cytotoxins comprising modified bouganin toxin for the treatment of cancer

Family Applications Before (3)

Application Number Title Priority Date Filing Date
US11/084,080 Active 2025-06-23 US7339031B2 (en) 2004-03-19 2005-03-18 Modified bouganin proteins, cytotoxins and methods and uses thereof
US11/971,660 Active 2025-05-08 US7750136B2 (en) 2004-03-19 2008-01-09 Modified bouganin proteins, cytotoxins and methods and uses thereof
US12/784,820 Active 2025-12-15 US8716234B2 (en) 2004-03-19 2010-05-21 Cytotoxins comprising modified bouganin toxin for the treatment of cancer

Country Status (18)

Country Link
US (4) US7339031B2 (en)
EP (1) EP1737961B1 (en)
JP (1) JP5025460B2 (en)
KR (1) KR101165867B1 (en)
AU (1) AU2005224942B2 (en)
BR (1) BRPI0508670B1 (en)
CA (1) CA2560278C (en)
DK (1) DK1737961T3 (en)
EA (1) EA010803B1 (en)
ES (1) ES2424643T3 (en)
HK (1) HK1102306A1 (en)
IL (1) IL177922A (en)
MX (1) MXPA06010716A (en)
NO (1) NO338293B1 (en)
NZ (1) NZ550339A (en)
PL (1) PL1737961T3 (en)
PT (1) PT1737961E (en)
WO (1) WO2005090579A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020033663A3 (en) * 2018-08-10 2020-03-19 Sanford Burnham Prebys Medical Discovery Institute Binding molecules to tumor associated macrophages and methods of use

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2382990T3 (en) 2003-04-30 2015-04-30 Univ Zuerich Methods for treating cancer using an immunotoxin
WO2005121341A1 (en) 2004-06-10 2005-12-22 Viventia Biotech Inc. Tumor specific antibody
EP1844074B1 (en) 2005-02-03 2013-04-24 Antitope Limited Human antibodies and proteins
CN101400793B (en) * 2005-12-21 2014-06-11 维文蒂阿生物技术股份有限公司 Novel cancer-associated antigen
EP1969165A4 (en) * 2005-12-23 2010-05-19 Viventia Biotech Inc Methods for generating and screening fusion protein libraries and uses thereof
WO2008052322A1 (en) * 2006-10-30 2008-05-08 Viventia Biotech Inc. Immunotoxγn fusions comprising an antibody fragment and a plant toxin linked by protease cleavable linkers
CA2963138C (en) * 2007-01-30 2019-05-14 Epivax, Inc. Regulatory t cell epitopes, compositions and uses thereof
US8263744B2 (en) 2007-04-19 2012-09-11 Viventia Biotechnologies Inc. Binding proteins that bind to EpCAM linked to an effector molecule
AU2008279550B2 (en) 2007-06-21 2012-08-09 Angelica Therapeutics, Inc. Modified toxins
US8318472B2 (en) 2007-09-27 2012-11-27 Viventia Biotechnologies Inc. Optimized nucleic acid sequences for the expression of VB4-845
EP2268297A4 (en) 2008-02-29 2011-11-16 Angelica Therapeutics Inc Modified toxins
US8932586B2 (en) 2011-09-06 2015-01-13 Intrexon Corporation Modified forms of Pseudomonas exotoxin A
WO2014127211A1 (en) * 2013-02-15 2014-08-21 Research Development Foundation Deimmunized gelonin molecules and therapies
JP2016519651A (en) 2013-03-15 2016-07-07 アンジェリカ セラピューティックス，インク． Modified toxin
EP2986324A4 (en) * 2013-04-12 2016-12-14 Viventia Bio Inc Compositions and methods for detection and treatment of hepatocellular carcinoma
KR102068519B1 (en) 2013-07-01 2020-01-21 삼성전자주식회사 Storage device for enhancing read performance, writing method and reading method thereof
JP2017504621A (en) * 2013-10-02 2017-02-09 ヴィヴェンティア バイオ インコーポレイテッド Anti-EPCAM antibodies and methods of use
US20160060358A1 (en) * 2014-08-28 2016-03-03 California Institute Of Technology Induction of antigen-specific tolerance
CA2979394A1 (en) 2015-03-12 2016-09-15 Viventia Bio Inc. Methods of treatment for epcam positive bladder cancer
JP6847846B2 (en) 2015-03-12 2021-03-24 セセン バイオ，インコーポレイテッド Dosing strategies targeting EPCAM-positive bladder cancer
WO2016187571A2 (en) * 2015-05-20 2016-11-24 Viventia Bio Inc. Her2 immunotoxins and methods of using the same
AU2018347796A1 (en) 2017-10-10 2020-05-07 Medicenna Therapeutics, Inc. IL-4-fusion formulations for treatment of central nervous system (CNS) tumors
JP7124034B2 (en) * 2020-11-05 2022-08-23 株式会社天柳 Method for producing food composition for dysphagia
JP7488928B1 (en) 2023-03-01 2024-05-22 積水フーラー株式会社 Hot Melt Adhesives

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2424255A1 (en) * 2003-03-26 2004-09-26 Claudio Di Paolo Immunotoxins
US20050069552A1 (en) * 2003-07-28 2005-03-31 Bleck Gregory T. Fusion antibodies

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6680295B1 (en) * 1994-09-22 2004-01-20 The Administrators Of The Tulane Educational Fund Method and pharmaceutical composition for prevention and treatment of brain damage
US6121416A (en) * 1997-04-04 2000-09-19 Genentech, Inc. Insulin-like growth factor agonist molecules
JP2002512624A (en) 1997-05-21 2002-04-23 バイオベーション リミテッド Method for producing non-immunogenic protein
AU8040898A (en) * 1997-06-06 1998-12-21 Tanox Pharma B.V. Type-1 ribosome-inactivating protein
JP2002507967A (en) * 1997-06-20 2002-03-12 パンゲネチックス・ベー・ファウ Anti-CD40L immunotoxin for disease treatment
EP1051432B1 (en) 1998-12-08 2007-01-24 Biovation Limited Method for reducing immunogenicity of proteins
WO2002069232A2 (en) 2001-02-19 2002-09-06 Merck Patent Gmbh Method for identification of t-cell epitopes and use for preparing molecules with reeduced immunogenicity
WO2002079415A2 (en) 2001-03-30 2002-10-10 Lexigen Pharmaceuticals Corp. Reducing the immunogenicity of fusion proteins
MXPA04012210A (en) 2002-06-11 2005-02-25 Merck Patent Gmbh Modified byrodin 1 with reduced immunogenicity.
DK1512004T3 (en) 2002-06-11 2006-06-06 Merck Patent Gmbh Method for mapping and eliminating T cell epitopes
WO2005121341A1 (en) * 2004-06-10 2005-12-22 Viventia Biotech Inc. Tumor specific antibody
WO2006066408A1 (en) * 2004-12-21 2006-06-29 Viventia Biotech Inc. Cancer specific antibody and cell surface proteins
EP1844074B1 (en) * 2005-02-03 2013-04-24 Antitope Limited Human antibodies and proteins

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2424255A1 (en) * 2003-03-26 2004-09-26 Claudio Di Paolo Immunotoxins
US20050069552A1 (en) * 2003-07-28 2005-03-31 Bleck Gregory T. Fusion antibodies

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020033663A3 (en) * 2018-08-10 2020-03-19 Sanford Burnham Prebys Medical Discovery Institute Binding molecules to tumor associated macrophages and methods of use
US20210299212A1 (en) * 2018-08-10 2021-09-30 Sanford Burnham Prebys Medical Discovery Institute Bindng molecules to tumor associated macrophages and methods of use

Also Published As

Publication number Publication date
MXPA06010716A (en) 2007-02-21
US20100254964A1 (en) 2010-10-07
US8716234B2 (en) 2014-05-06
AU2005224942A1 (en) 2005-09-29
PL1737961T3 (en) 2013-12-31
WO2005090579A1 (en) 2005-09-29
PT1737961E (en) 2013-08-26
EP1737961A1 (en) 2007-01-03
US7339031B2 (en) 2008-03-04
US20050238642A1 (en) 2005-10-27
CA2560278C (en) 2012-11-20
CA2560278A1 (en) 2005-09-29
HK1102306A1 (en) 2007-11-16
US20080219994A1 (en) 2008-09-11
IL177922A (en) 2011-06-30
JP2008500811A (en) 2008-01-17
AU2005224942B2 (en) 2011-08-11
NO20064134L (en) 2006-11-08
BRPI0508670B1 (en) 2023-01-24
US7750136B2 (en) 2010-07-06
EP1737961A4 (en) 2008-12-17
EA010803B1 (en) 2008-12-30
BRPI0508670A (en) 2007-08-14
KR20070000494A (en) 2007-01-02
NO338293B1 (en) 2016-08-08
JP5025460B2 (en) 2012-09-12
EP1737961B1 (en) 2013-05-08
NZ550339A (en) 2009-11-27
EA200601738A1 (en) 2007-04-27
KR101165867B1 (en) 2012-07-13
IL177922A0 (en) 2006-12-31
DK1737961T3 (en) 2013-08-05
ES2424643T3 (en) 2013-10-07

Similar Documents

Publication Publication Date Title
US7750136B2 (en) Modified bouganin proteins, cytotoxins and methods and uses thereof
KR20060136464A (en) Modified Bouganin proteins, Cytotoxins and Methods and Uses Thereof
US8734795B2 (en) Light targeting molecules and uses thereof
EP1997894B1 (en) Biosynthetic binding protein for cancer marker
CN110312736B (en) PD-L1 binding polypeptides or compounds
EP2899277A1 (en) Compound with affinity for the cytotoxic T lymphocyte-associated antigen (CTLA-4)
US20130101549A1 (en) Light targeting molecules and uses thereof
US6576232B1 (en) IL13 mutants
EA012622B1 (en) Bispecific fusion antibodies with enhanced serum half-life
JPH07504883A (en) Materials containing ribosome-inactivating proteins and methods of preparing and using them
KR101100628B1 (en) Compositions and methods for modifying toxic effects of proteinaceous compounds
JPH09509043A (en) A novel ribosome-inactivating protein isolated from the plant Bryonia dioica
ZA200608696B (en) Modified bouganin proteins, cytotoxins and methods and uses thereof
AU7863900A (en) Il13 mutants
WO2016187585A1 (en) Deimmunized linker and methods of use
KR20020049054A (en) Antibodies
AU2016202118A1 (en) Carrier immunoglobulins and uses thereof
WO2016187571A2 (en) Her2 immunotoxins and methods of using the same

Legal Events

Date Code Title Description
AS Assignment

Owner name: MERCK PATENT GMBH, GERMANY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BAKER, MATTHEW;CARR, FRANCIS J.;HELLENDOORN, KOEN;SIGNING DATES FROM 20060802 TO 20060904;REEL/FRAME:032574/0112

Owner name: VIVENTIA BIOTECH INC., CANADA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:CIZEAU, JEANNICK;MACDONALD, GLEN CHRISTOPHER;ENTWISTLE, JOYCELYN;AND OTHERS;SIGNING DATES FROM 20060706 TO 20060710;REEL/FRAME:032573/0991

Owner name: MERCK PATENT GMBH, GERMANY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:VIVENTIA BIOTECH INC.;REEL/FRAME:032574/0154

Effective date: 20060706

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION